RESULT_COUNT: 934,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
EXEL,EXEL:UW,BBG000BQ56F4,"Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies Inc.",2017-10-21 14:48:00 +0000,https://finance.yahoo.com/news/better-buy-exelixis-inc-vs-144800569.html?.tsrc=rss,Exelixis has enjoyed a meteoric rise already. Is it now time for Intra-Cellular Therapies to have its turn?
EXEL,EXEL:UW,BBG000BQ56F4,Cancer Treatment Update: Second Gene Therapy Receives Approval,2017-10-20 21:28:09 +0000,https://finance.yahoo.com/news/cancer-treatment-second-gene-therapy-212809708.html?.tsrc=rss,"The FDA approved Gilead&apos;s Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs."
EXEL,EXEL:UW,BBG000BQ56F4,"ETFs with exposure to Exelixis, Inc. : October 20, 2017",2017-10-20 14:12:00 +0000,http://finance.yahoo.com/r/3f6ba68b-f8d1-30f2-b244-f34272ef4696/etfs-with-exposure-to-exelixis-inc-october-20-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Exelixis, Inc. Here are 5 ETFs with the largest exposure to EXEL-US. Comparing the performance and risk of Exelixis, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Positive News from Celestial Study, Cabometyx Label Review Due February 15, 2018",2017-10-19 12:00:00 +0000,https://finance.yahoo.com/news/exelixis-positive-news-celestial-study-120000545.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / October 19, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ..."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis to Release Third Quarter 2017 Financial Results on Wednesday, November 1, 2017",2017-10-18 20:05:00 +0000,https://finance.yahoo.com/news/exelixis-release-third-quarter-2017-200500819.html?.tsrc=rss,"Exelixis, Inc. announced today that its third quarter 2017 financial results will be released on Wednesday, November 1, 2017 after the markets close. At 5:00 p.m. EDT / 2:00 p.m."
EXEL,EXEL:UW,BBG000BQ56F4,Featured Company News - Exelixis' Cabozantinib Met Primary Endpoint in Phase-3 CELESTIAL Trial for Advanced Hepatocellular Carcinoma,2017-10-18 11:50:00 +0000,https://finance.yahoo.com/news/featured-company-news-exelixis-cabozantinib-115000404.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / October 18, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Exelixis, Inc. (NASDAQ: EXEL ), following which we have published a ..."
EXEL,EXEL:UW,BBG000BQ56F4,"Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug",2017-10-18 11:32:11 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-exelixis-soars-113211834.html?.tsrc=rss,Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.
EXEL,EXEL:UW,BBG000BQ56F4,FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx,2017-10-17 14:55:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZZXqkk2SHBQ/fda-grants-priority-review-for-exelixis-rcc-drug-cabomteyx-cm860718,Exelixis Inc EXEL announced that the FDA has granted priority review to its supplemental New Drug Application sNDA for Cabomteyx The sNDA seeks approval of Cabometyx for patients with previously untreated advanced renal cell carcinoma RCC The FDA determined the sNDA to be
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Earns Relative Strength Rating Upgrade,2017-10-17 14:53:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JE_WDkUmyVw/exelixis-earns-relative-strength-rating-upgrade-cm860672,Exelixis EXEL saw a positive improvement to its Relative Strength RS Rating on Tuesday rising from 89 to 95 ibd display video id 2102289 width 50 float left autostart true IBD s proprietary RS Rating identifies market leadership by showing how a stock s
EXEL,EXEL:UW,BBG000BQ56F4,Why Exelixis' Rebound Is Just Getting Started,2017-10-17 14:52:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VV9IeqBxtJ8/why-exelixis-rebound-is-just-getting-started-cm860648,Exelixis NASDAQ EXEL stock had been in the doldrums After roaring for much of the first eight months of the year the biotech s share price sank more than 15 during September All of that is history now On Monday Exelixis stock soared yet again fueled by not just one piece
EXEL,EXEL:UW,BBG000BQ56F4,"Company News For Oct 17, 2017",2017-10-17 14:03:02 +0000,https://finance.yahoo.com/news/company-news-oct-17-2017-140302145.html?.tsrc=rss,"Companies in the news are: EXEL,TSLA,SONC,BMI"
EXEL,EXEL:UW,BBG000BQ56F4,FDA Grants Priority Review for Exelixis&apos; RCC Drug Cabomteyx,2017-10-17 13:15:01 +0000,https://finance.yahoo.com/news/fda-grants-priority-review-exelixis-131501065.html?.tsrc=rss,Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session,2017-10-17 12:33:12 +0000,https://finance.yahoo.com/news/exelixis-exel-looks-good-stock-123312553.html?.tsrc=rss,"Exelixis (EXEL) was a big mover last session, as the company saw its shares rise more than 17% on the day amid huge volumes."
EXEL,EXEL:UW,BBG000BQ56F4,Why Exelixis&apos; Rebound Is Just Getting Started,2017-10-17 12:18:00 +0000,https://finance.yahoo.com/news/why-exelixis-apos-rebound-just-121800622.html?.tsrc=rss,Buy the bounce? Signs point to &quot;yes.&quot;
EXEL,EXEL:UW,BBG000BQ56F4,Today's Research Reports on Stocks to Watch: Dynavax and Exelixis,2017-10-17 12:10:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-121000374.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / October 17, 2017 / Dynavax saw some gains on Monday, though there was no major catalyst to explain the small and modest pop. Earlier in the month shares had broken out over ..."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : October 17, 2017",2017-10-17 12:05:54 +0000,http://finance.yahoo.com/r/1600aa2f-311f-3f46-8874-c322c50884c6/exelixis-inc-breached-its-50-day-moving-average-in-a-bullish-manner-exel-us-october-17-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Exelixis, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,"HIIQ In Good Health, BOLD Awaits ASPIRO Data, CELESTIAL Lights Up EXEL",2017-10-16 21:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4hhrQ3h8PGQ/hiiq-in-good-health-bold-awaits-aspiro-data-celestial-lights-up-exel-20171016-01420,"HIIQ In Good Health, BOLD Awaits ASPIRO Data, CELESTIAL Lights Up EXEL"
EXEL,EXEL:UW,BBG000BQ56F4,What Happened in the Stock Market Today,2017-10-16 21:04:00 +0000,https://finance.yahoo.com/news/happened-stock-market-today-210400015.html?.tsrc=rss,"On another record day for major benchmarks, Exelixis soared on news about its cancer drug, and PG&E sank on concerns about a potential role in the California fires."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis Rockets To 17-Year High On Kidney, Liver Cancer News",2017-10-16 20:40:29 +0000,http://finance.yahoo.com/r/af7c4635-cb76-3088-84cd-cc463c6b6aa5/exelixis-rockets-after-fda-grants-kidney-cancer-drug-priority-review?src=A00220&yptr=yahoo&.tsrc=rss,"Exelixis popped early Monday after the FDA granted its drug, Cabometyx, priority review to treat advanced kidney cancer."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis and Ruby Tuesday rise while Nordstrom and Tesla dip,2017-10-16 20:32:06 +0000,https://finance.yahoo.com/news/exelixis-ruby-tuesday-rise-while-203206988.html?.tsrc=rss,"Stocks that moved substantially or traded heavily Monday: Aramark, up 20 cents to $42.53 The food, facilities and uniform company agreed to make two acquisitions for $2.35 billion. Tesla Inc., down $4.97 ..."
EXEL,EXEL:UW,BBG000BQ56F4,"Health Care Sector Update for 10/16/2017: AIMI,REGN,SNY,EXEL,TGTX",2017-10-16 20:17:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9LSxlGCPl4Q/health-care-sector-update-for-10162017-aimiregnsnyexeltgtx-cm860316,Top Health Care StocksTop Health Care Stocks JJNJ 0 51 JJNJ 0 51 PFE 1 22 PFE 1 22 ABT 0 02 ABT 0 02 MRK 0 21 MRK 0 21 AMGN 0 80 AMGN 0 80 Health care stocks missed out on the late day bounce for most sectors today with the NYSE Health Care Index falling almost 0 3 while shares
EXEL,EXEL:UW,BBG000BQ56F4,Mid-Afternoon Market Update: Sears Tumbles After Bruce Berkowitz Resigns From Board; Exelixis Shares Surge,2017-10-16 19:50:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XH7y3hVlqYk/mid-afternoon-market-update-sears-tumbles-after-bruce-berkowitz-resigns-from-board-exelixis-shares-surge-cm860313,Toward the end of trading Monday the Dow traded up 0 25 percent to 22 929 55 while the NASDAQ climbed 0 14 percent to 6 615 28 The S amp P also rose gaining 0 11 percent to 2 555 89 Leading and Lagging Sectors Monday afternoon the energy shares surged 0 54 percent Meanwhile
EXEL,EXEL:UW,BBG000BQ56F4,Wall Street High on Monday,2017-10-16 19:49:46 +0000,https://finance.yahoo.com/news/wall-street-high-monday-194946661.html?.tsrc=rss,Stocks jump in response to announcement and better rating
EXEL,EXEL:UW,BBG000BQ56F4,"Monday's ETF Movers: PDP, XRT",2017-10-16 19:17:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LWk7G1yyWio/mondays-etf-movers-pdp-xrt-cm860267,In trading on Monday the PowerShares DWA Momentum Portfolio ETF PDP is outperforming other ETFs up about 0 7 on the day Components of that ETF showing particular strength include shares of Exelixis EXEL up about 24 7 and shares of National Beverage FIZZ up about 2 2 on
EXEL,EXEL:UW,BBG000BQ56F4,Monday's ETF with Unusual Volume: PDP,2017-10-16 19:16:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sIdfPbzqqvQ/mondays-etf-with-unusual-volume-pdp-cm860265,The PowerShares DWA Momentum Portfolio ETF PDP is seeing unusually high volume in afternoon trading Monday with over 101 000 shares traded versus three month average volume of about 65 000 Shares of PDP were up about 0 7 on the day Components of that ETF with the highest volume
EXEL,EXEL:UW,BBG000BQ56F4,Traders buy calls on Exelixis,2017-10-16 18:35:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MVyQ0tEn6fk/traders-buy-calls-on-exelixis-cm860286,Option traders are building a position in options on Exelixis EXEL Monday So far 3 763 contracts of the May 35 call have changed hands today against open interest of 61 contracts Today s volume includes a single trade of 3 500 contracts that moved a few minutes before 10 a m
EXEL,EXEL:UW,BBG000BQ56F4,Mid-Day Market Update: TransEnterix Climbs Following FDA Clearance Of Senhance Surgical Robot; TG Therapeutics Shares Decline,2017-10-16 17:45:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GgmMPrTbdJY/mid-day-market-update-transenterix-climbs-following-fda-clearance-of-senhance-surgical-robot-tg-therapeutics-shares-decline-cm860257,Midway through trading Monday the Dow traded up 0 11 percent to 22 895 94 while the NASDAQ climbed 0 23 percent to 6 620 70 The S amp P also rose gaining 0 06 percent to 2 554 69 Leading and Lagging Sectors On Monday the energy shares surged 0 54 percent Meanwhile top gainers
EXEL,EXEL:UW,BBG000BQ56F4,"Health Care Sector Update for 10/16/2017: AMPE,EXEL,TGTX",2017-10-16 17:17:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X9ArFm6vs2s/health-care-sector-update-for-10162017-ampeexeltgtx-cm860241,Top Health Care StocksTop Health Care Stocks JNJ 0 37 JNJ 0 37 PFE 0 78 PFE 0 78 ABT 0 04 ABT 0 04 MRK 0 14 MRK 0 14 AMGN 0 56 AMGN 0 56 Health care stocks were retreating again on Monday with the NYSE Health Care Index falling almost 0 2 while shares of health care companies
EXEL,EXEL:UW,BBG000BQ56F4,"Why Exelixis, Inc. Rose Higher Today",2017-10-16 16:57:00 +0000,https://finance.yahoo.com/news/why-exelixis-inc-rose-higher-165700866.html?.tsrc=rss,Positive phase 3 data for Cabometyx in liver cancer sends shares of the biotech higher.
EXEL,EXEL:UW,BBG000BQ56F4,Mid-Morning Market Update: Markets Open Higher; Charles Schwab Earnings Top Views,2017-10-16 15:45:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0Ws7xOpD1uM/mid-morning-market-update-markets-open-higher-charles-schwab-earnings-top-views-cm860182,Following the market opening Monday the Dow traded up 0 21 percent to 22 918 90 while the NASDAQ climbed 0 35 percent to 6 628 83 The S amp P also rose gaining 0 17 percent to 2 557 63 Leading and Lagging Sectors Monday morning the energy shares surged 0 66 percent
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Remains Sharply Higher After Early Rally,2017-10-16 14:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xw1GTFlItaA/exelixis-remains-sharply-higher-after-early-rally-20171016-01074,Exelixis Remains Sharply Higher After Early Rally
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers,2017-10-16 13:22:00 +0000,http://finance.yahoo.com/r/f8ab7513-7571-3b46-9c8c-d957304b192e/exelixis-pops-phase-3-data-liver-cancer-drug-biotech-movers?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Pops as FDA Gives Kidney Cancer Drug Priority Review -- Biotech Movers,2017-10-16 13:22:00 +0000,http://finance.yahoo.com/r/f8ab7513-7571-3b46-9c8c-d957304b192e/exelixis-pops-fda-gives-kidney-cancer-drug-priority-review-biotech-movers?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The FDA has granted has granted priority review for the company's supplemental new drug application for Cabometyx (cabozantinib) for patients with previously untreated advanced renal cell carcinoma.
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Cancer Treatment Hits Key Milestone,2017-10-16 13:10:08 +0000,https://finance.yahoo.com/news/exelixis-cancer-treatment-hits-key-131008181.html?.tsrc=rss,Exelixis kicked off the week with a couple updates that are already having a big impact on the stock. These updates came in the form of a key FDA approval.
EXEL,EXEL:UW,BBG000BQ56F4,"Pre-Market Most Active for Oct 16, 2017 :  F, EXEL, GSK, VALE, NVO, BAC, JD, MNKD, TEVA, AAPL, MU, XT",2017-10-16 12:55:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fQcGC3YCL_0/pre-market-most-active-for-oct-16-2017-f-exel-gsk-vale-nvo-bac-jd-mnkd-teva-aapl-mu-xt-cm859997,The NASDAQ 100 Pre Market Indicator is up 12 88 to 6 105 33 The total Pre Market volume is currently 6 077 323 shares traded The following are the most active stocks for the pre market session Ford Motor Company F is 0 08 at 11 97 with 1 260 112 shares traded F
EXEL,EXEL:UW,BBG000BQ56F4,Modest Strength Remains Visible On Wall Street - U.S. Commentary,2017-10-16 11:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Rny6sW125MI/modest-strength-remains-visible-on-wall-street--us-commentary-20171016-00960,Modest Strength Remains Visible On Wall Street - U.S. Commentary
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis shares surge 19% premarket after FDA grants priority review to kidney cancer drug,2017-10-16 11:26:12 +0000,http://finance.yahoo.com/r/a5231fc8-5568-3c55-b3e6-8d763318cb30/Story.aspx?guid=5EFA701F-9793-4629-A74D-76DEB9368818&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Shares of biotech Exelixis Inc. rallied 19% in premarket trade Monday, after the company said it has won U.S. Food and Drug Administration priority review status for its supplemental New Drug Application ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis cancer drug meets key goal in late-stage trial,2017-10-16 11:15:38 +0000,https://finance.yahoo.com/news/exelixis-cancer-drug-meets-key-111538059.html?.tsrc=rss,"Exelixis Inc said on Monday its drug met the main goal in a late stage study for treating patients with a type of liver cancer. The drug, Cabometyx, showed statistically significant improvement in overall ..."
EXEL,EXEL:UW,BBG000BQ56F4,Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma,2017-10-16 11:02:00 +0000,https://finance.yahoo.com/news/ipsen-announces-phase-3-celestial-110200108.html?.tsrc=rss,Regulatory News:
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma,2017-10-16 10:59:00 +0000,https://finance.yahoo.com/news/exelixis-announces-u-fda-grants-105900644.html?.tsrc=rss,"Exelixis, Inc. today announced that the U.S. Food and Drug Administration has determined the company’s supplemental New Drug Application for CABOMETYX® for patients with previously untreated advanced renal cell carcinoma to be sufficiently complete to permit a substantive review."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma,2017-10-16 10:58:00 +0000,https://finance.yahoo.com/news/exelixis-phase-3-celestial-trial-105800536.html?.tsrc=rss,"Exelixis, Inc. today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival , with cabozantinib providing a statistically significant and clinically meaningful improvement in median OS compared to placebo in patients with advanced hepatocellular carcinoma ."
EXEL,EXEL:UW,BBG000BQ56F4,Major Averages Reach New Record Intraday Highs - U.S. Commentary,2017-10-16 10:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/URoEgUPi3GM/major-averages-reach-new-record-intraday-highs--us-commentary-20171016-00869,Major Averages Reach New Record Intraday Highs - U.S. Commentary
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Inc. (EXEL) Has Broken Out To A New High On FDA Priority Review,2017-10-16 09:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rONssE921VI/exelixis-inc-exel-has-broken-out-to-a-new-high-on-fda-priority-review-20171016-00800,Exelixis Inc. (EXEL) Has Broken Out To A New High On FDA Priority Review
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis' Cabozantinib: Trial In HCC Meets Main Goal; FDA Priority Review In RCC,2017-10-16 08:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DoUtxFYwMjo/exelixis-cabozantinib-trial-in-hcc-meets-main-goal-fda-priority-review-in-rcc-20171016-00577,Exelixis' Cabozantinib: Trial In HCC Meets Main Goal; FDA Priority Review In RCC
EXEL,EXEL:UW,BBG000BQ56F4,Ipsen : Phase 3 CELESTIAL Trial Of Cabozantinib Meets Primary Endpoint In HCC,2017-10-16 07:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pJB-o_atELc/ipsen--phase-3-celestial-trial-of-cabozantinib-meets-primary-endpoint-in-hcc-20171016-00414,Ipsen : Phase 3 CELESTIAL Trial Of Cabozantinib Meets Primary Endpoint In HCC
EXEL,EXEL:UW,BBG000BQ56F4,"Rhenman & Partners Asset Management AB Buys Arena Pharmaceuticals Inc, Vertex ...",2017-10-14 19:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dI2fm6sZbJ4/rhenman-partners-asset-management-ab-buys-arena-pharmaceuticals-inc-vertex-cm859858,Rhenman Partners Asset Management AB New Purchases ARNA BSX LOXO MYOK JUNO NVO DERM RARX NLNK AGIO Added Positions VRTX ADMS PTLA GKOS AGN HZNP ABMD ESRX ITCI ANTM Reduced Positions PFE NVCR GILD BIIB HCA LLY MRK INCY
EXEL,EXEL:UW,BBG000BQ56F4,Top 5 Biotech Stocks for 2017,2017-10-12 18:35:00 +0000,http://finance.yahoo.com/r/26ddb200-f2e8-37d5-8acd-b9613f65a9c4/biotech-stocks?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Biotech can be risky, but these top biotech stocks have stable track records."
EXEL,EXEL:UW,BBG000BQ56F4,"ETFs with exposure to Exelixis, Inc. : October 9, 2017",2017-10-09 15:30:59 +0000,http://finance.yahoo.com/r/101f76b8-9cb4-39ac-a0bd-62b17cd9fbd7/etfs-with-exposure-to-exelixis-inc-october-9-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Exelixis, Inc. Here are 5 ETFs with the largest exposure to EXEL-US. Comparing the performance and risk of Exelixis, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,See what the IHS Markit Score report has to say about Exelixis Inc.,2017-10-09 12:04:35 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120435559.html?.tsrc=rss,Exelixis Inc NASDAQ/NGS:EXEL
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. :EXEL-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017",2017-10-06 13:11:46 +0000,http://finance.yahoo.com/r/cdaea3b4-e4fc-3f72-a763-4e3f326a26f9/exelixis-inc-exel-us-earnings-analysis-q2-2017-by-the-numbers-october-6-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Exelixis, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 99.01 million, Net Earnings of USD 17.60 million. Gross margins widened from 95.70% to 96.96% compared to the same period last year, operating (EBITDA) margins now 28.40% from -53.21%. Change in operating cash ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,"New Research: Key Drivers of Growth for Bed Bath and Beyond, The Finish Line, Exelixis, Garmin, Juno Therapeutics, and Mattel - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production",2017-10-06 12:15:00 +0000,https://finance.yahoo.com/news/research-key-drivers-growth-bed-121500435.html?.tsrc=rss,"NEW YORK, Oct. 06, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Bed ..."
EXEL,EXEL:UW,BBG000BQ56F4,"The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September",2017-10-05 15:48:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7FpgaUqxtks/the-2-surprising-reasons-exelixis-inc-lost-17-in-september-cm855703,What happened Shares of Exelixis NASDAQ EXEL a biotech company focused on the development of therapies to treat cancer plunged 17 during the month of September according to data from S amp P Global Market Intelligence Two factors including new clinical data from
EXEL,EXEL:UW,BBG000BQ56F4,"The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September",2017-10-05 14:37:00 +0000,http://finance.yahoo.com/r/c97280b3-dbf2-39de-876a-9072bf6b6b31/the-2-surprising-reasons-exelixis-inc-lost-17-in-s.aspx?yptr=yahoo&.tsrc=rss,"Despite a poor showing last month, the outlook for Exelixis&apos; lead drug remains positive."
EXEL,EXEL:UW,BBG000BQ56F4,Could Cabometyx Be Exelixis’s Long-Term Growth Driver?,2017-10-05 11:42:02 +0000,http://finance.yahoo.com/r/545a3bb8-4184-3e3e-91c2-c3130fcca429/could-cabometyx-be-exelixiss-long-term-growth-driver?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In August 2017, Exelixis (EXEL) submitted an sNDA to the FDA for Cabometyx as a treatment for previously untreated individuals with advanced renal cell carcinoma."
EXEL,EXEL:UW,BBG000BQ56F4,How Is Cabometyx and Cometriq Positioned after 1H17?,2017-10-04 21:35:56 +0000,http://finance.yahoo.com/r/051a4125-b6bf-3497-a2f9-dd65afab7b3a/how-is-cabometyx-and-cometriq-positioned-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Exelixis’s (EXEL) Cabometyx generated revenues of ~$80.9 million compared to ~$17.6 million in 2Q16."
EXEL,EXEL:UW,BBG000BQ56F4,Why These Biotechs Are Leading The Group Near A 21-Month High,2017-10-04 20:47:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tK5nDHbzrYg/why-these-biotechs-are-leading-the-group-near-a-21-month-high-cm855432,Biotech stocks narrowed in on a 21 month high Wednesday with big rises coming from the likes of Intercept Pharmaceuticals ICPT Amicus Therapeutics FOLD and Exelixis EXEL on positive drug and partnership news ibd display video id 2326965 width
EXEL,EXEL:UW,BBG000BQ56F4,Why These Biotechs Are Leading The Group Near A 21-Month High,2017-10-04 20:43:47 +0000,http://finance.yahoo.com/r/cc618335-cdcd-3443-8e65-2dd940e1ab7c/why-these-biotechs-are-leading-the-group-near-a-21-month-high?src=A00220&yptr=yahoo&.tsrc=rss,"Biotech stocks narrowed in on a 21-month high Wednesday with big rises coming from the likes of Intercept, Amicus and Exelixis on positive drug and partnership news."
EXEL,EXEL:UW,BBG000BQ56F4,How Did Exelixis Perform in 1H17?,2017-10-04 20:06:55 +0000,http://finance.yahoo.com/r/0418ecb8-8df5-3e1a-9d4f-ecf4d1ab1ff5/how-did-exelixis-perform-in-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Exelixis (EXEL) generated revenues of ~$99.0 million compared to ~$36.3 million in 2Q16."
EXEL,EXEL:UW,BBG000BQ56F4,Analyst Recommendations for Exelixis in October 2017,2017-10-04 18:11:50 +0000,http://finance.yahoo.com/r/7684181c-a32f-3c53-a398-5c8aa6b811e6/analysts-recommendations-exelixis-october-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Ten analysts were covering Exelixis in October 2017. One analyst suggested a “strong buy,” and five analysts suggested a “buy” rating."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical Trial Authorization for RORγt Inverse Agonist Program,2017-10-04 12:00:00 +0000,https://finance.yahoo.com/news/exelixis-receive-milestone-payment-bristol-120000232.html?.tsrc=rss,"Exelixis, Inc. today announced that it has earned a $10 million milestone payment from Bristol-Myers Squibb under the terms of the two companies’ worldwide collaboration for compounds targeting retinoic acid-related orphan receptor , a family of nuclear hormone receptors implicated in inflammatory conditions."
EXEL,EXEL:UW,BBG000BQ56F4,3 Beaten-Down Biotech Stocks to Buy Right Now,2017-10-02 19:47:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4A0Q-MhnbSY/3-beaten-down-biotech-stocks-to-buy-right-now-cm854165,Biotech stocks that crater on negative clinical results or unfavorable regulatory developments can sometimes represent outstanding investing opportunities Not all beaten down biotech stocks though are diamonds in the rough Among the 15 biotech companies that saw their shares slide
EXEL,EXEL:UW,BBG000BQ56F4,3 Beaten-Down Biotech Stocks to Buy Right Now,2017-10-02 18:00:00 +0000,http://finance.yahoo.com/r/3244bc14-3f9f-3527-9131-4b08c8b8533b/3-beaten-down-biotech-stocks-to-buy-right-now.aspx?yptr=yahoo&.tsrc=rss,"Intercept Pharmaceuticals, Exelixis, and Sage Therapeutics got pummeled in the markets last month. Each drugmaker has a solid shot at rebounding."
EXEL,EXEL:UW,BBG000BQ56F4,See what the IHS Markit Score report has to say about Exelixis Inc.,2017-10-02 12:02:52 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120252098.html?.tsrc=rss,Exelixis Inc NASDAQ/NGS:EXEL
EXEL,EXEL:UW,BBG000BQ56F4,"Better Buy: Exelixis, Inc. vs. Immunogen, Inc.",2017-09-30 16:34:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nunALW1ECZM/better-buy-exelixis-inc-vs-immunogen-inc-cm853454,It s been a really good year for Exelixis NASDAQ EXEL The biotech s share price has jumped more than 60 so far in 2017 thanks to continued momentum for its kidney cancer drug Cabometyx But it s been a really great year for Immunogen NASDAQ IMGN The stock has
EXEL,EXEL:UW,BBG000BQ56F4,"Better Buy: Exelixis, Inc. vs. Immunogen, Inc.",2017-09-30 14:47:00 +0000,http://finance.yahoo.com/r/2885c8c2-1e27-3c1a-92b5-f819de1cbb89/better-buy-exelixis-inc-vs-immunogen-inc.aspx?yptr=yahoo&.tsrc=rss,Two hot biotech stocks with exciting cancer drugs. But which is the better pick in a head-to-head match-up?
EXEL,EXEL:UW,BBG000BQ56F4,"XBI, CLVS, EXEL, SRPT: Large Outflows Detected at ETF",2017-09-27 16:55:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jW-pUueK1X8/xbi-clvs-exel-srpt-large-outflows-detected-at-etf-cm851981,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 49 9 million dollar outflow that s a 1 2 decrease week over week from 48 950 000
EXEL,EXEL:UW,BBG000BQ56F4,3 Reasons to Buy the Dip With Exelixis,2017-09-26 13:54:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5e3WC7Biph0/3-reasons-to-buy-the-dip-with-exelixis-cm850884,In just two days Exelixis NASDAQ EXEL has lost over 15 of its market cap The tumble for the once hot biotech stock started last week with a downgrade of the stock by an analyst at Leerink Partners It wasn t over anything Exelixis did analyst Mike Schmidt said the biotech
EXEL,EXEL:UW,BBG000BQ56F4,Look Under The Hood: FXH Has 10% Upside,2017-09-26 12:51:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k4BzsjrrOVA/look-under-the-hood-fxh-has-10-upside-cm850902,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
EXEL,EXEL:UW,BBG000BQ56F4,3 Reasons to Buy the Dip With Exelixis,2017-09-26 12:18:00 +0000,http://finance.yahoo.com/r/931c2541-5c88-3007-b0a0-63833cbf8297/3-reasons-to-buy-the-dip-with-exelixis.aspx?yptr=yahoo&.tsrc=rss,Does the recent drop of Exelixis stock mean doom and gloom for the biotech? Not at all.
EXEL,EXEL:UW,BBG000BQ56F4,Relative Strength Alert For Exelixis,2017-09-25 17:48:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2-SMFjQE32w/relative-strength-alert-for-exelixis-cm850505,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
EXEL,EXEL:UW,BBG000BQ56F4,Today's Research Reports on Stocks to Watch: Exelixis and Versartis,2017-09-25 12:20:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-122000174.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / September 25, 2017 / Shares of Exelixis saw losses on Friday after a downgrade from Leerink Partners. The stock was also downgraded last month by Deutsche Bank. Shares of Versartis ..."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : September 25, 2017",2017-09-25 12:19:34 +0000,http://finance.yahoo.com/r/b3ddfca7-b0fa-3210-baf0-8a815a4696cf/exelixis-inc-breached-its-50-day-moving-average-in-a-bearish-manner-exel-us-september-25-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Exelixis, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis Provides Update on Collaborator Daiichi Sankyo’s Phase 3 Clinical Progress with Esaxerenone (CS-3150), Including Positive Top-Line Results and Additional Pivotal Study",2017-09-25 01:00:00 +0000,https://finance.yahoo.com/news/exelixis-provides-collaborator-daiichi-sankyo-010000794.html?.tsrc=rss,"Exelixis, Inc. today announced that its partner Daiichi Sankyo Company, Limited has reported positive top-line results from a phase 3 pivotal trial of esaxerenone , a product of the companies’ prior research collaboration, in patients with essential hypertension in Japan."
EXEL,EXEL:UW,BBG000BQ56F4,"Opdivo, Keytruda Back In The News, FDA Snubs AGN, EARS Catches Eyes",2017-09-24 22:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6nJFlMBC3uc/opdivo-keytruda-back-in-the-news-fda-snubs-agn-ears-catches-eyes-20170924-00100,"Opdivo, Keytruda Back In The News, FDA Snubs AGN, EARS Catches Eyes"
EXEL,EXEL:UW,BBG000BQ56F4,3 Monster Biotech Stocks in the Making,2017-09-24 14:47:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FyF3LstFq3A/3-monster-biotech-stocks-in-the-making-cm850149,Were the biggest biotechs in the world today always so big Of course not They all started out as much smaller companies Along the way each of today s big biotechs had a successful product that helped them launch yet another successful product They made a few acquisitions to drive
EXEL,EXEL:UW,BBG000BQ56F4,3 Monster Biotech Stocks in the Making,2017-09-24 13:09:00 +0000,http://finance.yahoo.com/r/a6e5ceb3-18b3-357a-8851-0cf528211cee/3-monster-biotech-stocks-in-the-making.aspx?yptr=yahoo&.tsrc=rss,They&apos;ve got successful drugs. They&apos;re profitable. All these biotechs need to become huge is a little luck and time.
EXEL,EXEL:UW,BBG000BQ56F4,"Why Exelixis, Inc. Slumped Today",2017-09-22 20:49:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ceBhZP8SWKI/why-exelixis-inc-slumped-today-cm849807,What happened Exelixis NASDAQ EXEL is down 12 3 at 2 18 p m EDT after an analyst at Leerink Partners downgraded 160 the biotech to market perform Management also sold some shares which could be contributing to the downward direction of the share price So what
EXEL,EXEL:UW,BBG000BQ56F4,"Why Exelixis, Inc. Slumped Today",2017-09-22 19:01:00 +0000,http://finance.yahoo.com/r/57a6ec78-f4a3-35ab-be11-bb49555941cc/why-exelixis-inc-slumped-today.aspx?yptr=yahoo&.tsrc=rss,Concerns over valuation have investors worried.
EXEL,EXEL:UW,BBG000BQ56F4,These 3 Stocks Are Priced for Perfection. Can They Deliver?,2017-09-22 11:37:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZVbgQ3BViVI/these-3-stocks-are-priced-for-perfection-can-they-deliver-cm849421,You expect a top ranked football team to play well every game You expect the Kentucky Derby winner to place in the Preakness Stakes And you expect a stock with a high valuation to generate strong sales and earnings growth every quarter Three healthcare stocks are especially priced
EXEL,EXEL:UW,BBG000BQ56F4,These 3 Stocks Are Priced for Perfection. Can They Deliver?,2017-09-22 10:08:00 +0000,http://finance.yahoo.com/r/5c61be05-6264-3950-ae71-23ad8556c012/these-3-stocks-are-priced-for-perfection-can-they.aspx?yptr=yahoo&.tsrc=rss,"Exelixis, Illumina, and Veeva Systems. Expensive, but worth it?"
EXEL,EXEL:UW,BBG000BQ56F4,Why Exelixis Wouldn't Be a Warren Buffett Stock,2017-09-20 11:35:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u2rY7wHJxyI/why-exelixis-wouldnt-be-a-warren-buffett-stock-cm848162,Warren Buffett is without question one of the greatest investors of all time His track record at Berkshire Hathaway NYSE BRK A NYSE BRK B and even before Berkshire proves it Exelixis NASDAQ EXEL is one of the greatest winners in the stock market in recent history
EXEL,EXEL:UW,BBG000BQ56F4,Why Exelixis Wouldn&apos;t Be a Warren Buffett Stock,2017-09-20 10:32:00 +0000,http://finance.yahoo.com/r/d21af59d-e9ff-37ac-bcb8-ca4fdcb03b6b/why-exelixis-wouldnt-be-a-warren-buffett-stock.aspx?yptr=yahoo&.tsrc=rss,Buffett and biotech mix like oil and water.
EXEL,EXEL:UW,BBG000BQ56F4,"[$$] Exelixis CEO, CFO Sell $11 Million in Stock",2017-09-20 09:37:00 +0000,http://finance.yahoo.com/r/ea8c19e3-8c37-32a1-8461-9a6b9af28d0e/exelixis-ceo-cfo-sell-11-million-in-stock-1505900236?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Exelixis is on a roll.  Exelixis (EXEL) was on the ropes only three years ago after its lead candidate, cabozantinib, failed in a Phase 3 trial to treat men with metastatic castration-resistant prostate cancer (mCRPC).  Exelixis reached a licensing pact with Ipsen (IPSEY) in 2016."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis to Present at the Cantor Fitzgerald Healthcare Conference on September 25,2017-09-19 20:05:00 +0000,https://finance.yahoo.com/news/exelixis-present-cantor-fitzgerald-healthcare-200500252.html?.tsrc=rss,"Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the Cantor Fitzgerald Healthcare Conference taking place September 25-27 in New York, NY."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Inc (EXEL) President and CEO Michael Morrissey Sold $8.1 million of Shares,2017-09-15 20:34:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ujo52t6iBwU/exelixis-inc-exel-president-and-ceo-michael-morrissey-sold-81-million-of-shares-cm846546,President and CEO of Exelixis Inc EXEL Michael Morrissey sold 300 000 shares of EXEL on 09 14 2017 at an average price of 26 9 a share The total sale was 8 1 million President and CEO of Exelixis Inc EXEL Michael Morrissey sold 300 000 shares of EXEL on 09 14 2017 at an average
EXEL,EXEL:UW,BBG000BQ56F4,"Why Amgen, Lilly, J&J Are Interested In These Small Biotechs",2017-09-15 17:18:04 +0000,http://finance.yahoo.com/r/bb7093cc-a209-3c81-b12b-373b56f01c80/why-amgen-lilly-jj-are-interested-in-these-small-biotechs?src=A00220&yptr=yahoo&.tsrc=rss,"Theravance and Exelixis tick off most of the acquisition boxes for Big Pharma, an analyst said Friday."
EXEL,EXEL:UW,BBG000BQ56F4,SPDR S&P Biotech ETF Experiences Big Outflow,2017-09-15 16:35:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gz3KhXTMUqg/spdr-sp-biotech-etf-experiences-big-outflow-cm846330,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 87 4 million dollar outflow that s a 2 1 decrease week over week from 49 600 000
EXEL,EXEL:UW,BBG000BQ56F4,Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis?,2017-09-15 11:37:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rdOxPWtmZx8/who-will-win-the-kidney-cancer-battle-between-bristol-myers-squibb-and-exelixis-cm846124,A head to head competition for market share in the renal cell carcinoma RCC market appears to be about to intensify In one corner is Bristol Myers Squibb NYSE BMY With a market cap of over 100 billion and a history dating back to 1887 the big pharma has a lot of muscle to
EXEL,EXEL:UW,BBG000BQ56F4,Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis?,2017-09-15 10:04:00 +0000,http://finance.yahoo.com/r/c5d8f8ee-4ea5-3c8a-b59b-0d3c3bf68279/who-will-win-the-kidney-cancer-battle-between-bris.aspx?yptr=yahoo&.tsrc=rss,The answer might surprise you.
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. – Value Analysis (NASDAQ:EXEL) : September 15, 2017",2017-09-15 00:21:12 +0000,http://finance.yahoo.com/r/c004258b-e33c-3b3f-9149-1d4bada17e9e/exelixis-inc-value-analysis-nasdaqexel-september-15-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Exelixis, Inc. a score of 75. Our analysis is based on comparing Exelixis, Inc. with the following peers – GlaxoSmithKline plc Sponsored ADR, Merck & Co., Inc., Sanofi Sponsored ADR, Bristol-Myers Squibb Company, Amgen Inc., ArQule, Inc., Pfizer Inc., Johnson & Johnson, Curis, Inc. and AVEO Pharmaceuticals, ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale",2017-09-14 20:35:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qfs_wrIDo2M/exelixis-inc-and-bristol-myers-squibb-co-gear-up-for-round-2-of-the-kidney-cancer-drug-battle-royale-cm845933,Take your seats investors The battle in first line advanced renal cell carcinoma the most common type of kidney cancer is about to begin In one corner weighing in at a market cap of 8 billion there s Exelixis NASDAQ EXEL and its tyrosine 160 kinase inhibitor
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale",2017-09-14 19:19:00 +0000,http://finance.yahoo.com/r/ef330264-d576-3c33-8519-fc4154094353/exelixis-inc-and-bristol-myers-squibb-co-gear-up-f.aspx?yptr=yahoo&.tsrc=rss,"Ironically, round three could have the companies fighting on the same side."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : September 13, 2017",2017-09-13 13:44:15 +0000,http://finance.yahoo.com/r/c56bccce-3b4f-3c18-a9a5-0f68b109a236/exelixis-inc-breached-its-50-day-moving-average-in-a-bullish-manner-exel-us-september-13-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Exelixis, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,See what the IHS Markit Score report has to say about Exelixis Inc.,2017-09-11 14:10:52 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-141052973.html?.tsrc=rss,Exelixis Inc NASDAQ/NGS:EXEL
EXEL,EXEL:UW,BBG000BQ56F4,"New Hope For AZN's Old Drug, More About BMY's Opdivo, IMDZ On Watch",2017-09-11 00:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YSrwGw-FWiI/new-hope-for-azns-old-drug-more-about-bmys-opdivo-imdz-on-watch-20170911-00011,"New Hope For AZN's Old Drug, More About BMY's Opdivo, IMDZ On Watch"
EXEL,EXEL:UW,BBG000BQ56F4,"Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors",2017-09-10 12:50:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SW5oi9U9BBE/why-exelixis-inc-could-be-a-gold-mine-for-growth-investors-cm843374,Exelixis NASDAQ EXEL was one of the top biotech stocks of 2016 It s also one of the best biotech stocks so far this year However Exelixis shares have pulled back in recent days primarily due to Bristol Myers Squibb s NYSE BMY announcement that it was halting
EXEL,EXEL:UW,BBG000BQ56F4,"Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors",2017-09-10 11:17:00 +0000,http://finance.yahoo.com/r/a81358fa-ba57-38b1-b612-ed0a344b09d0/why-exelixis-inc-could-be-a-gold-mine-for-growth-i.aspx?yptr=yahoo&.tsrc=rss,Don&apos;t worry about competition from Bristol-Myers Squibb. Exelixis stock should still be a huge winner.
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017,2017-09-09 22:09:00 +0000,https://finance.yahoo.com/news/exelixis-ipsen-announce-results-phase-220900364.html?.tsrc=rss,"Exelixis, Inc. and Ipsen today announced updated results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium ."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Recovers From Bristol-Inspired Pitfall In Kidney Cancer,2017-09-08 19:22:42 +0000,http://finance.yahoo.com/r/11b37dc4-dd13-3797-a422-9138423f29e7/exelixis-recovers-from-bristol-inspired-pitfall-in-kidney-cancer?src=A00220&yptr=yahoo&.tsrc=rss,Exelixis recovered Friday from a pitfall earlier in the week on updated guidelines for kidney cancer treatment.
EXEL,EXEL:UW,BBG000BQ56F4,"2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August",2017-09-08 15:54:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VrMH7AIeGws/2-big-reasons-exelixis-inc-added-626-million-to-its-market-cap-in-august-cm842952,What happened Shares of Exelixis NASDAQ EXEL a biotech company primarily focused on developing drugs to treat cancer rallied more than 2 per share during the month of August according to data from S amp P Global Market Intelligence adding 626 million to
EXEL,EXEL:UW,BBG000BQ56F4,"2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August",2017-09-08 14:34:00 +0000,http://finance.yahoo.com/r/124805ac-4f3f-32c5-aa2d-c0f4b8ed8d4b/2-big-reasons-exelixis-inc-added-626-million-to-it.aspx?yptr=yahoo&.tsrc=rss,Cabometyx remains the key to a higher valuation.
EXEL,EXEL:UW,BBG000BQ56F4,See what the IHS Markit Score report has to say about Exelixis Inc.,2017-09-08 14:23:33 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-142333816.html?.tsrc=rss,Exelixis Inc NASDAQ/NGS:EXEL
EXEL,EXEL:UW,BBG000BQ56F4,Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock,2017-09-08 11:51:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zKuAyp3NiX0/good-news-for-opdivo-shows-why-you-shouldnt-give-up-on-bristol-myers-squibb-stock-cm842738,Bristol Myers Squibb NYSE BMY investors might have been just a bit worried on Wednesday After all the U S Food and Drug Administration FDA had just placed a partial clinical hold on three clinical trials for Opdivo in combination with other drugs in treating multiple
EXEL,EXEL:UW,BBG000BQ56F4,Good News for Opdivo Shows Why You Shouldn&apos;t Give Up on Bristol-Myers Squibb Stock,2017-09-08 10:08:00 +0000,http://finance.yahoo.com/r/5cb1860f-309b-3f80-aa0e-b0e87141fa74/good-news-for-opdivo-shows-why-you-shouldnt-give-u.aspx?yptr=yahoo&.tsrc=rss,An early halt to a late-stage study of Opdivo points to the potential for Bristol-Myers Squibb in the years ahead.
EXEL,EXEL:UW,BBG000BQ56F4,"NLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted",2017-09-07 22:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5UtajTIgaUI/nlnk-rallies-on-indoximod-data-vrna-breathes-easy-alny-jolted-20170907-01658,"NLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy,2017-09-07 12:16:00 +0000,https://finance.yahoo.com/news/exelixis-debuts-mission-driven-corporate-121600612.html?.tsrc=rss,"Exelixis, Inc. today introduced new corporate branding aligned with its mission, growth strategy and commitment to bring best-in-class oncology medicines to market that give patients and their families hope for the future."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress,2017-09-06 21:23:00 +0000,https://finance.yahoo.com/news/exelixis-co-host-investor-media-212300581.html?.tsrc=rss,"Exelixis, Inc. today announced that the company, along with its partner Ipsen, will host a live briefing event for investors and media to discuss data for cabozantinib presented at the European Society for Medical Oncology 2017 Congress."
EXEL,EXEL:UW,BBG000BQ56F4,"Notable ETF Inflow Detected - XBI, JUNO, EXEL, ACAD",2017-09-06 16:51:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YhXEKrFaXWo/notable-etf-inflow-detected-xbi-juno-exel-acad-cm841734,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 121 7 million dollar inflow that s a 3 0 increase week over week in outstanding
EXEL,EXEL:UW,BBG000BQ56F4,See what the IHS Markit Score report has to say about Exelixis Inc.,2017-09-02 12:09:50 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120950216.html?.tsrc=rss,Exelixis Inc NASDAQ/NGS:EXEL
EXEL,EXEL:UW,BBG000BQ56F4,Can Exelixis (EXEL) Run Higher on Strong Earnings Estimate Revisions?,2017-09-01 14:55:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZbAETkrUIX8/can-exelixis-exel-run-higher-on-strong-earnings-estimate-revisions-cm840197,Exelixis Inc EXEL is a biopharmaceutical company which could be an interesting play for investors That is because not only does the stock have decent short term momentum but it is seeing solid activity on the earnings estimate revision front as well These positive earnings
EXEL,EXEL:UW,BBG000BQ56F4,Can Exelixis (EXEL) Run Higher on Strong Earnings Estimate Revisions?,2017-09-01 12:47:12 +0000,https://finance.yahoo.com/news/exelixis-exel-run-higher-strong-124712516.html?.tsrc=rss,"Exelixis (EXEL) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well."
EXEL,EXEL:UW,BBG000BQ56F4,See what the IHS Markit Score report has to say about Exelixis Inc.,2017-09-01 12:03:27 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120327129.html?.tsrc=rss,Exelixis Inc NASDAQ/NGS:EXEL
EXEL,EXEL:UW,BBG000BQ56F4,"Today's Research Reports on Trending Tickers: Exelixis, Inc. and Incyte Corporation",2017-08-31 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000395.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 31, 2017 / U.S. markets were lifted higher Wednesday as stronger-than-expected economic data outweighed the recent rising geopolitical tensions. The Dow Jones Industrial ..."
EXEL,EXEL:UW,BBG000BQ56F4,"XBI, EXEL, ALXN, VRTX: ETF Inflow Alert",2017-08-30 16:52:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7J8CNknYz9I/xbi-exel-alxn-vrtx-etf-inflow-alert-cm839245,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 334 6 million dollar inflow that s a 9 1 increase week over week in outstanding
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13,2017-08-29 20:05:00 +0000,https://finance.yahoo.com/news/exelixis-present-morgan-stanley-global-200500935.html?.tsrc=rss,"Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the Morgan Stanley Global Healthcare Conference taking place September 11-13 in New York, NY."
EXEL,EXEL:UW,BBG000BQ56F4,Analyst Recommendations for Regeneron Pharmaceuticals in August,2017-08-29 17:59:04 +0000,http://finance.yahoo.com/r/222b1ea6-7dea-30e9-9848-77c730981f72/analyst-recommendations-for-regeneron-pharmaceuticals-in-august?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Twenty-five analysts were analyzing Regeneron Pharmaceuticals in August 2017. Seven of them recommended a “strong buy,” and five recommended a “buy.”"
EXEL,EXEL:UW,BBG000BQ56F4,Can Buying Exelixis Stock Still Make You Rich?,2017-08-27 20:48:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pSpoif0i4-k/can-buying-exelixis-stock-still-make-you-rich-cm837666,What were you doing on Friday Jan 2 2015 It s OK if you don t remember I certainly can t But there were some investors who did something on that date who probably recall it with a smile Anyone who bought shares of Exelixis NASDAQ EXEL at the beginning of 2015 and held on
EXEL,EXEL:UW,BBG000BQ56F4,Can Buying Exelixis Stock Still Make You Rich?,2017-08-27 19:04:00 +0000,http://finance.yahoo.com/r/99743af0-beda-3b65-83a4-c68d64345767/can-buying-exelixis-stock-still-make-you-rich.aspx?yptr=yahoo&.tsrc=rss,The potential for Cabometyx -- and the potential for an acquisition -- could drive Exelixis stock a lot higher.
EXEL,EXEL:UW,BBG000BQ56F4,4 of the Highest-Growth Stocks in Biotech Today,2017-08-24 16:39:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qgR39DTR7ek/4-of-the-highest-growth-stocks-in-biotech-today-cm836626,Investing in the biotech industry can be a risky business In most instances the deck is stacked against a company succeeding The vast majority of preclinical studies will fail to reach human trials and there s no guarantee that a compound in clinical trials will reach pharmacy
EXEL,EXEL:UW,BBG000BQ56F4,4 of the Highest-Growth Stocks in Biotech Today,2017-08-24 14:35:00 +0000,http://finance.yahoo.com/r/2c003ae5-c604-3e98-b01c-63fda8d763e8/4-of-the-highest-growth-stocks-in-biotech-today.aspx?yptr=yahoo&.tsrc=rss,"How does a compound annual growth rate of 50%, 60%, or 70% sound?"
EXEL,EXEL:UW,BBG000BQ56F4,See what the IHS Markit Score report has to say about Exelixis Inc.,2017-08-24 12:02:35 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120235694.html?.tsrc=rss,Exelixis Inc NASDAQ/NGS:EXEL
EXEL,EXEL:UW,BBG000BQ56F4,"Noteworthy ETF Inflows: XBI, EXEL, ALXN, VRTX",2017-08-22 16:40:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9eaHHlBLeXc/noteworthy-etf-inflows-xbi-exel-alxn-vrtx-cm835446,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 37 7 million dollar inflow that s a 1 1 increase week over week in outstanding
EXEL,EXEL:UW,BBG000BQ56F4,Surprising Analyst 12-Month Target For FXH,2017-08-21 14:41:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sw_pTDg4aIA/surprising-analyst-12-month-target-for-fxh-cm834587,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
EXEL,EXEL:UW,BBG000BQ56F4,Corporate News Blog - Exelixis Submits US Supplemental New Drug Application for CABOMETYX(R) for the Treatment of Previously Untreated Advanced Kidney Cancer,2017-08-18 11:40:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-exelixis-submits-114000306.html?.tsrc=rss,"Research Desk Line-up: Bio-Techne Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Exelixis, ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx,2017-08-17 23:38:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y9_Gf8HnLpY/exelixis-submits-snda-for-kidney-cancer-drug-cabometyx-cm833643,Exelixis Inc EXEL announced that it has completed the submission of a supplemental New Drug Application sNDA to the FDA for Cabometyx tablets for patients with previously untreated advanced renal cell carcinoma RCC The sNDA submission was based on positive results from phase II
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx,2017-08-17 21:59:09 +0000,https://finance.yahoo.com/news/exelixis-submits-snda-kidney-cancer-215909367.html?.tsrc=rss,"Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer."
EXEL,EXEL:UW,BBG000BQ56F4,Edited Transcript of EXEL earnings conference call or presentation 2-Aug-17 9:00pm GMT,2017-08-17 16:31:01 +0000,https://finance.yahoo.com/news/edited-transcript-exel-earnings-conference-051044057.html?.tsrc=rss,Q2 2017 Exelixis Inc Earnings Call
EXEL,EXEL:UW,BBG000BQ56F4,See what the IHS Markit Score report has to say about Exelixis Inc.,2017-08-17 12:03:36 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120336377.html?.tsrc=rss,Exelixis Inc NASDAQ/NGS:EXEL
EXEL,EXEL:UW,BBG000BQ56F4,Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis,2017-08-16 13:45:00 +0000,http://finance.yahoo.com/r/c215e62a-fbc5-34af-9d33-ce30a659cc34/biotech-movers-disappointment-for-bristol-myers-kidney-cancer-combo-boosts-exel.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.
EXEL,EXEL:UW,BBG000BQ56F4,Today's Research Reports on Trending Tickers: Exelixis Inc. and Sarepta Therapeutics Inc.,2017-08-16 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000861.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 16, 2017 / U.S. markets swung between gains and losses on Tuesday as disappointing earnings from major retailers were offset by positive U.S. retail sales data. The Dow ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (cabozantinib) for the Treatment of Previously Untreated Advanced Kidney Cancer,2017-08-16 11:00:00 +0000,https://finance.yahoo.com/news/exelixis-submits-u-supplemental-drug-110000246.html?.tsrc=rss,"Exelixis, Inc. today announced it has completed the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for CABOMETYX® tablets as a treatment for patients with previously untreated advanced renal cell carcinoma ."
EXEL,EXEL:UW,BBG000BQ56F4,Why Gilead Sciences Might Not Make an Oncology Acquisition,2017-08-15 21:37:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OrEq6-IqO44/why-gilead-sciences-might-not-make-an-oncology-acquisition-cm832462,Is Gilead Sciences NASDAQ GILD backing away from its plans to acquire a smaller biotech focusing on oncology That could be the case Gilead CEO John Milligan reportedly told 160 Leerink analyst Geoffrey Porges that the company 160 might end up doing nothing in oncology
EXEL,EXEL:UW,BBG000BQ56F4,Why Gilead Sciences Might Not Make an Oncology Acquisition,2017-08-15 20:22:00 +0000,http://finance.yahoo.com/r/7073c7dc-fc6b-3075-8dbd-f9d84ffe0986/why-gilead-sciences-might-not-make-an-oncology-acq.aspx?yptr=yahoo&.tsrc=rss,Gilead Sciences&apos; CEO hints that buying a biotech with an oncology focus might not happen. Here&apos;s what this could mean for the big biotech.
EXEL,EXEL:UW,BBG000BQ56F4,What Amgen’s Analysts Recommend in August 2017,2017-08-14 17:06:02 +0000,http://finance.yahoo.com/r/205360e6-56ec-32cf-96ab-0b70c70309cd/what-amgens-analysts-recommend-in-august-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”"
EXEL,EXEL:UW,BBG000BQ56F4,See what the IHS Markit Score report has to say about Exelixis Inc.,2017-08-14 12:03:02 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120302806.html?.tsrc=rss,"This could indicate that investors who seek to profit from falling equity prices are not currently targeting EXEL.  Over the last one-month, outflows of investor capital in ETFs holding EXEL totaled $697 million."
EXEL,EXEL:UW,BBG000BQ56F4,Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?,2017-08-13 19:34:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7QOdJOxSe7Y/why-has-2017-been-a-horrible-year-so-far-for-biotech-acquisitions-cm831433,How many big biotech acquisitions can you name that have occurred so far in 2017 Johnson amp Johnson NYSE JNJ spent 30 billion to buy Swiss biotech Actelion That s one Then there s well actually that s it J amp J s acquisition of Actelion is the only truly big
EXEL,EXEL:UW,BBG000BQ56F4,"XBI, EXEL, ALXN, CLVS: ETF Outflow Alert",2017-08-11 16:36:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hKewXWR9bgA/xbi-exel-alxn-clvs-etf-outflow-alert-cm830991,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 63 3 million dollar outflow that s a 1 8 decrease week over week from 46 500 000
EXEL,EXEL:UW,BBG000BQ56F4,"IHS Markit Score upgrades Exelixis Inc to 72 out of 100, despite ranking positively in only one IHS Markit category.",2017-08-11 12:02:51 +0000,https://finance.yahoo.com/news/ihs-markit-score-upgrades-exelixis-120251330.html?.tsrc=rss,"This could indicate that investors who seek to profit from falling equity prices are not currently targeting EXEL.  Over the last one-month, outflows of investor capital in ETFs holding EXEL totaled $323 million."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts",2017-08-09 16:36:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_t0ubY-u81o/exelixis-inc-continued-its-winning-ways-and-rose-10-in-july-thanks-to-these-3-catalysts-cm829504,What happened Shares of Exelixis NASDAQ EXEL a biotechnology company focused on the development of drugs to treat various types of cancer moved steadily higher by a cool 10 in July according to data from S amp P Global Market Intelligence A confluence of
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts",2017-08-09 15:18:00 +0000,http://finance.yahoo.com/r/6854002c-942f-3c13-8418-c2dfada2ab73/exelixis-inc-continued-its-winning-ways-and-rose-1.aspx?yptr=yahoo&.tsrc=rss,Can nothing slow down this biotech rocket?
EXEL,EXEL:UW,BBG000BQ56F4,"Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass",2017-08-04 22:59:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vqSM8N6U090/juno-therapeutics-juno-q2-loss-widens-revenues-surpass-cm827597,Juno Therapeutics Inc JUNO reported second quarter 2017 loss of 75 cents per share including stock based compensation expenses wider than both the Zacks Consensus Estimate of a loss of 74 cents and the year ago loss of 65 cents per share Juno s shares have significantly outperformed
EXEL,EXEL:UW,BBG000BQ56F4,"Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass",2017-08-04 20:35:08 +0000,https://finance.yahoo.com/news/juno-therapeutics-juno-q2-loss-203508633.html?.tsrc=rss,"Juno Therapeutics (JUNO) reports wider-than-expected loss but revenues beat estimates. However, revenue decreased year-over-year."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. Grows Revenue, Eyes Treating More Patients",2017-08-04 20:00:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q8IrOzACAYE/exelixis-inc-grows-revenue-eyes-treating-more-patients-cm827473,Sales of Exelixis NASDAQ EXEL kidney cancer drug Cabometyx continued to grow at a torrid pace in the second quarter allowing the company to post another profitable quarter Exelixis results The raw numbers
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. Grows Revenue, Eyes Treating More Patients",2017-08-04 18:50:00 +0000,http://finance.yahoo.com/r/e939a0cf-af98-3cb2-88c1-05847938d593/exelixis-inc-grows-revenue-eyes-treating-more-pati.aspx?yptr=yahoo&.tsrc=rss,"Cabometyx is still in hypergrowth, and approvals for additional indications could be here shortly."
EXEL,EXEL:UW,BBG000BQ56F4,"Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag",2017-08-04 16:04:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iT4OHxU526c/agenus-agen-q2-loss-narrower-than-expected-revenues-lag-cm827244,Agenus Inc AGEN incurred second quarter 2017 loss of 32 cents per share narrower than the Zacks Consensus Estimate of a loss of 36 cents and the year ago loss of 33 cents Revenues were 4 2 million and missed the Zacks Consensus Estimate of 6 million Also the top line was down from 6
EXEL,EXEL:UW,BBG000BQ56F4,"Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag",2017-08-04 14:12:02 +0000,https://finance.yahoo.com/news/agenus-agen-q2-loss-narrower-141202491.html?.tsrc=rss,"Agenus Inc. (AGEN) witnesses narrower-than-expected loss and also misses revenue estimates. However, the company is progressing well with the candidates in its pipeline in Q2."
EXEL,EXEL:UW,BBG000BQ56F4,AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2,2017-08-04 14:02:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qe8hjXiLxMY/amag-pharma-amag-incurs-narrower-than-expected-loss-in-q2-cm827195,AMAG Pharmaceuticals Inc AMAG witnessed loss of 40 cents per share in the second quarter of 2017 compared with loss of 2 cents in the year ago quarter The reported figure is narrower than the Zacks Consensus Estimate of a loss of 58 cents The company s quarterly revenues came in at 158
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales",2017-08-03 23:01:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4Edc4AFmYYQ/exelixis-exel-q2-earnings-sales-beat-on-cabometyx-sales-cm826925,Exelixis Inc EXEL reported impressive results for the second quarter on the back of increased Cabometyx sales The company posted second quarter 2017 earnings of 8 cents beating the Zacks Consensus Estimate of 3 cents Notably the company had reported a loss of 15 cents per share in
EXEL,EXEL:UW,BBG000BQ56F4,"Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates",2017-08-03 23:00:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UhsweFmr03E/conatus-cnat-q2-loss-narrows-yy-revenues-beat-estimates-cm826918,Conatus Pharmaceuticals Inc 160 CNAT reported second quarter 2017 loss of 19 cents per share wider than the Zacks Consensus Estimate of 11 cents However the loss was narrower than the year ago figure of 30 cents Conatus shares have underperformed the 160 industry so far this
EXEL,EXEL:UW,BBG000BQ56F4,3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance,2017-08-03 21:01:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/25XNDWK8t5s/3-reasons-to-still-buy-exelixis-stock-after-its-strong-q2-performance-cm826819,Any way you look at Exelixis NASDAQ EXEL just reported an impressive second quarter performance The biotech posted its second quarter of profitability with earnings topping Wall Street expectations Revenue for Cabometyx soared Exelixis even emerged from the period without
EXEL,EXEL:UW,BBG000BQ56F4,"Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates",2017-08-03 20:41:08 +0000,https://finance.yahoo.com/news/conatus-cnat-q2-loss-narrows-204108656.html?.tsrc=rss,"Conatus (CNAT) reports wider-than-expected loss in Q2. However, revenue beat estimates, courtesy higher collaboration benefits."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales",2017-08-03 20:21:08 +0000,https://finance.yahoo.com/news/exelixis-exel-q2-earnings-sales-202108127.html?.tsrc=rss,Exelixis&apos; (EXEL) second-quarter results were impressive where in both earnings and sales beat estimates driven by strong uptake of Cabometyx.
EXEL,EXEL:UW,BBG000BQ56F4,3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance,2017-08-03 19:41:00 +0000,http://finance.yahoo.com/r/e4559d84-0899-354b-9ba1-1b523ca73dd8/3-reasons-to-still-buy-exelixis-stock-after-its-bl.aspx?yptr=yahoo&.tsrc=rss,"Another quarter, another great performance from Exelixis. Here&apos;s why the hot biotech stock remains a smart pick."
EXEL,EXEL:UW,BBG000BQ56F4,The Risk/Reward Potential For Exelixis Has Balanced As Catalysts Loom,2017-08-03 18:41:18 +0000,https://finance.yahoo.com/news/risk-reward-potential-exelixis-balanced-184118298.html?.tsrc=rss,"Deutsche Bank analyst Andrew Peters downgraded shares of Exelixis, Inc (NASDAQ: EXEL ) on Thursday, while raising his price target from $26 to $29. The company had been Deutsche Bank’s top pick since initiating ..."
EXEL,EXEL:UW,BBG000BQ56F4,"Dynavax Technologies Corporation (DVAX) Has the Market Buzzing with Heplisav Approval at the Finish Line, Exelixis, Inc. (EXEL) Refractory RCC Drug Going Strong in its Launch",2017-08-03 15:33:59 +0000,https://finance.yahoo.com/news/dynavax-technologies-corporation-dvax-market-153359389.html?.tsrc=rss,"Cowen analyst Phil Nadeau has been awaiting Heplisav's ""torturous FDA review"" for five years, two Complete Response Letters, two VRBPAC meetings coupled with one that never saw the light of day- and he for one is enthusiastic for the good prospects for this HBV vaccine's approval.  As such, the analyst reiterates an Outperform rating on shares of DVAX with a $30 price target, which represents a 79% increase from where the stock is currently trading."
EXEL,EXEL:UW,BBG000BQ56F4,"Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss",2017-08-03 13:03:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y-cfKrDS4Wc/pacira-pcrx-q2-loss-wider-than-expected-revenues-miss-cm826305,Pacira Pharmaceuticals Inc PCRX incurred second quarter 2017 loss of 29 cents per share including the impact of stock based compensation wider than the Zacks Consensus Estimate loss of 28 cents and the year ago loss of 2 cents Higher costs and soft revenues hurt earnings in the
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis tops Street 2Q forecasts,2017-08-03 05:07:48 +0000,https://finance.yahoo.com/news/exelixis-tops-street-2q-forecasts-030443311.html?.tsrc=rss,"On a per-share basis, the South San Francisco, California-based company said it had net income of 6 cents. Earnings, adjusted to extinguish debt, were 8 cents per share. The results surpassed Wall Street ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update,2017-08-02 20:05:00 +0000,https://finance.yahoo.com/news/exelixis-announces-second-quarter-2017-200500274.html?.tsrc=rss,"Exelixis, Inc. today reported financial results for the second quarter of 2017 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones."
EXEL,EXEL:UW,BBG000BQ56F4,"Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised",2017-08-02 17:00:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Li-Pjlf1kMM/corcept-cort-q2-earnings-beat-estimates-guidance-raised-cm825879,Corcept Therapeutics Incorporated s CORT adjusted second quarter 2017 earnings including stock based compensation expense of 10 cents per share surpassed the Zacks Consensus Estimate of 8 cents 160 The reported figure also topped the year ago adjusted earnings of 1 cent Revenues
EXEL,EXEL:UW,BBG000BQ56F4,"Investor Network: Exelixis, Inc. to Host Earnings Call",2017-08-02 16:20:00 +0000,https://finance.yahoo.com/news/investor-network-exelixis-inc-host-162000734.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 2, 2017 / Exelixis, Inc. (NASDAQ: EXEL ) will be discussing their earnings results in their Q2 Earnings Call to be held on Wednesday, August 2, 2017 at 5:00 PM Eastern ..."
EXEL,EXEL:UW,BBG000BQ56F4,"Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised",2017-08-02 14:24:02 +0000,https://finance.yahoo.com/news/corcept-cort-q2-earnings-beat-142402572.html?.tsrc=rss,Corcept Therapeutics Incorporated&apos;s (CORT) top line was driven by the strong sales of its only market drug Korlym. Thus the company raised its 2017 revenue guidance.
EXEL,EXEL:UW,BBG000BQ56F4,Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2,2017-08-01 16:59:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d2BWA3c-znY/intercept-icpt-posts-narrower-than-expected-loss-in-q2-cm825073,Intercept Pharmaceuticals Inc ICPT reported a loss of 3 46 per share in the second quarter of 2017 narrower than the Zacks Consensus Estimate of a loss of 3 62 but wider than the year ago loss of 3 14 Quarterly revenues were 30 9 million up significantly from 5 5 million in
EXEL,EXEL:UW,BBG000BQ56F4,Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2,2017-08-01 14:46:02 +0000,https://finance.yahoo.com/news/intercept-icpt-posts-narrower-expected-144602471.html?.tsrc=rss,Intercept Pharmaceuticals (ICPT) reported a narrower-than-expected loss in Q2 on the back of higher Ocaliva sales.
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 Congress,2017-08-01 12:00:00 +0000,https://finance.yahoo.com/news/exelixis-discovered-compounds-featured-10-120000452.html?.tsrc=rss,"Exelixis, Inc. today announced that data from clinical trials of cabozantinib and cobimetinib will be the subject of 10 presentations at the European Society for Medical Oncology 2017 Congress in Madrid, September 8 – 12, 2017."
EXEL,EXEL:UW,BBG000BQ56F4,"ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up",2017-07-31 19:54:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FKww86w8HQI/immunogen-imgn-q2-loss-narrows-sales-cash-outlook-up-cm824468,ImmunoGen Inc IMGN reported a loss of 10 cents per share in the second quarter of 2017 narrower than both the Zacks Consensus Estimate of 14 cents and the year ago loss of 53 cents We note that effective from Jan 1 2017 ImmunoGen has transitioned to a fiscal year ending Dec 31 ImmunoGen
EXEL,EXEL:UW,BBG000BQ56F4,"ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up",2017-07-31 17:56:05 +0000,https://finance.yahoo.com/news/immunogen-imgn-q2-loss-narrows-175605814.html?.tsrc=rss,ImmunoGen&apos;s (IMGN) Q2 results report a narrower-than-expected loss with revenue beating the estimates. The company also significantly raises the cash and revenue guidance this quarter.
EXEL,EXEL:UW,BBG000BQ56F4,"Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise",2017-07-31 16:57:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yQRyrwVVp8E/dr-reddys-rdy-earnings-decline-yy-in-q1-sales-rise-cm824338,Dr Reddy s Laboratories Ltd RDY reported first quarter fiscal 2018 earnings per American Depositary Share ADS of 6 cents down from 12 cents in the year ago quarter Revenues increased 2 4 year over year to 513 million Notably the company s share price declined 18 8 year to
EXEL,EXEL:UW,BBG000BQ56F4,"Commit To Buy Exelixis At $17, Earn 11.5% Using Options",2017-07-31 15:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4TUgVixMyEI/commit-to-buy-exelixis-at-17-earn-115-using-options-cm824331,Investors considering a purchase of Exelixis Inc Symbol EXEL stock but cautious about paying the going market price of 27 58 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the January
EXEL,EXEL:UW,BBG000BQ56F4,"Dr. Reddy&apos;s (RDY) Earnings Decline Y/Y in Q1, Sales Rise",2017-07-31 14:44:02 +0000,https://finance.yahoo.com/news/dr-reddy-apos-rdy-earnings-144402500.html?.tsrc=rss,Dr. Reddy&apos;s Laboratories Ltd.&apos;s (RDY) first-quarter fiscal 2018 earnings per American Depositary Share (ADS) declined year over year while sales increased from the year ago quarter.
EXEL,EXEL:UW,BBG000BQ56F4,"Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line",2017-07-28 18:33:06 +0000,https://finance.yahoo.com/news/acorda-acor-q2-earnings-miss-183306874.html?.tsrc=rss,"Acorda&apos;s (ACOR) dismal performance in Q2 significantly misses earnings expectations. However, the company&apos;s revenues met estimates on the back of strong Ampyra sales."
EXEL,EXEL:UW,BBG000BQ56F4,"Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat",2017-07-28 15:03:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TR_SPCvQ9n4/alkermes-alks-q2-loss-narrower-than-expected-sales-beat-cm823331,Alkermes plc ALKS incurred loss of 13 cents per share including the impact of share based compensation expense in the second quarter of 2017 narrower than the Zacks Consensus Estimate of a loss of 26 cents In fact the reported loss was wider than the year ago loss of 18 cents
EXEL,EXEL:UW,BBG000BQ56F4,"Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat",2017-07-28 15:03:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yZfaV_vHUNg/keryx-kerx-posts-wider-than-expected-loss-in-q2-sales-beat-cm823325,Keryx Biopharmaceuticals Inc KERX incurred second quarter 2017 loss of 21 cents per share narrower than the year ago loss of 42 cents However the loss was wider than the Zacks Consensus Estimate loss of 17 cents Revenues came in at 15 1 million in the quarter exceeding the Zacks
EXEL,EXEL:UW,BBG000BQ56F4,"Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View",2017-07-27 17:58:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EWmGOLf8H4g/celgene-celg-beats-q2-earnings-sales-estimates-ups-view-cm822690,Celgene Corporation CELG reported second quarter 2017 earnings of 1 68 per share including share based compensation expense and tax adjustments beating the Zacks Consensus Estimate of 1 61 and up from 1 28 per share in the year ago quarter Celgene s share price movement shows
EXEL,EXEL:UW,BBG000BQ56F4,"Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View",2017-07-27 17:03:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u18ba8GNAfo/alexion-alxn-tops-q2-earnings-revenues-ups-2017-view-cm822597,Alexion Pharmaceuticals Inc s ALXN posted second quarter 2017 adjusted earnings including after tax impact of stock based compensation expense of 1 31 per share higher than the year ago earnings of 93 cents as well as the Zacks Consensus Estimate of 1 08 Strong product revenues drove
EXEL,EXEL:UW,BBG000BQ56F4,"Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View",2017-07-27 16:04:04 +0000,https://finance.yahoo.com/news/celgene-celg-beats-q2-earnings-160404446.html?.tsrc=rss,Celgene Corporation (CELG) beat earnings and revenue estimates in the second quarter and upped view.
EXEL,EXEL:UW,BBG000BQ56F4,"GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance",2017-07-27 15:27:03 +0000,https://finance.yahoo.com/news/glaxosmithkline-gsk-beats-q2-earnings-152703657.html?.tsrc=rss,"Glaxo&apos;s (GSK) second-quarter earnings beat estimates, while revenues miss the same. The company cuts its core 2017 earnings growth at CER, with no Advair generics launched this year."
EXEL,EXEL:UW,BBG000BQ56F4,"Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up",2017-07-27 13:00:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IhX_01R-Ga0/gilead-gild-tops-q2-earnings-revenue-estimates-stock-up-cm822274,Gilead Sciences Inc s GILD reported results for the second quarter wherein both earnings and revenues surpassed expectations Second quarter 2017 earnings including the impact of stock based compensation expenses of 2 51 per share beat the Zacks Consensus Estimate of 2 11
EXEL,EXEL:UW,BBG000BQ56F4,"Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up",2017-07-27 12:00:12 +0000,https://finance.yahoo.com/news/gilead-gild-tops-q2-earnings-120012053.html?.tsrc=rss,Gilead Sciences&apos; (GILD) better-than-expected second-quarter results boosted investors sentiments.
EXEL,EXEL:UW,BBG000BQ56F4,"XBI, CLVS, EXEL, ALXN: ETF Outflow Alert",2017-07-26 15:57:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QwxLkjjKPJc/xbi-clvs-exel-alxn-etf-outflow-alert-cm821649,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 112 8 million dollar outflow that s a 2 8 decrease week over week from 50 050 000
EXEL,EXEL:UW,BBG000BQ56F4,Three biotech companies to watch ahead of earnings,2017-07-25 20:25:19 +0000,http://finance.yahoo.com/r/50754d51-b05d-3600-9e44-0edfe3eb0cd5/Story.aspx?guid=540543A8-7174-11E7-81F5-2E0BEB3FFDC0&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Harry Boxer focuses on Exelixis, ImmunoGen and Impax Laboratories."
EXEL,EXEL:UW,BBG000BQ56F4,What's in the Cards for Exelixis (EXEL) in Q2 Earnings?,2017-07-24 17:09:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tPDyd3kQAmk/whats-in-the-cards-for-exelixis-exel-in-q2-earnings-cm820318,Exelixis Inc EXEL is scheduled to report second quarter 2017 results on Aug 2 after the market closes Exelixis track record is outstanding The company has surpassed expectations in all the four trailing quarters with an average positive earnings surprise of 512 1
EXEL,EXEL:UW,BBG000BQ56F4,What&apos;s in the Cards for Exelixis (EXEL) in Q2 Earnings?,2017-07-24 14:44:02 +0000,https://finance.yahoo.com/news/apos-cards-exelixis-exel-q2-144402398.html?.tsrc=rss,"Exelixis, Inc.&apos;s (EXEL) efforts to develop its pipeline and uptake in Cabometyx sales should be the key areas of focus when the company reports second-quarter results."
EXEL,EXEL:UW,BBG000BQ56F4,2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't,2017-07-21 20:04:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IM7_-ts66fs/2-reasons-incyte-is-a-better-growth-stock-than-exelixis-and-1-reason-it-isnt-cm819529,Exelixis NASDAQ EXEL is without question one of the hottest biotech stocks on the market We re talking about a stock that has more than tripled in value in just the last 12 months and has soared over 70 so far this year Exelixis is simply put a fantastic growth stock But
EXEL,EXEL:UW,BBG000BQ56F4,2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn&apos;t,2017-07-21 18:42:00 +0000,http://finance.yahoo.com/r/9efdd973-40b9-31c0-b41e-1203bf4ca5a9/2-reasons-incyte-is-a-better-growth-stock-than-exe.aspx?yptr=yahoo&.tsrc=rss,Which is the better growth stock going forward -- Exelixis or Incyte? It depends.
EXEL,EXEL:UW,BBG000BQ56F4,"William Blair Bullish on Biotech: Sarepta Therapeutics Inc (SRPT), Dynavax Technologies Corporation (DVAX), and Exelixis, Inc. (EXEL)",2017-07-21 16:57:22 +0000,https://finance.yahoo.com/news/william-blair-bullish-biotech-sarepta-165722479.html?.tsrc=rss,"Sarepta Therapeutics Inc (NASDAQ:SRPT) Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) has outclassed expectation, leading the biotech firm to soar 20% yesterday in trading following a wow factor second-quarter earnings top-line performance.  While consensus had been angling for Sarepta's second full quarter of Exondys 51 to yield $22.5 million, the firm powered through with a 114% quarterly rise to a hefty $35 million, leading management to boost full year 2017 guidance now for the second time in a year, rising from ""exceeding 95 million"" to an even more bullish range of $125 million to $130 million.  William Blair analyst Tim Lugo highlights strong commercial trends that also led Sarepta to beat his own forecast of $20 million."
EXEL,EXEL:UW,BBG000BQ56F4,Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab,2017-07-20 22:19:10 +0000,https://finance.yahoo.com/news/emergent-inks-agreement-acquire-anthrax-221910214.html?.tsrc=rss,Emergent&apos;s shares inched up post announcement of its deal inked with GlaxoSmithKline to acquire the latter&apos;s anthrax monoclonal antibody raxibacumab.
EXEL,EXEL:UW,BBG000BQ56F4,"PGX, PTH: Big ETF Inflows",2017-07-20 17:06:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K5uuwuWW06Q/pgx-pth-big-etf-inflows-cm818805,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the PowerShares Preferred Portfolio PGX which added 4 500 000 units or a 1 3 increase week over week And on a percentage change basis the ETF with
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Settlement of Dispute with Genentech Regarding Companies’ Collaboration Agreement for Cobimetinib,2017-07-20 11:00:00 +0000,https://finance.yahoo.com/news/exelixis-announces-settlement-dispute-genentech-110000307.html?.tsrc=rss,"Exelixis, Inc. announced today a settlement of the company’s dispute with Genentech, a member of the Roche Group, concerning the parties’ collaboration for the development and commercialization of cobimetinib, which is marketed as COTELLIC®."
EXEL,EXEL:UW,BBG000BQ56F4,Vertex (VRTX) Triple Combination CF Studies Data Positive,2017-07-19 16:06:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i5oT8kavhNc/vertex-vrtx-triple-combination-cf-studies-data-positive-cm818097,Vertex Pharmaceuticals Incorporated VRTX announced data from three studies wherein three different triple combination regimens were evaluated for the treatment of cystic fibrosis CF These led to pronounced improvements in lung function Shares of the company surged more than 25 in after
EXEL,EXEL:UW,BBG000BQ56F4,Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt,2017-07-19 14:16:02 +0000,https://finance.yahoo.com/news/valeant-vrx-sell-obagi-190-141602222.html?.tsrc=rss,Valeant (VRX) has decided to sell Obagi Medical for $190 million and use the proceeds for reducing down debt.
EXEL,EXEL:UW,BBG000BQ56F4,Agenus (AGEN) Catches Eye: Stock Moves Up 8.7% in Session,2017-07-19 12:15:12 +0000,https://finance.yahoo.com/news/agenus-agen-catches-eye-stock-121512920.html?.tsrc=rss,"Agenus Inc. (AGEN) moved big last session, as its shares rose over 8% on the day."
EXEL,EXEL:UW,BBG000BQ56F4,Tuesday's ETF with Unusual Volume: PTH,2017-07-18 19:03:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h8d_PPDAzas/tuesdays-etf-with-unusual-volume-pth-cm817662,The PowerShares DWA Healthcare Momentum Portfolio ETF PTH is seeing unusually high volume in afternoon trading Tuesday with over 83 000 shares traded versus three month average volume of about 27 000 Shares of PTH were up about 0 2 on the day Components of that ETF with the
EXEL,EXEL:UW,BBG000BQ56F4,Cramer&apos;s lightning round: This business is better than people think,2017-07-17 22:49:49 +0000,https://finance.yahoo.com/news/cramer-apos-lightning-round-business-224949864.html?.tsrc=rss,"Jim Cramer rattles off his take on callers&apos; favorite stocks at lightning speed, including one popular coupon company."
EXEL,EXEL:UW,BBG000BQ56F4,Cramer's lightning round: This business is better than people think,2017-07-17 22:49:49 +0000,http://finance.yahoo.com/r/bf897c23-0610-3562-bf19-5f07d5d6415d/104590676?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104590676&yptr=yahoo&.tsrc=rss,"Jim Cramer rattles off his take on callers' favorite stocks at lightning speed, including one popular coupon company."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017",2017-07-17 20:05:00 +0000,https://finance.yahoo.com/news/exelixis-release-second-quarter-2017-200500804.html?.tsrc=rss,"Exelixis, Inc. announced today that its second quarter 2017 financial results will be released on Wednesday, August 2, 2017 after the markets close. At 5:00 p.m. EDT / 2:00 p.m."
EXEL,EXEL:UW,BBG000BQ56F4,Arena Announces Secondary Stock Worth $150M (revised),2017-07-17 19:11:07 +0000,https://finance.yahoo.com/news/arena-announces-secondary-stock-worth-191107891.html?.tsrc=rss,"Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions."
EXEL,EXEL:UW,BBG000BQ56F4,Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit,2017-07-17 18:48:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qRuWWnHB8JY/emergent-biosolutions-to-buy-sanofis-smallpox-vaccine-unit-cm817070,Emergent BioSolutions Inc EBS announced that it has inked an agreement to acquire the 160 FDA licensed smallpox vaccine s business of 160 Sanofi SNY in an all cash deal of up to 125 million 160 ACAM2000 is the only vaccine licensed by the FDA for active immunization against
EXEL,EXEL:UW,BBG000BQ56F4,Company Spotlight: Exelixis,2017-07-14 09:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gezjVTluDzI/company-spotlight-exelixis-20170714-00441,Company Spotlight: Exelixis
EXEL,EXEL:UW,BBG000BQ56F4,Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?,2017-07-13 22:11:10 +0000,https://finance.yahoo.com/news/why-shares-exelixis-exel-77-221110564.html?.tsrc=rss,"Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company&apos;s shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized industry during this period."
EXEL,EXEL:UW,BBG000BQ56F4,BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug,2017-07-13 22:03:10 +0000,https://finance.yahoo.com/news/biodelivery-purdue-pharma-ink-marketing-220310007.html?.tsrc=rss,"BioDelivery Sciences International, Inc. (BDSI) announced an exclusive partnership agreement with Purdue Pharma, a Canadian pharmaceutical company, for commercializing its pain drug Belbuca in Canada."
EXEL,EXEL:UW,BBG000BQ56F4,"XBI, CLVS, EXEL, ALXN: Large Inflows Detected at ETF",2017-07-13 16:51:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n377MjGb2Vs/xbi-clvs-exel-alxn-large-inflows-detected-at-etf-cm815708,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 196 6 million dollar inflow that s a 5 4 increase week over week in outstanding
EXEL,EXEL:UW,BBG000BQ56F4,Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform,2017-07-13 16:50:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YOfVEHaGDI8/endocyte-ecyt-to-focus-on-promising-car-t-cell-platform-cm815672,We issued an updated research report Endocyte Inc ECYT on Jul 12 In Jun 2017 Endocyte 160 announced plans to reduce its workforce by about 40 in order to divert more of its resources toward valuable opportunities The company also looks forward to shift its focus on its most
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Reaches Analyst Target Price,2017-07-13 14:47:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j36YFC049MI/exelixis-reaches-analyst-target-price-cm815480,In recent trading shares of Exelixis Inc Symbol EXEL have crossed above the average analyst 12 month target price of 26 60 changing hands for 26 61 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation or re
EXEL,EXEL:UW,BBG000BQ56F4,Why Exelixis (EXEL) Could Be an Impressive Growth Stock,2017-07-13 12:50:12 +0000,https://finance.yahoo.com/news/why-exelixis-exel-could-impressive-125012787.html?.tsrc=rss,"Exelixis (EXEL) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank."
EXEL,EXEL:UW,BBG000BQ56F4,Arena Announces Secondary Stock Offering of 150M Shares,2017-07-12 14:13:02 +0000,https://finance.yahoo.com/news/arena-announces-secondary-stock-offering-141302964.html?.tsrc=rss,"Arena Pharmaceuticals, Inc. (ARNA) plans to offer and sell 150 million shares of its common stock, subject to customary closing conditions."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx,2017-07-11 22:44:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1E9pc97kLoM/exelixis-bristol-myers-initiate-trial-on-opdivo-cabometyx-cm814746,Exelixis Inc EXEL and Bristol Myers Squibb Company BMY announced that they have initiated a phase III trial CheckMate 9ER The trial will evaluate Bristol Myers immuno oncology drug Opdivo in combination with Exelixis Cabometyx or Opdivo and Yervoy in combination with Cabometyx
EXEL,EXEL:UW,BBG000BQ56F4,Five Scorching Hot Stocks Screaming Higher,2017-07-11 21:08:09 +0000,https://finance.yahoo.com/news/five-scorching-hot-stocks-screaming-210809297.html?.tsrc=rss,Five Zacks Rank #1 (Strong Buy) stocks at 52-week highs pushing even higher
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx,2017-07-11 20:44:08 +0000,https://finance.yahoo.com/news/exelixis-bristol-myers-initiate-trial-204408859.html?.tsrc=rss,"Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC."
EXEL,EXEL:UW,BBG000BQ56F4,"Biotech Movers: Exelixis, Omeros, Inovio",2017-07-10 13:40:00 +0000,http://finance.yahoo.com/r/ba9434b8-c931-3009-8a70-8c18feb8909a/biotech-movers-exelixis-omeros-inovio.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Exelixis, Omeros and Inovio Pharmaceuticals were among the biotech movers in premarket trading on July 10."
EXEL,EXEL:UW,BBG000BQ56F4,Today's Research Reports on Stocks to Watch: RXi Pharmaceuticals Corporation and Exelixis Inc.,2017-07-10 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000496.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / July 10, 2017 / Rxi Pharmaceuticals sees unusual gains and trading volume on Friday despite any catalyst. The company is involved in a consumer/functional testing program with ..."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",2017-07-10 12:00:00 +0000,https://finance.yahoo.com/news/exelixis-bristol-myers-squibb-initiate-120000837.html?.tsrc=rss,"Exelixis, Inc. and Bristol-Myers Squibb Company today announced the initiation of the phase 3 CheckMate 9ER trial to evaluate Opdivo® in combination with CABOMETYX™ tablets, a small molecule inhibitor of receptor tyrosine kinases, or Opdivo and Yervoy® in combination with CABOMETYX versus sunitinib in patients with previously untreated, advanced or metastatic renal cell carcinoma ."
EXEL,EXEL:UW,BBG000BQ56F4,This Biotech Finds Its Stride With Kidney Cancer Treatment,2017-07-07 13:05:52 +0000,http://finance.yahoo.com/r/875d0337-e50c-3571-ad2c-fd75d996995c/exelixis-new-america?src=A00220&yptr=yahoo&.tsrc=rss,Improving fundamentals and market-share growth have transformed Exelixis from a development-stage firm to a commercially viable biotech.
EXEL,EXEL:UW,BBG000BQ56F4,"The Cabosun Shone on Exelixis in June, Sending Its Shares Up 32%",2017-07-07 12:24:00 +0000,http://finance.yahoo.com/r/53ce2538-b027-361a-bf1a-bfa4865a0f5a/the-cabosun-shone-on-exelixis-in-june-sending-its.aspx?yptr=yahoo&.tsrc=rss,Exelixis&apos; lead drug appears to have a good chance of having its label expanded by the FDA.
EXEL,EXEL:UW,BBG000BQ56F4,"After Hours Most Active for Jul 6, 2017 :  WY, PHM, OKE, MRK, QQQ, SRC, APC, TTWO, AAPL, ATVI, EXEL, CSCO",2017-07-06 21:03:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n3EvCCzzWdM/after-hours-most-active-for-jul-6-2017-wy-phm-oke-mrk-qqq-src-apc-ttwo-aapl-atvi-exel-csco-cm812736,The NASDAQ 100 After Hours Indicator is up 2 2 to 5 600 11 The total After hours volume is currently 45 039 379 shares traded The following are the most active stocks for the after hours session Weyerhaeuser Company WY is 0 437 at 32 50 with 6 226 942 shares
EXEL,EXEL:UW,BBG000BQ56F4,"These 6 Biotech, Drug Plays Are In Buy Range: Investing Action Plan",2017-07-05 20:12:28 +0000,http://finance.yahoo.com/r/71be4e45-6819-36e8-8405-b096d99fe3bb/these-6-biotech-drug-plays-are-in-buy-range-investing-action-plan?src=A00220&yptr=yahoo&.tsrc=rss,Here&apos;s your Investing Action Plan for Thursday: what you need to know as an investor for the coming day.
EXEL,EXEL:UW,BBG000BQ56F4,"Noteworthy ETF Outflows: XBI, CLVS, EXEL, ALXN",2017-07-05 16:45:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pDZmOw0HFkE/noteworthy-etf-outflows-xbi-clvs-exel-alxn-cm811897,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 155 9 million dollar outflow that s a 4 2 decrease week over week from 48 000 000
EXEL,EXEL:UW,BBG000BQ56F4,3 Mid-Cap Biotech Stocks That May Be Red-Hot Takeover Candidates,2017-07-05 15:44:00 +0000,http://finance.yahoo.com/r/6629dbc8-b315-367e-a80e-d74673c30b34/3-mid-cap-biotech-stocks-that-may-be-red-hot-takeo.aspx?yptr=yahoo&.tsrc=rss,"If Big Pharma is looking to boost its growth rate, these three biotech stocks would likely do just that."
EXEL,EXEL:UW,BBG000BQ56F4,"The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners",2017-07-05 13:30:01 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-malibu-133001166.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners"
EXEL,EXEL:UW,BBG000BQ56F4,"Top Analyst Reports for Disney, Charter Communications & Monsanto",2017-07-03 18:43:06 +0000,https://finance.yahoo.com/news/top-analyst-reports-disney-charter-184306122.html?.tsrc=rss,"Top Analyst Reports for Disney, Charter Communications & Monsanto"
EXEL,EXEL:UW,BBG000BQ56F4,Best Stocks For The Second Half of 2017,2017-07-03 15:43:03 +0000,https://finance.yahoo.com/news/best-stocks-second-half-2017-154303963.html?.tsrc=rss,Best Stocks For The Second Half of 2017
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis Repays Deerfield Notes One Year Ahead of Maturity Date, Addressing Last Major Source of Indebtedness",2017-06-29 12:00:00 +0000,https://finance.yahoo.com/news/exelixis-repays-deerfield-notes-one-120000392.html?.tsrc=rss,"Exelixis, Inc. today announced that it has addressed its last major source of indebtedness by retiring the Deerfield Notes, a series of Secured Convertible Notes originally issued in July 2010 to entities associated with Deerfield Management Company, L.P."
EXEL,EXEL:UW,BBG000BQ56F4,SPDR S&P Biotech ETF Experiences Big Inflow,2017-06-27 16:51:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MZr0g5PMcjY/spdr-sp-biotech-etf-experiences-big-inflow-cm808861,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 264 2 million dollar inflow that s a 7 4 increase week over week in outstanding
EXEL,EXEL:UW,BBG000BQ56F4,AVEO's Kidney Cancer Candidate Gets CHMP Recommendation,2017-06-27 14:54:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YreC2kI--0M/aveos-kidney-cancer-candidate-gets-chmp-recommendation-cm808839,AVEO Pharmaceuticals Inc AVEO announced on Friday that the Committee for Medicinal Products for Human Use CHMP has recommended the approval of its lead candidate Fotivda tivozanib for the treatment of advanced renal cell carcinoma RCC We note that the European Commission
EXEL,EXEL:UW,BBG000BQ56F4,Top Ranked Momentum Stocks to Buy for June 27th,2017-06-27 14:28:02 +0000,https://finance.yahoo.com/news/top-ranked-momentum-stocks-buy-142802703.html?.tsrc=rss,Top Ranked Momentum Stocks to Buy for June 27th
EXEL,EXEL:UW,BBG000BQ56F4,Cara Therapeutics (CARA) Shows Strength: Stock Adds 12.2 % in Session,2017-06-27 13:53:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1yEJ-kUxY00/cara-therapeutics-cara-shows-strength-stock-adds-122-in-session-cm808750,Cara Therapeutics Inc CARA was a big mover last session as the company saw its shares rise over 12 on the day The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend 160 for the company as the stock is now up 53
EXEL,EXEL:UW,BBG000BQ56F4,Today's Research Reports on Trending Tickers: Exelixis and Seattle Genetics,2017-06-27 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000524.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 27, 2017 / The Dow and S&P 500 eked out modest gains on Monday, despite a poor performance from the technology sector. The Dow Jones Industrial Average gained 0.07 percent ..."
EXEL,EXEL:UW,BBG000BQ56F4,Biotech Rally Gets Second Wind As This Small Cap Nears Breaks Out,2017-06-26 20:20:36 +0000,http://finance.yahoo.com/r/f7421e3a-05bc-371f-b95e-da9fdbb4f07a/biotech-rally-gets-second-wind-as-this-small-cap-nears-breaks-out?src=A00220&yptr=yahoo&.tsrc=rss,"Exelixis stock flirted with a breakout Monday, helping the biotech sector regain its speed on a seven-day running spree."
EXEL,EXEL:UW,BBG000BQ56F4,"Biotech Stock With 497% Growth, Positive Trial Results Nears Buy Zone",2017-06-26 20:17:13 +0000,http://finance.yahoo.com/r/e32db28c-ac13-3d88-a192-80537472c311/exelexis-biotech-stock-with-497-growth-positive-trial-results-nears-buy-zone-celgene-climbs?src=A00220&yptr=yahoo&.tsrc=rss,"With biotech stocks like Celgene, Bluebird Bio and Regeneron on the move, cancer treatment developer Exelixis may be poised to pop into a new buy zone."
EXEL,EXEL:UW,BBG000BQ56F4,This Drugmaker Flirts With Breakout As Some Biotechs Rally,2017-06-26 15:32:00 +0000,http://finance.yahoo.com/r/186f1955-c261-3214-9d21-ca4fe87d901a/this-drugmaker-flirts-with-breakout-as-some-biotechs-rally?src=A00220&yptr=yahoo&.tsrc=rss,"Exelixis flirted with a buy point Monday, finishing just below that level. But the relative strength line hit a new high."
EXEL,EXEL:UW,BBG000BQ56F4,The Reason for the Big Rise in Biotech Stocks,2017-06-26 10:00:00 +0000,http://finance.yahoo.com/r/bb87573d-590a-38db-a1ea-e99e069063d4/reason-big-rise-biotech-stocks?partner=YahooSA&yptr=yahoo&.tsrc=rss,Biotech shares have surged during the week of June 19.
EXEL,EXEL:UW,BBG000BQ56F4,These 3 Stocks Are Up Over 500% in the Last 3 Years,2017-06-25 15:50:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RLBeL88Fy7Q/these-3-stocks-are-up-over-500-in-the-last-3-years-cm807850,Image seeing your investment of 10 000 grow to more than 60 000 in just three years That would be awesome wouldn t it Investors who bought big enough stakes in three stocks in mid 2014 and held on don t have to imagine that scenario Eagle Pharmaceuticals NASDAQ
EXEL,EXEL:UW,BBG000BQ56F4,These 3 Stocks Are Up Over 500% in the Last 3 Years,2017-06-25 13:42:00 +0000,http://finance.yahoo.com/r/b3f0fdd1-6dcc-31fa-8deb-e538bed1cd6a/these-3-stocks-are-up-over-500-in-the-last-3-years.aspx?yptr=yahoo&.tsrc=rss,"How Eagle Pharmaceuticals, Exelixis, and NVIDIA stocks have made some investors rich."
EXEL,EXEL:UW,BBG000BQ56F4,"Better Buy: Exelixis, Inc. vs. Novartis AG",2017-06-24 11:49:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1OVrGan_6Y4/better-buy-exelixis-inc-vs-novartis-ag-cm807723,Several innovative new ways of fighting cancer are now either available or probably soon will be That s generating excitement in the oncology community and among investors Two companies that are front and center in the development of new treatments for cancer are Exelixis
EXEL,EXEL:UW,BBG000BQ56F4,"Better Buy: Exelixis, Inc. vs. Novartis AG",2017-06-24 10:42:00 +0000,http://finance.yahoo.com/r/39f1a352-5fbb-3dd1-a475-d97531d3d0a9/better-buy-exelixis-inc-vs-novartis.aspx?yptr=yahoo&.tsrc=rss,Is fast-rising Exelixis a better stock pick than huge drugmaker Novartis?
EXEL,EXEL:UW,BBG000BQ56F4,"After Hours Most Active for Jun 23, 2017 :  EXEL, EBAY, AVP, FNB, GRPN, BGCP, NRZ, CVS, MU, ESV, BMY, AAPL",2017-06-23 20:59:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BgumOuwTx-4/after-hours-most-active-for-jun-23-2017-exel-ebay-avp-fnb-grpn-bgcp-nrz-cvs-mu-esv-bmy-aapl-cm807652,The NASDAQ 100 After Hours Indicator is up 17 to 5 803 28 The total After hours volume is currently 712 465 360 shares traded The following are the most active stocks for the after hours session Exelixis Inc EXEL is 0 0047 at 23 78 with 16 395 951 shares traded
EXEL,EXEL:UW,BBG000BQ56F4,Roundtable: 1 Stock I Brag About Owning,2017-06-23 17:51:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vywjzvIPGv0/roundtable-1-stock-i-brag-about-owning-cm807540,Every investor has been that person at least once standing around the office water cooler or coffeepot bragging about the stock you tripled your investment on Whether you own something unique or bought a stock before it was a household name or just have an entertaining story
EXEL,EXEL:UW,BBG000BQ56F4,Roundtable: 1 Stock I Brag About Owning,2017-06-23 16:06:00 +0000,http://finance.yahoo.com/r/d456aa9f-f0f5-32ee-9019-494eeac5e285/roundtable-1-stock-i-brag-about-owning.aspx?yptr=yahoo&.tsrc=rss,Here are three stocks that our analysts enjoy saying &quot;I told you so&quot; about.
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. – Value Analysis (NASDAQ:EXEL) : June 22, 2017",2017-06-22 20:55:41 +0000,http://finance.yahoo.com/r/e5425c97-1659-3fde-94db-f470edb1b902/exelixis-inc-value-analysis-nasdaqexel-june-22-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Exelixis, Inc. a score of 50. Our analysis is based on comparing Exelixis, Inc. with the following peers – Sanofi Sponsored ADR, Merck & Co., Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Amgen Inc., Johnson & Johnson, ArQule, Inc., Pfizer Inc., AVEO Pharmaceuticals, Inc. and Curis, ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,"After Celgene, Regeneron Breakouts, This Biotech Stock May Be Next",2017-06-22 20:27:26 +0000,http://finance.yahoo.com/r/d0b07bb5-6147-3b54-bf95-33df8542698b/after-celgene-regeneron-breakouts-this-biotech-stock-may-be-next?src=A00220&yptr=yahoo&.tsrc=rss,"With biotech stocks like Celgene, Bluebird Bio and Regeneron on the move, cancer treatment developer Exelixis may be poised to pop into a new buy zone."
EXEL,EXEL:UW,BBG000BQ56F4,Biotech Exelixis May Break Out On Cancer Drug Trial Results,2017-06-22 06:50:00 +0000,http://finance.yahoo.com/r/30ce9fcb-6d91-307f-9567-d7f00e559bd3/biotech-exelixis-may-break-out-on-cancer-drug-trial-results?src=A00220&yptr=yahoo&.tsrc=rss,"With biotech stocks like Celgene, Bluebird Bio and Regeneron on the move, Exelixis may be poised to pop into a new buy zone."
EXEL,EXEL:UW,BBG000BQ56F4,"Noteworthy Wednesday Option Activity: ACIA, EXEL, ULTA",2017-06-21 21:21:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/siU0mX4w9-Q/noteworthy-wednesday-option-activity-acia-exel-ulta-cm806531,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Acacia Communications Inc Symbol ACIA where a total of 4 871 contracts have traded so far representing approximately 487 100 underlying shares That amounts to about 58 3 of ACIA
EXEL,EXEL:UW,BBG000BQ56F4,Two Bullish Biotech Stocks And A Very Bearish Looking Yelp,2017-06-21 18:58:00 +0000,http://finance.yahoo.com/r/a42dbe21-cbf0-3dd5-96b2-83bca69156c0/two-bullish-biotech-stocks-and-a-very-bearish-looking-yelp?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,Here are two stocks with strong upside technical momentum and two to watch for downside continuation.
EXEL,EXEL:UW,BBG000BQ56F4,2 Longs And 2 Shorts to Watch: June 21,2017-06-21 17:20:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IkUmy93eRZ4/2-longs-and-2-shorts-to-watch-june-21-cm806419,"By Harry Boxer,  TheTechTrader.com    ImmunoGen ( IMGN ) reached a high of $5.66 and then closed back at $5.42, up 10.4% on Tuesday. Price has risen 18% in two sessions after a Leerink analyst raised his price target to $11 from $8. On Tuesday the biotechnology stock traded on heavy volume of 6.7 million shares,"
EXEL,EXEL:UW,BBG000BQ56F4,Mid-Day Market Update: Red Hat Rises After Strong Q1 Results; CIRCOR Shares Slide,2017-06-21 17:09:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YW0y_T6gSMI/mid-day-market-update-red-hat-rises-after-strong-q1-results-circor-shares-slide-cm806404,Midway through trading Wednesday the Dow traded down 0 18 percent to 21 428 71 while the NASDAQ climbed 0 47 percent to 6 216 97 The S amp P also fell dropping 0 05 percent to 2 435 90 Leading and Lagging Sectors Healthcare shares rose by 0 78 percent in the US market
EXEL,EXEL:UW,BBG000BQ56F4,Mid-Morning Market Update: Markets Mostly Higher; CarMax Tops Q1 Expectations,2017-06-21 15:39:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wgBRFuT1nr4/mid-morning-market-update-markets-mostly-higher-carmax-tops-q1-expectations-cm806310,Following the market opening Wednesday the Dow traded down 0 04 percent to 21 458 28 while the NASDAQ climbed 0 38 percent to 6 211 72 The S amp P also rose gaining 0 06 percent to 2 438 52 Leading and Lagging Sectors Healthcare shares rose by 0 81 percent in the US market
EXEL,EXEL:UW,BBG000BQ56F4,AVEO Reaches Enrollment Target in Pivotal Tivozanib Study,2017-06-21 14:57:02 +0000,https://finance.yahoo.com/news/aveo-reaches-enrollment-target-pivotal-145702909.html?.tsrc=rss,"AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis's Cabometyx Positive for First-Line Kidney Cancer,2017-06-20 23:19:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hViLhjShXlw/exelixiss-cabometyx-positive-for-first-line-kidney-cancer-cm805981,Exelixis Inc EXEL announced results from an analysis of the data from the phase II trial CABOSUN The study compared Cabometyx to Pfizer s PFE Sutent in the first line treatment of intermediate or poor risk advanced renal cell carcinoma RCC patients We note that Cabometyx tablets
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis&apos;s Cabometyx Positive for First-Line Kidney Cancer,2017-06-20 21:35:09 +0000,https://finance.yahoo.com/news/exelixis-apos-cabometyx-positive-first-213509570.html?.tsrc=rss,"Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : June 20, 2017",2017-06-20 12:27:19 +0000,http://finance.yahoo.com/r/ca063e44-fc0b-3db8-876e-0a4b2d4015fa/exelixis-inc-breached-its-50-day-moving-average-in-a-bullish-manner-exel-us-june-20-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Exelixis, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,Today's Research Reports on Stocks to Watch: Exelixis and Westport Fuel Systems,2017-06-20 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000395.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 20, 2017 / Exelixis had some big news on Monday, announcing that an independent group of reviewers confirmed the company's own conclusion on a phase ii clinical trial of ..."
EXEL,EXEL:UW,BBG000BQ56F4,"AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade",2017-06-20 02:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mVef7veM52A/amgns-xgeva-to-face-fda-in-feb-double-treat-for-lpcn-sgen-drops-cascade-20170620-00069,"AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade"
EXEL,EXEL:UW,BBG000BQ56F4,"Why Exelixis, Inc. Zoomed Higher Today",2017-06-19 23:19:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qFiERU3TZHc/why-exelixis-inc-zoomed-higher-today-cm805394,What happened Exelixis NASDAQ EXEL ended the day up 12 after announcing 160 that the 160 blinded independent radiology review committee confirmed the progression free survival as measured by the investigators of the CABOSUN clinical trial So what CABOSUN was a phase
EXEL,EXEL:UW,BBG000BQ56F4,"Why Exelixis, Inc. Zoomed Higher Today",2017-06-19 21:21:00 +0000,http://finance.yahoo.com/r/da3a7824-eac6-3d59-a41c-eb13fc8ca2db/why-exelixis-inc-zoomed-higher-today.aspx?yptr=yahoo&.tsrc=rss,The CABOSUN data is real.
EXEL,EXEL:UW,BBG000BQ56F4,"Monday Sector Leaders: Medical Instruments & Supplies, Biotechnology Stocks",2017-06-19 18:19:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MzBGiuKih9Y/monday-sector-leaders-medical-instruments-supplies-biotechnology-stocks-cm805248,In trading on Monday medical instruments amp supplies shares were relative leaders up on the day by about 2 5 Leading the group were shares of Novadaq Technologies NVDQ up about 95 8 and shares of Transenterix TRXC up about 22 2 on the day Also showing relative
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis Announces Independent Radiology Committee Review Confirms Results from CABOSUN, the Phase 2 Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma",2017-06-19 12:00:00 +0000,https://finance.yahoo.com/news/exelixis-announces-independent-radiology-committee-120000930.html?.tsrc=rss,"Exelixis, Inc. announced today that the analysis of the review by a blinded independent radiology review committee has confirmed the primary efficacy endpoint results of investigator-assessed progression-free survival from the CABOSUN randomized phase 2 trial of cabozantinib as compared with sunitinib in patients with previously untreated advanced renal cell carcinoma with intermediate- or poor-risk ..."
EXEL,EXEL:UW,BBG000BQ56F4,"Key Takeaways From William Blair’s Annual Growth Stock Conference: Gilead Sciences, Inc. (GILD), Exelixis, Inc. (EXEL)",2017-06-14 13:34:05 +0000,https://finance.yahoo.com/news/key-takeaways-william-blair-annual-133405832.html?.tsrc=rss,"William Blair analyst John Sonnier is out highlighting standout insights from his 37th Annual Growth Stock Conference held yesterday. Gilead Sciences, Inc. (NASDAQ:GILD) and Exelixis, Inc. (NASDAQ:EXEL) revealed corporate updates regarding business proceedings and clinical development program progress that have the analyst rooting for GILD's HIV franchise and Exelixis' strong short and long-term commercial staying power.Before we start, as usual, we like to include the analyst’s trackrecord when reporting on new analyst notes. ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Initiates Cabozantinib-Tecentriq Combination Trial,2017-06-13 23:27:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/61L82vUyd4U/exelixis-initiates-cabozantinib-tecentriq-combination-trial-cm802995,Exelixis Inc EXEL announced that it initiated the dose escalation stage of a phase Ib trial of cabozantinib in combination with Roche s RHHBY Tecentriq The drug will be evaluated in patients suffering from locally advanced or metastatic urothelial carcinoma UC or renal cell carcinoma
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Initiates Cabozantinib-Tecentriq Combination Trial,2017-06-13 21:32:09 +0000,https://finance.yahoo.com/news/exelixis-initiates-cabozantinib-tecentriq-combination-213209427.html?.tsrc=rss,"Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche&apos;s (RHHBY) Tecentriq."
EXEL,EXEL:UW,BBG000BQ56F4,Today's Research Reports on Stocks to Watch: Exelixis and Opko Health,2017-06-13 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000099.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 13, 2017 / The Biotech Industry has continued to outperform the broader markets in 2017. Biotech companies appear to be benefitting from a speedier FDA approval process ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors,2017-06-12 12:05:00 +0000,https://finance.yahoo.com/news/exelixis-announces-initiation-phase-1b-120500628.html?.tsrc=rss,"Exelixis, Inc. today announced the initiation of the dose-escalation stage of a phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma or renal cell carcinoma ."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis to Present at the William Blair & Co. 37th Annual Growth Stock Conference on June 13,2017-06-08 20:05:00 +0000,https://finance.yahoo.com/news/exelixis-present-william-blair-co-200500489.html?.tsrc=rss,"Exelixis, Inc. today announced that management will present a corporate overview at the William Blair Growth Stock Conference taking place June 13-14 in Chicago, IL. The Exelixis presentation is scheduled for 12:30 PM EDT / 11:30 AM local Chicago time / 9:30 AM PDT on Tuesday, June 13, 2017."
EXEL,EXEL:UW,BBG000BQ56F4,"2 Reasons Exelixis, Inc. Shares Sank 16% in May",2017-06-06 14:03:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FThT8jp1ZsU/2-reasons-exelixis-inc-shares-sank-16-in-may-cm799192,What happened Shares of Exelixis NASDAQ EXEL a biotech company focused on the development of novel therapies to fight cancer plunged 16 in May according to data from S amp P Global Market Intelligence With little in the way of news last month the drop
EXEL,EXEL:UW,BBG000BQ56F4,"2 Reasons Exelixis, Inc. Shares Sank 16% in May",2017-06-06 12:09:00 +0000,http://finance.yahoo.com/r/36ca9858-c6c3-3d3c-9dff-507d3d50d978/2-reasons-exelixis-inc-shares-sank-16-in-may.aspx?yptr=yahoo&.tsrc=rss,Potentially fleeting short-term concerns weighed on Exelixis last month.
EXEL,EXEL:UW,BBG000BQ56F4,3 Stocks With Exelixis-Like Return Potential,2017-06-05 22:01:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9LhKNxX_KEw/3-stocks-with-exelixis-like-return-potential-cm799014,Over the past year Exelixis NASDAQ EXEL stock has more than doubled in value because of the successful commercial launch of advanced kidney cancer drug 160 Cabometyx Of course it wasn t that long ago that investors left this high flying cancer company for dead
EXEL,EXEL:UW,BBG000BQ56F4,3 Stocks With Exelixis-Like Return Potential,2017-06-05 20:29:00 +0000,http://finance.yahoo.com/r/4891d901-bd23-336c-bce4-0c73d92814a8/3-stocks-with-exelixis-like-return-potential.aspx?yptr=yahoo&.tsrc=rss,"Agenus, ImmunoGen, and Omeros Corporation could all produce explosive gains for risk-tolerant investors."
EXEL,EXEL:UW,BBG000BQ56F4,"Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data",2017-06-05 17:48:02 +0000,https://finance.yahoo.com/news/notes-asco-2017-tesaro-amgen-174802731.html?.tsrc=rss,The 2017 American Society of Clinical Oncology annual meeting is taking place in Chicago from last Friday through Tuesday. There have already been several companies that have updated shareholders with ...
EXEL,EXEL:UW,BBG000BQ56F4,Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU,2017-06-02 17:31:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ga407wuWx7s/pfizers-kidney-cancer-drug-gets-acceptance-in-the-us-eu-cm798076,Pfizer Inc PFE announced encouraging news with the FDA and the European Medicines Agency EMA accepting the company s regulatory submission for label expansion of its cancer drug Sutent sunitinib The company is looking to expand Sutent s label for adjuvant treatment of adult patients
EXEL,EXEL:UW,BBG000BQ56F4,Why Is Exelixis (EXEL) Down 20.9% Since the Last Earnings Report?,2017-06-01 15:36:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/egnNnT3et6w/why-is-exelixis-exel-down-209-since-the-last-earnings-report-cm797427,It has been about a month since the last earnings report for Exelixis Inc EXEL Shares have lost about 20 9 in that time frame underperforming the market Will the recent negative trend continue leading up to the stock s next earnings release or is it due for a breakout Before we
EXEL,EXEL:UW,BBG000BQ56F4,Why Is Exelixis (EXEL) Down 20.9% Since the Last Earnings Report?,2017-06-01 13:27:01 +0000,https://finance.yahoo.com/news/why-exelixis-exel-down-20-132701906.html?.tsrc=rss,Exelixis (EXEL) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
EXEL,EXEL:UW,BBG000BQ56F4,"ETFs with exposure to Exelixis, Inc. : May 26, 2017",2017-05-26 17:07:14 +0000,http://finance.yahoo.com/r/13e53a88-deb7-3ee2-b2ed-4d78a585653f/etfs-with-exposure-to-exelixis-inc-may-26-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Exelixis, Inc. Here are 5 ETFs with the largest exposure to EXEL-US. Comparing the performance and risk of Exelixis, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,"Biotech Movers: Immunomedics, Aerie, Exelixis",2017-05-26 13:33:00 +0000,http://finance.yahoo.com/r/d75e5b28-21b4-33f7-8a5f-053b56380e02/biotech-movers-immunomedics-aerie-exelixis.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Immunomedics, Aerie Pharmaceuticals and Exelixis were among the biotech movers in premarket trading on Friday."
EXEL,EXEL:UW,BBG000BQ56F4,3 Stocks That Tripled in a Single Year,2017-05-25 18:32:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vZogzpOqqT0/3-stocks-that-tripled-in-a-single-year-cm794729,The stock market has done extremely well since 2009 and major market benchmarks have more than tripled from their weakest levels during the financial crisis But for some individual stocks gains have come more quickly Emerge Energy Services NYSE EMES Weibo NASDAQ WB
EXEL,EXEL:UW,BBG000BQ56F4,3 Stocks That Tripled in a Single Year,2017-05-25 17:05:00 +0000,http://finance.yahoo.com/r/60e76c6f-764c-3ddc-99a0-84864d161319/3-stocks-that-tripled-in-a-single-year.aspx?yptr=yahoo&.tsrc=rss,Find out why these big winners have done so well and whether they can climb further.
EXEL,EXEL:UW,BBG000BQ56F4,Mid-Afternoon Market Update: Dow Climbs 150 Points; Foot Locker Shares Drop On Earnings Miss,2017-05-19 19:41:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HLFZpi54-W0/mid-afternoon-market-update-dow-climbs-150-points-foot-locker-shares-drop-on-earnings-miss-cm792108,Toward the end of trading Friday the Dow traded up 0 75 percent to 20 817 44 while the NASDAQ climbed 0 76 percent to 6 101 02 The S amp P also rose gaining 0 84 percent to 2 385 56 Leading and Lagging Sectors Basic materials sector was the top gainer in the US market on
EXEL,EXEL:UW,BBG000BQ56F4,Top 5 Biotech Stocks for 2017,2017-05-19 12:00:00 +0000,http://finance.yahoo.com/r/9faea74e-596a-3c50-9c59-fd8ba54d4ff6/biotech-stocks?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Biotech can be risky, but these top biotech stocks have stable track records."
EXEL,EXEL:UW,BBG000BQ56F4,Today's Research Reports on Biotech Stocks to Watch: Exelixis and Amicus Therapeutics,2017-05-18 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-biotech-stocks-120000509.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 18, 2017 / Despite the recent sell-off triggered by the recent health-care bill that is meant to take the place of the Affordable Care Act, the Biotech Industry has continued ..."
EXEL,EXEL:UW,BBG000BQ56F4,"ETFs with exposure to Exelixis, Inc. : May 15, 2017",2017-05-15 19:41:35 +0000,http://finance.yahoo.com/r/23d276b9-4bf1-3322-bffe-2904ad6d5f21/etfs-with-exposure-to-exelixis-inc-may-15-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Exelixis, Inc. Here are 5 ETFs with the largest exposure to EXEL-US. Comparing the performance and risk of Exelixis, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,Edited Transcript of EXEL earnings conference call or presentation 1-May-17 9:00pm GMT,2017-05-11 01:31:18 +0000,http://finance.yahoo.com/news/edited-transcript-exel-earnings-conference-020210134.html?.tsrc=rss,Q1 2017 Exelixis Inc Earnings Call
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : May 9, 2017",2017-05-09 12:59:08 +0000,http://finance.yahoo.com/r/9b0d07c0-5071-3852-ab15-a4fab5fc0212/exelixis-inc-breached-its-50-day-moving-average-in-a-bearish-manner-exel-us-may-9-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Exelixis, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,"ETFs with exposure to Exelixis, Inc. : May 4, 2017",2017-05-04 19:56:17 +0000,http://finance.yahoo.com/r/a2eb73c9-2cd8-3d0a-974d-deed37f111b5/etfs-with-exposure-to-exelixis-inc-may-4-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Exelixis, Inc. Here are 5 ETFs with the largest exposure to EXEL-US. Comparing the performance and risk of Exelixis, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,3 Biotech Stocks Projected to Grow Their EPS by at Least 415% in 2018,2017-05-04 15:59:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1TN0ZO4lncI/3-biotech-stocks-projected-to-grow-their-eps-by-at-least-415-in-2018-cm784149,There are few industries as hit and miss as biotech In many instances the deck is stacked against biotech companies succeeding Most discovery stage preclinical and clinical trials fail to meet the mark meaning most discoveries made in a lab won t make it to pharmacy shelves
EXEL,EXEL:UW,BBG000BQ56F4,3 Biotech Stocks Projected to Grow Their EPS by at Least 415% in 2018,2017-05-04 13:08:00 +0000,http://finance.yahoo.com/r/9834c0e0-afba-3c1e-98de-79778b2a945e/3-biotech-stocks-projected-to-grow-their-eps-by-at.aspx?yptr=yahoo&.tsrc=rss,You&apos;ll struggle to find quicker year-over-year earnings growth.
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2017-05-03 20:05:00 +0000,http://finance.yahoo.com/news/exelixis-reports-inducement-grants-under-200500393.html?.tsrc=rss,"Exelixis, Inc. announced that today it granted restricted stock unit awards representing an aggregate of 19,000 shares of Exelixis common stock and stock options to purchase an aggregate of 38,000 shares of Exelixis common stock to 11 new employees."
EXEL,EXEL:UW,BBG000BQ56F4,Will Exelixis Break Out from Key Resistance?,2017-05-03 16:45:00 +0000,http://finance.yahoo.com/r/cdac6f46-bb84-32c4-8544-5d1caf7639b2/will-exelixis-break-out-key-resistance-exel?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Exelixis recently reported strong earnings, but the stock failed to break out from an ascending triangle. We take a look at where it's headed from here."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. :EXEL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017",2017-05-03 14:43:11 +0000,http://finance.yahoo.com/r/2b54467b-500c-3921-9789-019ae0b6c783/exelixis-inc-exel-us-earnings-analysis-q1-2017-by-the-numbers-may-3-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Exelixis, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Exelixis, Inc. – Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Amgen Inc. and Johnson & Johnson (BMY-US, GSK-US, AMGN-US and JNJ-US) that have also reported for this period. Highlights ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,"Zacks.com featured highlights: Sonus Networks, CNH Industrial, WellCare Health Plans, Exelixis and Best Buy",2017-05-03 13:30:01 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-sonus-133001875.html?.tsrc=rss,"Zacks.com featured highlights: Sonus Networks, CNH Industrial, WellCare Health Plans, Exelixis and Best Buy"
EXEL,EXEL:UW,BBG000BQ56F4,Blog Coverage Sunesis Pharma Withdraws European Marketing Authorization Application for Vosaroxin,2017-05-03 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-sunesis-pharma-withdraws-121500703.html?.tsrc=rss,"Upcoming AWS Coverage on Exelixis Post-Earnings Results LONDON, UK / ACCESSWIRE / May 3, 2017 / Active Wall St. blog coverage looks at the headline from Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) as ..."
EXEL,EXEL:UW,BBG000BQ56F4,Five Breakout Zacks Rank #1 (Strong Buy) Stocks on the Move,2017-05-03 01:25:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HLLq6e2facA/five-breakout-zacks-rank-1-strong-buy-stocks-on-the-move-cm783148,Good news on a day where the market just managed to squeak itself in to the green A major concern for markets a few weeks ago was Trump s ability to get legislation passed Skepticism ruled the day and traders were worried that he may not be able to get all these wonderful tax cuts
EXEL,EXEL:UW,BBG000BQ56F4,Five Breakout Zacks Rank #1 (Strong Buy) Stocks on the Move,2017-05-02 23:35:11 +0000,http://finance.yahoo.com/news/five-breakout-zacks-rank-1-233511412.html?.tsrc=rss,Good news on a day where the market just managed to squeak itself in to the green
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus",2017-05-02 22:27:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J__3lkUeK2E/exelixis-exel-posts-earnings-in-q1-cabometyx-in-focus-cm783071,Exelixis Inc EXEL posted first quarter 2017 earnings of 5 cents compared with a loss of 26 cents per share in the year ago quarter The Zacks Consensus Estimate was a loss of 1 cent Net revenue came in at 80 9 million significantly up from 15 4 million in the prior year quarter
EXEL,EXEL:UW,BBG000BQ56F4,"Whoa, an Operating Profit for Exelixis, Inc.",2017-05-02 21:29:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8al41ykMgG4/whoa-an-operating-profit-for-exelixis-inc-cm783047,Exelixis NASDAQ EXEL reported first quarter earnings posting something many biotechs never achieve profitability on an operating basis Exelixis results The raw numbers Metric Q1 2017
EXEL,EXEL:UW,BBG000BQ56F4,Biotech And Pharma Industry And Stock News,2017-05-02 21:08:44 +0000,http://finance.yahoo.com/r/d95a9140-bcb4-38ab-b942-e0c45662051a/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead?src=A00220&yptr=yahoo&.tsrc=rss,Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
EXEL,EXEL:UW,BBG000BQ56F4,This Biotech Is Flirting With A Breakout After &apos;Another Strong Quarter&apos;,2017-05-02 20:26:40 +0000,http://finance.yahoo.com/r/03149e53-f63d-35d1-aa05-985a250f0729/this-biotech-is-flirting-with-a-breakout-after-another-strong-quarter?src=A00220&yptr=yahoo&.tsrc=rss,Exelixis stock flirted with a breakout point Tuesday after the small-cap biotech unveiled &quot;yet another strong quarter&quot; late Monday.
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus",2017-05-02 20:09:08 +0000,http://finance.yahoo.com/news/exelixis-exel-posts-earnings-q1-200908967.html?.tsrc=rss,Exelixis posted earnings in the first quarter of 2017 while revenues beat estimates driven by Cabometyx.
EXEL,EXEL:UW,BBG000BQ56F4,"Whoa, an Operating Profit for Exelixis, Inc.",2017-05-02 19:39:00 +0000,http://finance.yahoo.com/r/84971164-32b6-311e-bc09-426dfe114f84/whoa-an-operating-profit-for-exelixis-inc.aspx?yptr=yahoo&.tsrc=rss,A solid start to Cabometyx&apos;s launch puts the biotech in the black.
EXEL,EXEL:UW,BBG000BQ56F4,5 Things Exelixis Inc. Management Said After the Q1 Earnings Blowout That You'll Want to Know,2017-05-02 18:29:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ci8qP1NwDLI/5-things-exelixis-inc-management-said-after-the-q1-earnings-blowout-that-youll-want-to-know-cm782908,Exelixis Inc NASDAQ EXEL just reported the best quarter the company has had Ever 160 The biotech beat analysts revenue estimates It beat analysts earnings estimates As you might imagine Exelixis executives were quite upbeat in the company s first quarter results
EXEL,EXEL:UW,BBG000BQ56F4,5 Things Exelixis Inc. Management Said After the Q1 Earnings Blowout That You&apos;ll Want to Know,2017-05-02 16:24:00 +0000,http://finance.yahoo.com/r/0dffe24a-ffde-34f3-ab50-ba8c2fdb683c/5-things-exelixis-inc-management-said-that-youll-w.aspx?yptr=yahoo&.tsrc=rss,Exelixis announced great results for Q1. Here&apos;s what management said afterwards.
EXEL,EXEL:UW,BBG000BQ56F4,"Biotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals",2017-05-02 13:19:00 +0000,http://finance.yahoo.com/r/ef196852-67ec-31b1-82a5-100c604e066b/biotech-movers-luminex-exelixis-amag-pharmaceuticals.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Luminex, Exelixis, AMAG Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday."
EXEL,EXEL:UW,BBG000BQ56F4,Play Potential Earnings Beat with These 5 Top-Ranked Stocks,2017-05-02 12:28:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ih4rlvEqTnU/play-potential-earnings-beat-with-these-5-top-ranked-stocks-cm782444,It is a common practice to scan stocks that can beat market expectation ahead of an earnings release This is because investors always try to position themselves ahead of time and look to tap stocks that are high quality in nature Why Is a Positive Earnings Surprise So
EXEL,EXEL:UW,BBG000BQ56F4,Today's Research Reports on Stocks to Watch: AEterna Zentaris and Exelixis,2017-05-02 11:30:00 +0000,http://finance.yahoo.com/news/todays-research-reports-stocks-watch-113000027.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 2, 2017 / Gains from major tech players, such as Alphabet, Facebook and Twitter, combined with continued strength in corporate earnings helped lift major indexes Monday. ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis beats Street 1Q forecasts,2017-05-01 20:38:35 +0000,http://finance.yahoo.com/news/exelixis-beats-street-1q-forecasts-203835808.html?.tsrc=rss,"On a per-share basis, the South San Francisco, California-based company said it had profit of 5 cents. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update,2017-05-01 20:05:00 +0000,http://finance.yahoo.com/news/exelixis-announces-first-quarter-2017-200500035.html?.tsrc=rss,"Exelixis, Inc. today reported financial results for the first quarter of 2017 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones."
EXEL,EXEL:UW,BBG000BQ56F4,"Earnings Reaction History: Exelixis, Inc., 60.0% Follow-Through Indicator, 7.5% Sensitive",2017-05-01 19:06:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uZLlPB-mF3A/earnings-reaction-history-exelixis-inc-600-follow-through-indicator-75-sensitive-cm782231,Expected Earnings Release 05 01 2017 After hoursExpected Earnings Release 05 01 2017 After hours Avg Extended Hours Dollar Volume 3 453 392Avg Extended Hours Dollar Volume 3 453 392 Exelixis Inc EXEL is due to issue its quarterly earnings report in the upcoming extended
EXEL,EXEL:UW,BBG000BQ56F4,Interesting EXEL Put And Call Options For June 16th,2017-05-01 16:27:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fi6TPWUN5v4/interesting-exel-put-and-call-options-for-june-16th-cm782044,Investors in Exelixis Inc Symbol EXEL saw new options begin trading this week for the June 16th expiration At Stock Options Channel our YieldBoost formula has looked up and down the EXEL options chain for the new June 16th contracts and identified one put and one call contract of
EXEL,EXEL:UW,BBG000BQ56F4,"Investor Network: Exelixis, Inc. to Host Earnings Call",2017-05-01 15:10:00 +0000,http://finance.yahoo.com/news/investor-network-exelixis-inc-host-151000917.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 1, 2017 / Exelixis, Inc. (NASDAQ: EXEL) will be discussing their earnings results in their Q1 Earnings Call to be held May 1, 2017 at 5:00 PM Eastern Time. To listen to ..."
EXEL,EXEL:UW,BBG000BQ56F4,5 Things Bristol-Myers Squibb's Management Wants You to Know,2017-04-29 12:26:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DuXc4S3g2rc/5-things-bristol-myers-squibbs-management-wants-you-to-know-cm781597,Bristol Myers Squibb NYSE BMY blew past all expectations when it reported first quarter results on Thursday Wall Street estimated earnings of 0 74 per share on revenue of 4 72 billion The drugmaker delivered first quarter adjusted earnings of 0 84 per share with revenue of 4
EXEL,EXEL:UW,BBG000BQ56F4,5 Things Bristol-Myers Squibb&apos;s Management Wants You to Know,2017-04-29 10:42:00 +0000,http://finance.yahoo.com/r/a4f10c0a-b2cc-3e52-b642-9d18bbc0d2a6/5-things-bristol-myers-squibbs-management-wants-yo.aspx?yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb knocked it out of the park with its Q1 earnings.
EXEL,EXEL:UW,BBG000BQ56F4,Is Intercept (ICPT) Poised for a Beat This Earnings Season?,2017-04-29 00:25:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/55jbLb6iAhI/is-intercept-icpt-poised-for-a-beat-this-earnings-season-cm781557,Intercept Pharmaceuticals Inc ICPT is scheduled to report first quarter 2017 results on May 4 before the market opens In the last reported quarter the company missed expectations by 35 2 Let s see how things are shaping up for this announcement Intercept s share price movement
EXEL,EXEL:UW,BBG000BQ56F4,Apple (AAPL) to Report Q2 Earnings: Is a Beat in Store?,2017-04-28 16:31:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_qMDF3ylfro/apple-aapl-to-report-q2-earnings-is-a-beat-in-store-cm781250,Apple Inc AAPL is set to report its second quarter fiscal 2017 results on May 2 Last quarter it posted a 4 35 positive earnings surprise The company has outperformed the Zacks Consensus Estimate in three of the last four quarters with an average positive earnings surprise of 0 89 Let
EXEL,EXEL:UW,BBG000BQ56F4,The High Hope of Exelixis’s Cabometyx Label Expansion,2017-04-28 11:36:40 +0000,http://finance.yahoo.com/r/29492b74-ef54-3ab9-b101-78ac4e4b95c0/cabometyxs-label-expansion-may-boost-exelixis-revenues-future-years?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. – Value Analysis (NASDAQ:EXEL) : April 27, 2017",2017-04-27 20:49:56 +0000,http://finance.yahoo.com/r/13de8c9a-e153-3df9-9a87-605b6c391d12/exelixis-inc-value-analysis-nasdaqexel-april-27-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Exelixis, Inc. a score of 31. Our analysis is based on comparing Exelixis, Inc. with the following peers – Sanofi Sponsored ADR, Merck & Co., Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Amgen Inc., Johnson & Johnson, ArQule, Inc., Pfizer Inc., AVEO Pharmaceuticals, Inc. and Curis, ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,Insperity (NSP) Q1 Earnings: Is a Surprise in the Cards?,2017-04-27 17:28:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TB_tfIgBvFM/insperity-nsp-q1-earnings-is-a-surprise-in-the-cards-cm780416,Insperity Inc 160 NSP is set to report first quarter 2017 results on May 1 Though the company reported a positive earnings surprise of 7 14 last quarter it has an average negative earnings surprise of 0 76 over the trailing four quarters Let s see how things are shaping up for
EXEL,EXEL:UW,BBG000BQ56F4,What to Expect from Quotient Technology (QUOT) Q1 Earnings?,2017-04-27 17:28:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GLoivfFn00E/what-to-expect-from-quotient-technology-quot-q1-earnings-cm780412,Quotient Technology Inc 160 QUOT is set to report first quarter 2017 results on May 2 Last quarter the company posted a 100 00 positive earnings surprise Moreover in the last four quarters the company delivered an average positive earnings surprise of 68 41 Let s see how things
EXEL,EXEL:UW,BBG000BQ56F4,Inside Exelixis’s Robust Growth Strategy for Cabometyx,2017-04-27 14:37:31 +0000,http://finance.yahoo.com/r/15977269-3e2d-345a-a3ce-cbb90043b281/exelixis-developed-robust-growth-strategy-cabometyx?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Exelixis is now developing a strong sales team to support the commercial launch of Cabometyx for indications like first-line RCC and second-line HCC.
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis’s Tough Competition in Renal Cell Carcinoma,2017-04-27 13:07:32 +0000,http://finance.yahoo.com/r/c5470d65-84a8-30a0-a956-712aeb02207f/exelixis-cabometyx-posing-tough-competition-drugs-renal-cell-carcinoma-segment?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"After the launch of Cabometyx in the US in 2Q16, Exelixis has focused its attention on promoting it to thought leaders and clinicians who have treated many RCC patients."
EXEL,EXEL:UW,BBG000BQ56F4,Behind Exelixis’s Successful Commercial Launch of Cabometyx in 2016,2017-04-27 11:38:02 +0000,http://finance.yahoo.com/r/60a5f6c5-48a7-3419-8272-53a937b52410/exelixis-cabometyx-witnessed-successful-commercial-launch-2016?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Launched in the US in 2Q16, Exelixis’s (EXEL) Cabometyx managed to fetch revenues of $31.2 million and $44.7 million in 3Q16 and 4Q16, respectively."
EXEL,EXEL:UW,BBG000BQ56F4,Understanding Exelixis’s Operating Expense Expectations for 1Q17,2017-04-26 19:05:43 +0000,http://finance.yahoo.com/r/dcbfdedf-10d2-3be6-9488-3c473d8e1932/exelixis-expected-witness-rise-operating-expenses-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1Q17, Wall Street analysts expect Exelixis (EXEL) to report losses of ~$2.6 million, mainly due to a significant projected rise in SG&A expenses."
EXEL,EXEL:UW,BBG000BQ56F4,Inside Exelixis’s Analyst Recommendations after 1Q17,2017-04-26 17:35:53 +0000,http://finance.yahoo.com/r/c80e7936-c784-32f2-bf59-9bd6e3549155/analysts-recommendations-exelixis-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Of the eight analysts covering Exelixis in April 2017, two have rated the stock as a “strong buy,” and four have rated it as a “buy.”"
EXEL,EXEL:UW,BBG000BQ56F4,Can Exelixis Beat the Analyst Revenue Estimates in 1Q17?,2017-04-26 15:47:25 +0000,http://finance.yahoo.com/r/ea05e8f4-a4a7-3a66-94d4-34513f95ce90/will-exelixis-revenues-surpass-analyst-estimates-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Wall Street analysts expect Exelixis to report revenues close to $65.23 million in 1Q17, which would be a YoY (year-over-year) growth of ~322.7%."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : April 26, 2017",2017-04-26 12:42:33 +0000,http://finance.yahoo.com/r/466b2f1e-0527-36ed-afd0-3da30b0f878d/exelixis-inc-breached-its-50-day-moving-average-in-a-bullish-manner-exel-us-april-26-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Exelixis, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?,2017-04-25 22:05:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c7aLBH0RhJw/exelixis-exel-q1-earnings-will-the-stock-disappoint-cm779088,Exelixis Inc EXEL is scheduled to report first quarter 2017 results on May 1 after the market close The company surpassed expectations thrice in the four trailing quarters and missed the same once with an average positive earnings surprise of 360 11 Exelixis share price has
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?,2017-04-25 19:54:07 +0000,http://finance.yahoo.com/news/exelixis-exel-q1-earnings-stock-195407227.html?.tsrc=rss,"Exelixis, Inc. (EXEL) is scheduled to report first-quarter 2017 results on May 1, after the market close."
EXEL,EXEL:UW,BBG000BQ56F4,"Meditor Group Ltd Buys Celldex Therapeutics, Sells VIVUS",2017-04-25 13:02:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u8rZxezfYpM/meditor-group-ltd-buys-celldex-therapeutics-sells-vivus-cm778451,Meditor Group Ltd New Purchases CLDX Reduced Positions EXEL EPI Sold Out VVUS New Purchases CLDX New Purchases CLDX Reduced Positions EXEL EPI Reduced Positions EXEL EPI Sold Out VVUS Sold Out
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis to Present at the Deutsche Bank 42nd Annual Health Care Conference on May 3,2017-04-24 20:05:00 +0000,http://finance.yahoo.com/news/exelixis-present-deutsche-bank-42nd-200500585.html?.tsrc=rss,"Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at Deutsche Bank’s Health Care Conference taking place May 3-4 in Boston, MA."
EXEL,EXEL:UW,BBG000BQ56F4,Read This Before You Buy Biotech Stocks,2017-04-24 11:45:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E0LEFm-9vUA/read-this-before-you-buy-biotech-stocks-cm777613,Investing in biotech tech stocks is a little like venturing into the Wild West of years ago It can be chaotic risky and unpredictable Biotech investing doesn t have to be too scary though Here are seven things you need to know before buying biotech stocks that should help you
EXEL,EXEL:UW,BBG000BQ56F4,Read This Before You Buy Biotech Stocks,2017-04-23 18:03:00 +0000,http://finance.yahoo.com/r/a11bb068-dc97-3408-93c2-eaf0f3556202/read-this-before-you-buy-biotech-stocks.aspx?yptr=yahoo&.tsrc=rss,Looking to buy biotech stocks? Here are 7 important things to know.
EXEL,EXEL:UW,BBG000BQ56F4,"Here's Why the Best Is Yet to Come for Exelixis, Inc.",2017-04-20 20:03:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GjYbrRouUCE/heres-why-the-best-is-yet-to-come-for-exelixis-inc-cm776657,Exelixis NASDAQ EXEL has been on a tear over the last year nearly quadrupling EXEL data by YCharts While much of the growth in Exelixis stock price has to do with the better than expected launch of Cabometyx in kidney cancer the
EXEL,EXEL:UW,BBG000BQ56F4,"Here&apos;s Why the Best Is Yet to Come for Exelixis, Inc.",2017-04-20 18:40:00 +0000,http://finance.yahoo.com/r/2535dd3e-b6b3-3cd5-bfba-ee1e25f19a39/heres-why-the-best-is-yet-to-come-for-exelixis-inc.aspx?yptr=yahoo&.tsrc=rss,There&apos;s more upside left in this biotech.
EXEL,EXEL:UW,BBG000BQ56F4,"ETFs with exposure to Exelixis, Inc. : April 19, 2017",2017-04-19 18:19:42 +0000,http://finance.yahoo.com/r/67debbfd-cee2-3676-9fcf-d1b6ee1d03ac/etfs-with-exposure-to-exelixis-inc-april-19-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Exelixis, Inc. Here are 5 ETFs with the largest exposure to EXEL-US. Comparing the performance and risk of Exelixis, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis to Release First Quarter 2017 Financial Results on Monday, May 1, 2017",2017-04-18 20:05:00 +0000,http://finance.yahoo.com/news/exelixis-release-first-quarter-2017-200500070.html?.tsrc=rss,"Exelixis, Inc. announced today that its first quarter 2017 financial results will be released on Monday, May 1, 2017 after the markets close. At 5:00 p.m. EDT / 2:00 p.m."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc.: Time to Move On?",2017-04-18 15:06:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zuNe1jxruAM/exelixis-inc-time-to-move-on-cm775044,Exelixis NASDAQ EXEL is without question one of the hottest biotech stocks around Shares have nearly quintupled in value over the last 12 months So far in 2017 Exelixis stock is up more than 40 But this tremendous success now raises questions about how much farther
EXEL,EXEL:UW,BBG000BQ56F4,"XBI, VRTX, BIVV, EXEL: Large Inflows Detected at ETF",2017-04-18 15:04:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T8E0Q3cUf7c/xbi-vrtx-bivv-exel-large-inflows-detected-at-etf-cm775227,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 72 2 million dollar inflow that s a 2 6 increase week over week in outstanding
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc.: Time to Move On?",2017-04-18 12:22:00 +0000,http://finance.yahoo.com/r/544bdbf3-fefa-384a-a321-24c122dc6615/exelixis-inc-time-to-move-on.aspx?yptr=yahoo&.tsrc=rss,Exelixis stock has soared to all-time highs. But will the biotech&apos;s share price soon reach a plateau?
EXEL,EXEL:UW,BBG000BQ56F4,"3 Stocks That Turned $5,000 Into More Than $18,000 in a Year or Less",2017-04-12 13:56:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bpk-v73_i70/3-stocks-that-turned-5000-into-more-than-18000-in-a-year-or-less-cm773104,There s usually a good reason a stock will tumble to a 52 week low but such low prices mean that investors should take a closer look to understand why it was beaten down in the first place and whether it could reveal a good chance of recovery That was 160 the case with
EXEL,EXEL:UW,BBG000BQ56F4,"3 Stocks That Turned $5,000 Into More Than $18,000 in a Year or Less",2017-04-12 12:04:00 +0000,http://finance.yahoo.com/r/a5d985e0-626d-3542-ba06-75c9b0bf8da5/3-stocks-turned-5000-into-more-than-18000-in-year.aspx?yptr=yahoo&.tsrc=rss,These three stocks didn&apos;t let a 52-week low stand in their way of a meteoric climb.
EXEL,EXEL:UW,BBG000BQ56F4,"XLF, PTH: Big ETF Outflows",2017-04-11 15:55:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S5GWR7i6m8Y/xlf-pth-big-etf-outflows-cm772662,Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel the biggest outflow was seen in the Financial Select Sector SPDR Fund XLF where 24 800 000 units were destroyed or a 2 5 decrease week over week Among the largest underlying components
EXEL,EXEL:UW,BBG000BQ56F4,"If You Love Exelixis, You Should Check Out Juno Therapeutics",2017-04-09 16:54:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_rlIYt_IsKc/if-you-love-exelixis-you-should-check-out-juno-therapeutics-cm771849,Don t you wish you d bought Exelixis NASDAQ EXEL stock three years ago The biotech s share price is up more than 460 since then including more than 350 in just the past 12 months Exelixis 160 is without question one of the hottest biotech stocks around Juno
EXEL,EXEL:UW,BBG000BQ56F4,"ETFs with exposure to Exelixis, Inc. : April 7, 2017",2017-04-07 20:30:10 +0000,http://finance.yahoo.com/r/d6c962a9-a17a-31c0-a240-f525fe6d2d21/etfs-with-exposure-to-exelixis-inc-april-7-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Exelixis, Inc. Here are 5 ETFs with the largest exposure to EXEL-US. Comparing the performance and risk of Exelixis, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2017-04-04 20:05:00 +0000,http://finance.yahoo.com/news/exelixis-reports-inducement-grants-under-200500409.html?.tsrc=rss,"Exelixis, Inc. announced that today it granted restricted stock unit awards representing an aggregate of 26,750 shares of Exelixis common stock and stock options to purchase an aggregate of 53,500 shares of Exelixis common stock to 9 new employees."
EXEL,EXEL:UW,BBG000BQ56F4,3 Winning Stocks You Never Saw Coming,2017-04-04 13:37:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zYbcblIPnD4/3-winning-stocks-you-never-saw-coming-cm769416,After suffering sharp sell offs in their share prices Shopify NYSE SHOP Exelixis NASDAQ EXEL and LogMeIn NASDAQ LOGM have rekindled investor s optimism and that s resulting in envy inspiring returns These companies have intriguing catalysts that are
EXEL,EXEL:UW,BBG000BQ56F4,3 Winning Stocks You Never Saw Coming,2017-04-04 12:02:00 +0000,http://finance.yahoo.com/r/9883f898-15a4-337a-b759-cffc3672ab10/3-winning-stocks-you-never-saw-coming.aspx?yptr=yahoo&.tsrc=rss,"Shopify, Exelixis, and LogMeIn have put up remarkable returns for shareholders, and our Motley Fool contributors think there are a few reasons more gains may still be on tap in the future."
EXEL,EXEL:UW,BBG000BQ56F4,Coverage initiated on Exelixis by Needham,2017-03-31 11:24:46 +0000,http://finance.yahoo.com/q/ud?s=EXEL,Coverage initiated on Exelixis by Needham
EXEL,EXEL:UW,BBG000BQ56F4,4:52 pm Exelixis further reduces indebtedness by repaying $80.1 mln Silicon Valley Bank term loan (was due for repayment on May 31) and plans for early repayment of Deerfield Notes,2017-03-29 20:52:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#exel,4:52 pm Exelixis further reduces indebtedness by repaying $80.1 mln Silicon Valley Bank term loan (was due for repayment on May 31) and plans for early repayment of Deerfield Notes
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Further Reduces Indebtedness by Repaying Silicon Valley Bank Term Loan,2017-03-29 20:50:00 +0000,http://finance.yahoo.com/news/exelixis-further-reduces-indebtedness-repaying-205000535.html?.tsrc=rss,"Exelixis, Inc. today announced that it has repaid all amounts outstanding under its term loan with Silicon Valley Bank initiated in 2010 and which was due for repayment on May 31, 2017."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Further Reduces Indebtedness by Repaying Silicon Valley Bank Term Loan,2017-03-29 20:50:00 +0000,http://finance.yahoo.com/news/exelixis-further-reduces-indebtedness-repaying-205000535.html,"[Business Wire] - Exelixis, Inc. today announced that it has repaid all amounts outstanding under its term loan with Silicon Valley Bank initiated in 2010 and which was due for repayment on May 31, 2017."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis to Present at the Needham & Company Healthcare Conference on April 4,2017-03-27 20:05:00 +0000,http://finance.yahoo.com/news/exelixis-present-needham-company-healthcare-200500391.html,"[Business Wire] - Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the 16th Annual Needham Healthcare Conference taking place April 4-5 in New York, NY."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis to Present at the Needham & Company Healthcare Conference on April 4,2017-03-27 20:05:00 +0000,http://finance.yahoo.com/news/exelixis-present-needham-company-healthcare-200500391.html?.tsrc=rss,"Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the 16th Annual Needham Healthcare Conference taking place April 4-5 in New York, NY."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : March 27, 2017",2017-03-27 12:07:17 +0000,http://www.capitalcube.com/blog/index.php/exelixis-inc-breached-its-50-day-moving-average-in-a-bullish-manner-exel-us-march-27-2017/,"Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : March 27, 2017"
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : March 27, 2017",2017-03-27 12:07:17 +0000,http://finance.yahoo.com/r/0885965c-b90f-3bcb-90d1-133ba85a2b30/exelixis-inc-breached-its-50-day-moving-average-in-a-bullish-manner-exel-us-march-27-2017?yptr=yahoo&.tsrc=rss,"Categories:   ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Exelixis, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more    
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,"IWM, AMD, EXEL, NRZ: Large Inflows Detected at ETF",2017-03-20 17:07:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kzVL2b5UB8Q/iwm-amd-exel-nrz-large-inflows-detected-at-etf-cm763007,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 2000 ETF Symbol IWM where we have detected an approximate 1 3 billion dollar inflow that s a 3 4 increase week over week in outstanding
EXEL,EXEL:UW,BBG000BQ56F4,When Profit Makers Can Be Active Profit Takers,2017-03-16 13:30:00 +0000,http://finance.yahoo.com/news/profit-makers-active-profit-takers-133000175.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 16, 2017 / The inside investors of Exelixis and MannKind corporations have sold some of their company stock today. One Director cashed in on a $20 a share price increase, ..."
EXEL,EXEL:UW,BBG000BQ56F4,When Profit Makers Can Be Active Profit Takers,2017-03-16 13:30:00 +0000,http://finance.yahoo.com/news/profit-makers-active-profit-takers-133000175.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / March 16, 2017 / The inside investors of Exelixis and MannKind corporations have sold some of their company stock today. One Director cashed in on a $20 a share price increase, ..."
EXEL,EXEL:UW,BBG000BQ56F4,Why Exelixis Is Already Up 55% This Year,2017-03-15 14:07:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Frh47VVMLHg/why-exelixis-is-already-up-55-this-year-cm760941,Exelixis NASDAQ EXEL kidney cancer drug Cabometyx is quickly winning market share and that s fueling a rapid run up in its revenue The company has a big opportunity in its sights to expand Cabometyx s addressable market and it s got other promising drugs in
EXEL,EXEL:UW,BBG000BQ56F4,Why Exelixis Is Already Up 55% This Year,2017-03-15 12:21:00 +0000,http://finance.yahoo.com/r/729319c4-a101-3874-b3e7-8563483f18e4/why-exelixis-is-already-up-55-this-year.aspx?yptr=yahoo&.tsrc=rss,A new cancer drug that's growing market share rapidly has been catapulting shares of this biotech higher.
EXEL,EXEL:UW,BBG000BQ56F4,Why Exelixis Is Already Up 55% This Year,2017-03-15 12:21:00 +0000,http://www.fool.com/investing/2017/03/15/why-exelixis-is-already-up-55-this-year.aspx,Why Exelixis Is Already Up 55% This Year
EXEL,EXEL:UW,BBG000BQ56F4,"The 3 Most Important Numbers for Exelixis, Inc.",2017-03-14 13:07:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jVK6gC-YaAk/the-3-most-important-numbers-for-exelixis-inc-cm760331,Exelixis NASDAQ EXEL boasts several numbers that make its shareholders smile The biotech s stock has soared more than 430 over the past 12 months Its most promising drug Cabometyx has quickly captured around 20 of the market share as a second line treatment for kidney cancer
EXEL,EXEL:UW,BBG000BQ56F4,"The 3 Most Important Numbers for Exelixis, Inc.",2017-03-14 11:23:00 +0000,http://finance.yahoo.com/r/34feea2c-c50c-3254-9a88-8baaf24919f4/the-3-most-important-numbers-for-exelixis.aspx?yptr=yahoo&.tsrc=rss,Two little numbers and one big number are key for Exelixis' future.
EXEL,EXEL:UW,BBG000BQ56F4,"The 3 Most Important Numbers for Exelixis, Inc.",2017-03-14 11:23:00 +0000,http://www.fool.com/investing/2017/03/14/the-3-most-important-numbers-for-exelixis.aspx,"The 3 Most Important Numbers for Exelixis, Inc."
EXEL,EXEL:UW,BBG000BQ56F4,Top Stocks That Are Already Crushing the Market in 2017,2017-03-13 16:10:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/un7WrfHTuq0/top-stocks-that-are-already-crushing-the-market-in-2017-cm760028,If you re looking for new stocks to buy for your portfolio you might want to consider digging deeper into the story behind Exelixis NASDAQ EXEL Pacira Pharmaceuticals NASDAQ PCRX Kite Pharma NASDAQ KITE Exact Sciences NASDAQ EXAS
EXEL,EXEL:UW,BBG000BQ56F4,Top Stocks That Are Already Crushing the Market in 2017,2017-03-13 14:11:00 +0000,http://www.fool.com/investing/2017/03/13/top-stocks-that-are-already-crushing-the-market-in.aspx,Top Stocks That Are Already Crushing the Market in 2017
EXEL,EXEL:UW,BBG000BQ56F4,Top Stocks That Are Already Crushing the Market in 2017,2017-03-13 14:11:00 +0000,http://finance.yahoo.com/r/1bf14d85-525f-3e9b-af79-fa6fb62ba897/top-stocks-that-are-already-crushing-the-market-in.aspx?yptr=yahoo&.tsrc=rss,"Exelixis, Pacira Pharmaceuticals, Kite Pharma, Exact Sciences, and Portola Pharmaceuticals are up more than 50% in the first two months of 2017."
EXEL,EXEL:UW,BBG000BQ56F4,3 Horrible Stocks for Retirees,2017-03-12 13:11:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BaK4YwJSRqY/3-horrible-stocks-for-retirees-cm759706,A common mistake for retirees is to invest too conservatively Not having enough of your retirement portfolio in stocks for example can result in running out of money too quickly However some stocks are horrible choices for retirees Here s how three in particular
EXEL,EXEL:UW,BBG000BQ56F4,3 Horrible Stocks for Retirees,2017-03-12 11:21:00 +0000,http://www.fool.com/investing/2017/03/12/3-horrible-stocks-for-retirees.aspx,3 Horrible Stocks for Retirees
EXEL,EXEL:UW,BBG000BQ56F4,3 Horrible Stocks for Retirees,2017-03-12 11:21:00 +0000,http://finance.yahoo.com/r/19e1af59-acd2-3266-9948-30f151d0915c/3-horrible-stocks-for-retirees.aspx?yptr=yahoo&.tsrc=rss,"Celldex Therapeutics, Exelixis, and Frontier Communications serve as perfect examples of the kinds of stocks retirees should avoid."
EXEL,EXEL:UW,BBG000BQ56F4,Is Exelixis' Balance Sheet Safe?,2017-03-08 00:13:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cZ-mehTT4bM/is-exelixis-balance-sheet-safe-cm757625,Exelixis Inc NASDAQ EXEL 160 is one of healthcare s brightest shining successes After winning approval for its kidney cancer drug last year the drugmaker is knee deep in researching new ways it can help more cancer patients The opportunity ahead of this company is big but
EXEL,EXEL:UW,BBG000BQ56F4,9 Stocks to Buy That Are Growing Faster Than Amazon,2017-03-08 00:12:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qF6mbGkVwL8/9-stocks-to-buy-that-are-growing-faster-than-amazon-cm757641,InvestorPlace Stock Market News Stock Advice amp Trading Tips Do you think Amazon com Inc NASDAQ AMZN is a growth machine like no other Source Shutterstock It s a beast to be sure with the most recently reported quarterly top line up a healthy 22 a pace that s
EXEL,EXEL:UW,BBG000BQ56F4,Is Exelixis' Balance Sheet Safe?,2017-03-07 22:42:00 +0000,http://www.fool.com/investing/2017/03/07/is-exelixis-balance-sheet-safe.aspx,Is Exelixis' Balance Sheet Safe?
EXEL,EXEL:UW,BBG000BQ56F4,Is Exelixis' Balance Sheet Safe?,2017-03-07 22:42:00 +0000,http://finance.yahoo.com/r/3a7f26c5-0529-33c8-9c45-c67f84469e59/is-exelixis-balance-sheet-safe.aspx?yptr=yahoo&.tsrc=rss,"This mid-cap cancer drug developer is growing quickly, but it's still losing money, and that's got investors wondering about its financial future."
EXEL,EXEL:UW,BBG000BQ56F4,"3 Factors That Drove Exelixis, Inc. Higher By 19% in February",2017-03-07 15:14:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y8pYbLDWL6s/3-factors-that-drove-exelixis-inc-higher-by-19-in-february-cm757149,What happened Shares of Exelixis NASDAQ EXEL a biopharmaceutical company focused on the development of medicines for the treatment of cancer surged 19 in February according to data from S amp P Global Market Intelligence While Exelixis stock has been on fire for
EXEL,EXEL:UW,BBG000BQ56F4,"3 Factors That Drove Exelixis, Inc. Higher By 19% in February",2017-03-07 13:47:00 +0000,http://www.fool.com/investing/2017/03/07/3-factors-that-drove-exelixis-inc-higher-by-19-in.aspx,"3 Factors That Drove Exelixis, Inc. Higher By 19% in February"
EXEL,EXEL:UW,BBG000BQ56F4,"3 Factors That Drove Exelixis, Inc. Higher By 19% in February",2017-03-07 13:47:00 +0000,http://finance.yahoo.com/r/da4acfd3-e8f9-334d-ba32-8ca526c10eef/3-factors-that-drove-exelixis-inc-higher-by-19-in.aspx?yptr=yahoo&.tsrc=rss,A sizable earnings beat and a bounty of new pipeline developments have investors rightfully excited.
EXEL,EXEL:UW,BBG000BQ56F4,"ETFs with exposure to Exelixis, Inc. : March 6, 2017",2017-03-06 18:39:01 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-exelixis-inc-march-6-2017/,"ETFs with exposure to Exelixis, Inc. : March 6, 2017"
EXEL,EXEL:UW,BBG000BQ56F4,"ETFs with exposure to Exelixis, Inc. : March 6, 2017",2017-03-06 18:39:01 +0000,http://finance.yahoo.com/r/5959688b-f99f-3efc-aa8e-5452dfcfd167/etfs-with-exposure-to-exelixis-inc-march-6-2017?yptr=yahoo&.tsrc=rss,"Categories:   ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Exelixis, Inc. Here are 5 ETFs with the largest exposure to EXEL-US. Comparing the performance and risk of Exelixis, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more    
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,"Noteworthy ETF Outflows: UWM, NRZ, XPO, EXEL",2017-03-06 17:14:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iKbFjarErO8/noteworthy-etf-outflows-uwm-nrz-xpo-exel-cm756665,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the ProShares Ultra Russell2000 Symbol UWM where we have detected an approximate 23 4 million dollar outflow that s a 10 5 decrease week over week from 1 900
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma,2017-03-06 14:04:00 +0000,http://finance.yahoo.com/news/exelixis-cabozantinib-granted-orphan-drug-140400177.html,"[Business Wire] - Exelixis, Inc. today announced that the U.S. Food & Drug Administration has granted orphan drug designation to cabozantinib for the treatment of hepatocellular carcinoma ."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma,2017-03-06 14:04:00 +0000,http://finance.yahoo.com/news/exelixis-cabozantinib-granted-orphan-drug-140400177.html?.tsrc=rss,"Exelixis, Inc. today announced that the U.S. Food & Drug Administration has granted orphan drug designation to cabozantinib for the treatment of hepatocellular carcinoma ."
EXEL,EXEL:UW,BBG000BQ56F4,Icahn's (Potential) Move Into Biotech,2017-03-05 00:25:01 +0000,http://finance.yahoo.com/news/icahns-potential-move-biotech-002501246.html,Icahn's (Potential) Move Into Biotech
EXEL,EXEL:UW,BBG000BQ56F4,"EXELIXIS, INC. Financials",2017-03-03 18:04:12 +0000,http://finance.yahoo.com/q/is?s=exel,"EXELIXIS, INC. Financials"
EXEL,EXEL:UW,BBG000BQ56F4,"Blog Coverage Intercept Pharmaceuticals Received NICE Approval for Ocaliva for Use in England, Wales and Northern Ireland",2017-03-03 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-intercept-pharmaceuticals-received-131500440.html?.tsrc=rss,"Upcoming AWS Coverage on Exelixis Post-Earnings Results LONDON, UK / ACCESSWIRE / March 3, 2017 / Active Wall St. blog coverage looks at the headline from Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT ..."
EXEL,EXEL:UW,BBG000BQ56F4,"Blog Coverage Intercept Pharmaceuticals Received NICE Approval for Ocaliva for Use in England, Wales and Northern Ireland",2017-03-03 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-intercept-pharmaceuticals-received-131500440.html,"[Accesswire] - Upcoming AWS Coverage on Exelixis Post-Earnings Results LONDON, UK / ACCESSWIRE / March 3, 2017 / Active Wall St. blog coverage looks at the headline from Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT ..."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. :EXEL-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017",2017-03-02 16:47:59 +0000,http://finance.yahoo.com/r/cde11a3c-f67c-3b87-8c96-87e5ee9fb285/exelixis-inc-exel-us-earnings-analysis-2016-by-the-numbers-march-2-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis Exelixis, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Exelixis, Inc. – Sanofi Sponsored ADR, Merck & Co., Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Amgen Inc., Johnson & Johnson and Pfizer Inc. (SNY-US, MRK-US, BMY-US, GSK-US, ... Read more    
<b>(Read more...)</b>"
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. :EXEL-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017",2017-03-02 16:47:59 +0000,http://www.capitalcube.com/blog/index.php/exelixis-inc-exel-us-earnings-analysis-2016-by-the-numbers-march-2-2017/,"Exelixis, Inc. :EXEL-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017"
EXEL,EXEL:UW,BBG000BQ56F4,"Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis",2017-03-02 16:16:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dIeJghG0Oak/zacks-industry-outlook-highlights-glaxosmithkline-celgene-and-exelixis-cm755339,For Immediate Release Chicago IL March 02 2017 Today Zacks Equity Research discusses the Industry Pharma Part 2 including GlaxoSmithKline plc NYSE GSK Free Report Celgene Corporation NASDAQ CELG Free Report and Exelixis Inc NASDAQ
EXEL,EXEL:UW,BBG000BQ56F4,"Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis",2017-03-02 14:30:02 +0000,http://finance.yahoo.com/news/zacks-industry-outlook-highlights-glaxosmithkline-143002187.html,"Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis"
EXEL,EXEL:UW,BBG000BQ56F4,"Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis",2017-03-02 14:30:02 +0000,http://finance.yahoo.com/news/zacks-industry-outlook-highlights-glaxosmithkline-143002187.html?.tsrc=rss,"Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Webcasts of Investor Conference Presentations in March,2017-03-01 21:05:00 +0000,http://finance.yahoo.com/news/exelixis-announces-webcasts-investor-conference-210500696.html?.tsrc=rss,"Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the f"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Webcasts of Investor Conference Presentations in March,2017-03-01 21:05:00 +0000,http://finance.yahoo.com/news/exelixis-announces-webcasts-investor-conference-210500696.html,"[Business Wire] - Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the f"
EXEL,EXEL:UW,BBG000BQ56F4,"M&As, Pipeline Catalysts to Drive Pharma Sector",2017-03-01 20:19:08 +0000,http://finance.yahoo.com/news/m-pipeline-catalysts-drive-pharma-201908607.html,"M&As, Pipeline Catalysts to Drive Pharma Sector"
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. Turns a Profit, but Don't Get Too Excited",2017-03-01 17:14:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9Ygqk3Rho9I/exelixis-inc-turns-a-profit-but-dont-get-too-excited-cm754867,Exelixis NASDAQ EXEL reported fourth quarter earnings on Monday showing solid growth in sales of Cabometyx The biotech reported a profit for the quarter but there were some extenuating circumstances that helped push Exelixis into the black Exelixis results The raw
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. Turns a Profit, but Don't Get Too Excited",2017-03-01 15:40:00 +0000,http://www.fool.com/investing/2017/03/01/exelixis-inc-turns-a-profit-but-dont-get-too-excit.aspx,"Exelixis, Inc. Turns a Profit, but Don't Get Too Excited"
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. :EXEL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 1, 2017",2017-03-01 14:02:04 +0000,http://www.capitalcube.com/blog/index.php/exelixis-inc-exel-us-earnings-analysis-q4-2016-by-the-numbers-march-1-2017/,"Exelixis, Inc. :EXEL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 1, 2017"
EXEL,EXEL:UW,BBG000BQ56F4,"Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals",2017-03-01 12:24:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-kite-soars-122412088.html,"Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2017-02-28 23:15:00 +0000,http://finance.yahoo.com/news/exelixis-reports-inducement-grants-under-231500687.html,"[Business Wire] - Exelixis, Inc. announced that today it granted restricted stock unit awards representing an aggregate of 11,000 shares of Exelixis common stock and stock options to purchase an aggregate of 22,000 shares of Exelixis common stock to 4 new employees."
EXEL,EXEL:UW,BBG000BQ56F4,"Kite, Ionis Outplay Med Sector As Perrigo, Tenet, Valeant Dive",2017-02-28 21:13:34 +0000,http://www.investors.com/news/technology/kite-ionis-outplay-med-sector-as-perrigo-tenet-valeant-dive/,"Kite, Ionis Outplay Med Sector As Perrigo, Tenet, Valeant Dive"
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y",2017-02-28 18:51:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qq2jtT2nnwA/exelixis-exel-reports-q4-earnings-revenues-beat-yy-cm754310,Exelixis Inc EXEL posted fourth quarter 2016 earnings of 12 cents compared with a loss of 18 cents per share in the year ago quarter Earnings surpassed Zacks Consensus Estimate of a loss of 1 cent Net revenue came in at 77 6 million significantly up from 9 9 million in the prior
EXEL,EXEL:UW,BBG000BQ56F4,"Zacks.com featured highlights: Exelixis, U.S. Silica Holdings, Intuit and RPC",2017-02-28 16:52:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jw_vLuK38VA/zackscom-featured-highlights-exelixis-us-silica-holdings-intuit-and-rpc-cm754239,For Immediate Release Chicago IL February 28 2017 Stocks in this week s article include Exelixis Inc NASDAQ EXEL Free Report U S Silica Holdings Inc NYSE SLCA Free Report Intuit Inc NASDAQ INTU Free Report and RPC Inc NYSE RES
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y",2017-02-28 16:46:04 +0000,http://finance.yahoo.com/news/exelixis-exel-reports-q4-earnings-164604240.html,"Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis 4Q Net 12 Cents a Share Vs Loss Last Year,2017-02-28 15:50:00 +0000,http://www.investopedia.com/news/exelixis-4q-net-12-cents-share-exel/?partner=YahooSA,Exelixis 4Q Net 12 Cents a Share Vs Loss Last Year
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis In Cancer Deals With Roche, Bristol Myers",2017-02-28 15:17:00 +0000,http://www.investopedia.com/news/exelixis-inks-cancer-deals-roche-bmy-exel/?partner=YahooSA,"Exelixis In Cancer Deals With Roche, Bristol Myers"
EXEL,EXEL:UW,BBG000BQ56F4,"Zacks.com featured highlights: Exelixis, U.S. Silica Holdings, Intuit and RPC",2017-02-28 14:30:02 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-exelixis-143002296.html,"Zacks.com featured highlights: Exelixis, U.S. Silica Holdings, Intuit and RPC"
EXEL,EXEL:UW,BBG000BQ56F4,Edited Transcript of EXEL earnings conference call or presentation 27-Feb-17 10:00pm GMT,2017-02-28 07:42:51 +0000,http://finance.yahoo.com/news/edited-transcript-exel-earnings-conference-074251075.html,Edited Transcript of EXEL earnings conference call or presentation 27-Feb-17 10:00pm GMT
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis tops Street 4Q forecasts,2017-02-27 22:18:42 +0000,http://sg.finance.yahoo.com/news/exelixis-tops-street-4q-forecasts-221842443.html,Exelixis tops Street 4Q forecasts
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Inc Earnings Call scheduled for 5:00 pm ET today,2017-02-27 22:00:00 +0000,http://biz.yahoo.com/cc/8/155468.html,Exelixis Inc Earnings Call scheduled for 5:00 pm ET today
EXEL,EXEL:UW,BBG000BQ56F4,"Noteworthy Monday Option Activity: WTFC, FCN, EXEL",2017-02-27 21:50:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/doRXcRdFAJ8/noteworthy-monday-option-activity-wtfc-fcn-exel-cm753802,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Wintrust Financial Corp Symbol WTFC where a total of 1 299 contracts have traded so far representing approximately 129 900 underlying shares That amounts to about 47 9 of WTFC
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis Rockets On Bristol, Roche I-O Ties Following Merck-Incyte Team",2017-02-27 21:34:10 +0000,http://www.investors.com/news/technology/exelixis-rockets-on-bristol-roche-i-o-ties-following-merck-incyte-team/,"Exelixis Rockets On Bristol, Roche I-O Ties Following Merck-Incyte Team"
EXEL,EXEL:UW,BBG000BQ56F4,"EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits",2017-02-27 21:11:53 +0000,http://biz.yahoo.com/e/170227/exel8-k.html,"EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update,2017-02-27 21:05:00 +0000,http://finance.yahoo.com/news/exelixis-announces-fourth-quarter-full-210500824.html,"[Business Wire] - Exelixis, Inc. today reported financial results for the fourth quarter and full year of 2016 and provided an update on progress toward delivering upon its key corporate objectives, as well as commercial and clinical development milestones."
EXEL,EXEL:UW,BBG000BQ56F4,"Earnings Reaction History: Exelixis, Inc., 60.0% Follow-Through Indicator, 7.4% Sensitive",2017-02-27 20:09:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gACgi-wlR-A/earnings-reaction-history-exelixis-inc-600-follow-through-indicator-74-sensitive-cm753786,Expected Earnings Release 02 27 2017 After hoursExpected Earnings Release 02 27 2017 After hours Avg Extended Hours Dollar Volume 2 080 524Avg Extended Hours Dollar Volume 2 080 524 Exelixis Inc EXEL is due to issue its quarterly earnings report in the upcoming extended
EXEL,EXEL:UW,BBG000BQ56F4,"After-Hours Earnings Report for February 27, 2017 :  PCLN, EOG, SBAC, PRGO, WDAY, OKE, OKS, ALB, EXEL, RSPP, APLE, BWXT",2017-02-27 19:59:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pZLyYCqOyKI/after-hours-earnings-report-for-february-27-2017-pcln-eog-sbac-prgo-wday-oke-oks-alb-exel-rspp-aple-bwxt-cm753758,The following companies are expected to report earnings after hours on 02 27 2017 Visit our Earnings Calendar for a full list of expected earnings releases The Priceline Group Inc PCLN is reporting for the quarter ending December 31 2016 The
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis shares jump after team up with Bristol-Myers on cancer trials,2017-02-27 17:02:58 +0000,http://www.cnbc.com/id/104307227?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104307227,Exelixis shares jump after team up with Bristol-Myers on cancer trials
EXEL,EXEL:UW,BBG000BQ56F4,Cooper (COO) to Report Q1 Earnings: Is a Surprise in Store?,2017-02-27 15:54:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pHV5y1IzC8o/cooper-coo-to-report-q1-earnings-is-a-surprise-in-store-cm753469,The Cooper Companies Inc COO is set to report first quarter fiscal 2017 results after the market closes on Mar 2 Cooper Companies has an impressive track of beating estimates in the trailing four quarters In the last reported quarter it recorded a positive earnings surprise of 1
EXEL,EXEL:UW,BBG000BQ56F4,4 Stocks to Buy with Superb Earnings Acceleration,2017-02-27 13:49:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8ZCDvaAaQcU/4-stocks-to-buy-with-superb-earnings-acceleration-cm753395,Earnings growth captivates almost everyone right from the top brass to research analysts This is simply because earnings are a measure of the money a company is making Take a company s revenues over a given period of time subtract the cost of production and you will have its earnings
EXEL,EXEL:UW,BBG000BQ56F4,Q4 2016 Exelixis Inc Earnings Release - After Market Close,2017-02-27 12:07:02 +0000,http://biz.yahoo.com/research/earncal/20170227.html?t=exel,Q4 2016 Exelixis Inc Earnings Release - After Market Close
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Clinical Trial Collaboration with Roche to Evaluate Cabozantinib and Atezolizumab in Locally Advanced or Metastatic Solid Tumors,2017-02-27 12:01:00 +0000,http://finance.yahoo.com/news/exelixis-announces-clinical-trial-collaboration-120100998.html,"[Business Wire] - Exelixis, Inc. today announced a new collaboration with Roche on a phase 1b dose escalation study that will evaluate the safety and tolerability of cabozantinib, Exelixis’ tyrosine kinase inhibitor , in combination with atezolizumab, Roche’s anti-PD-L1 immunotherapy, in patients with locally advanced or metastatic solid tumors."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis and Bristol-Myers Squibb Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma,2017-02-27 11:59:00 +0000,http://finance.yahoo.com/news/exelixis-bristol-myers-squibb-enter-115900280.html,"[Business Wire] - Exelixis, Inc. and Bristol-Myers Squibb Company today announced the companies have entered into a clinical development collaboration to evaluate CABOMETYX™ , Exelixis’ small molecule inhibitor of receptor tyrosine kinases, with Opdivo , Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, either alone or in combination with Yervoy ."
EXEL,EXEL:UW,BBG000BQ56F4,4 Stocks to Buy with Superb Earnings Acceleration,2017-02-27 11:44:11 +0000,http://finance.yahoo.com/news/4-stocks-buy-superb-earnings-114411331.html,4 Stocks to Buy with Superb Earnings Acceleration
EXEL,EXEL:UW,BBG000BQ56F4,Keryx (KERX) Q4 Earnings: What's in Store for the Stock?,2017-02-24 23:49:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0qrucxa5Nqg/keryx-kerx-q4-earnings-whats-in-store-for-the-stock-cm753120,Keryx Biopharmaceuticals Inc KERX is expected to report fourth quarter 2016 results on Mar 1 Last quarter the company recorded a negative earnings surprise of 77 27 Let s see how things are shaping up for this announcement Keryx s share price has decreased 16 6 year to date while
EXEL,EXEL:UW,BBG000BQ56F4,Radius Health (RDUS) Posts Wider Loss in Q4,2017-02-24 22:51:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MM6qRtO6g14/radius-health-rdus-posts-wider-loss-in-q4-cm753108,Radius Health Inc RDUS posted a loss of 1 22 per share in the fourth quarter of 2016 compared with a loss of 77 cents per share in the year ago quarter and wider than the Zacks Consensus Estimate loss of 1 16 The year over year increase in net loss was attributable to an increase
EXEL,EXEL:UW,BBG000BQ56F4,Keryx (KERX) Q4 Earnings: What's in Store for the Stock?,2017-02-24 22:06:10 +0000,http://finance.yahoo.com/news/keryx-kerx-q4-earnings-whats-220610810.html,Keryx (KERX) Q4 Earnings: What's in Store for the Stock?
EXEL,EXEL:UW,BBG000BQ56F4,"What's in the Cards for Box, Inc. (BOX) in Q4 Earnings?",2017-02-24 16:54:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rPtAi28a8VU/whats-in-the-cards-for-box-inc-box-in-q4-earnings-cm752829,Box Inc BOX is set to report fourth quarter fiscal 2017 results on Mar 1 Last quarter the company posted a positive earnings surprise of 14 29 Coming to the price performance the company has been steadily treading higher over the last one year The stock generated a return of 47
EXEL,EXEL:UW,BBG000BQ56F4,Why Earnings Season Could Be Great for Exelixis (EXEL),2017-02-24 15:54:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FHPmrT4RD0I/why-earnings-season-could-be-great-for-exelixis-exel-cm752748,Investors are always looking for stocks that are poised to beat at earnings season and Exelixis Inc EXEL may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because Exelixisis seeing favorable earnings
EXEL,EXEL:UW,BBG000BQ56F4,Tenet Healthcare (THC) Q4 Earnings: What's in the Cards?,2017-02-24 14:53:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KgcGrO2sS7E/tenet-healthcare-thc-q4-earnings-whats-in-the-cards-cm752583,Tenet Healthcare Corporation THC will release fourth quarter 2016 results on Feb 27 after the market closes Last quarter the company posted a negative earnings surprise of 15 79 Let s see how things are shaping up for this announcement Factors to be Considered this Quarter
EXEL,EXEL:UW,BBG000BQ56F4,DexCom (DXCM) Q4 Earnings: What to Expect from the Stock?,2017-02-24 14:53:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U_PRU68jtf8/dexcom-dxcm-q4-earnings-what-to-expect-from-the-stock-cm752569,DexCom Inc DXCM is set to report fiscal fourth quarter 2017 results on Feb 28 DexCom does not have an impressive track of beating estimates in the four trailing quarters In the last reported quarter it recorded a negative earnings surprise of 57 14 bringing the four quarter average
EXEL,EXEL:UW,BBG000BQ56F4,Why Earnings Season Could Be Great for Exelixis (EXEL),2017-02-24 13:38:01 +0000,http://finance.yahoo.com/news/why-earnings-season-could-great-133801144.html,Why Earnings Season Could Be Great for Exelixis (EXEL)
EXEL,EXEL:UW,BBG000BQ56F4,ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?,2017-02-23 23:49:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6U0jO_CrH2I/acadia-pharma-acad-q4-earnings-whats-in-store-this-time-cm752452,ACADIA Pharmaceuticals Inc ACAD is expected to report fourth quarter 2016 results on Feb 28 The company s track record is dismal ACADIA has missed estimates in all the trailing four quarters bringing the average negative earnings surprise to 19 07 ACADIA s share price increased 35
EXEL,EXEL:UW,BBG000BQ56F4,Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint?,2017-02-23 23:49:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EexAISVIypI/horizon-hznp-q4-earnings-stock-likely-to-disappoint-cm752448,Horizon Pharma plc HZNP is scheduled to report fourth quarter 2016 results on Feb 27 before the opening bell Horizon s performance has been dismal with the company missing earnings estimates in the four trailing quarters Overall the company has an average negative earnings surprise of 15
EXEL,EXEL:UW,BBG000BQ56F4,Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?,2017-02-23 23:49:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EmH81ji40XM/endocyte-ecyt-to-post-q4-earnings-whats-in-the-cards-cm752446,Endocyte Inc ECYT is expected to report fourth quarter 2016 results on Mar 1 The company has an impressive track record having beaten estimates on three of the trailing four quarters and reporting in line results in the remaining quarter Overall the company has recorded an average
EXEL,EXEL:UW,BBG000BQ56F4,Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?,2017-02-23 21:43:09 +0000,http://finance.yahoo.com/news/endocyte-ecyt-post-q4-earnings-214309313.html,Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?
EXEL,EXEL:UW,BBG000BQ56F4,ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?,2017-02-23 21:16:09 +0000,http://finance.yahoo.com/news/acadia-pharma-acad-q4-earnings-211609482.html,ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?
EXEL,EXEL:UW,BBG000BQ56F4,TriMas (TRS) to Post Q4 Earnings: What's in the Cards?,2017-02-23 16:53:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ekS81-40IE8/trimas-trs-to-post-q4-earnings-whats-in-the-cards-cm752044,TriMas Corporation TRS is scheduled to report fourth quarter 2014 results on Feb 28 before the opening bell Last quarter this diversified global manufacturer of engineered and applied products posted a 10 decline in earnings as lower sales offset the benefits made by the company s
EXEL,EXEL:UW,BBG000BQ56F4,Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?,2017-02-23 14:50:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iloLklQr6rg/jazz-pharma-jazz-q4-earnings-is-a-surprise-in-store-cm751915,Jazz Pharmaceuticals plc JAZZ is scheduled to report fourth quarter 2016 results on Feb 28 after the market closes Jazz s shares have outperformed the Zacks classified Medical Drugs industry so far this year Specifically the company s stock gained 23 7 during the period while
EXEL,EXEL:UW,BBG000BQ56F4,Juno Therapeutics (JUNO) Q4 Earnings: What's in the Cards?,2017-02-23 14:50:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/75Y4PGTBy-M/juno-therapeutics-juno-q4-earnings-whats-in-the-cards-cm751912,Juno Therapeutics Inc JUNO is set to report fourth quarter 2016 results on Mar 1 after the market closes Juno s shares have outperformed the Zacks classified Medical Biomedical and Genetics industry year to date Shares of the company gained 22 3 so far this year while the
EXEL,EXEL:UW,BBG000BQ56F4,TriMas (TRS) to Post Q4 Earnings: What's in the Cards?,2017-02-23 14:45:02 +0000,http://finance.yahoo.com/news/trimas-trs-post-q4-earnings-144502453.html,TriMas (TRS) to Post Q4 Earnings: What's in the Cards?
EXEL,EXEL:UW,BBG000BQ56F4,Endo (ENDP) to Post Q4 Earnings: Will the Stock Disappoint?,2017-02-23 00:50:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ztenwzFoWAg/endo-endp-to-post-q4-earnings-will-the-stock-disappoint-cm751697,Endo International plc ENDP is scheduled to report fourth quarter 2016 results on Feb 28 before the opening bell The company has been consistently beating earnings expectations In fact Endo posted a positive surprise in each of the trailing four quarters with an average positive surprise
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?,2017-02-22 22:49:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DY5IzZNQ5QQ/exelixis-exel-q4-earnings-is-positive-surprise-in-store-cm751652,Exelixis Inc EXEL is scheduled to report fourth quarter 2016 results on Feb 27 after the market close Exelixis had a mixed track record over the last four quarters The company surpassed expectations thrice in the four trailing quarters and missed the same in the remaining with an
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?,2017-02-22 20:10:08 +0000,http://finance.yahoo.com/news/exelixis-exel-q4-earnings-positive-201008166.html,Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
EXEL,EXEL:UW,BBG000BQ56F4,First Week of EXEL April 21st Options Trading,2017-02-22 19:51:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6fw-ha28Wzc/first-week-of-exel-april-21st-options-trading-cm751551,Investors in Exelixis Inc Symbol EXEL saw new options begin trading this week for the April 21st expiration At Stock Options Channel our YieldBoost formula has looked up and down the EXEL options chain for the new April 21st contracts and identified one put and one call contract
EXEL,EXEL:UW,BBG000BQ56F4,Can Penumbra (PEN) Spring a Surprise this Earnings Season?,2017-02-22 14:09:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RG5SLfEBu-Y/can-penumbra-pen-spring-a-surprise-this-earnings-season-cm751137,Penumbra Inc PEN is slated to release fourth quarter 2016 results on Feb 28 after market close Last quarter the company posted a positive earnings surprise of 63 64 The four quarter average earnings beat is 115 07 Let s see how things are shaping up for this
EXEL,EXEL:UW,BBG000BQ56F4,Can Penumbra (PEN) Spring a Surprise this Earnings Season?,2017-02-22 13:16:01 +0000,http://finance.yahoo.com/news/penumbra-pen-spring-surprise-earnings-131601711.html,Can Penumbra (PEN) Spring a Surprise this Earnings Season?
EXEL,EXEL:UW,BBG000BQ56F4,Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?,2017-02-22 01:06:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OLMZz2LbYGI/ionis-ions-q4-earnings-whats-in-the-cards-for-the-stock-cm750955,Ionis Pharmaceuticals Inc IONS is scheduled to report fourth quarter 2016 results on Feb 28 Last quarter the company recorded a negative earnings surprise of 14 29 Let s see how things are shaping up for this announcement Ionis share price decreased 1 9 year to date compared with
EXEL,EXEL:UW,BBG000BQ56F4,Intercept (ICPT) to Post Q4 Earnings: What's in the Cards?,2017-02-22 01:06:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MOpZcR8fkc4/intercept-icpt-to-post-q4-earnings-whats-in-the-cards-cm750953,Intercept Pharmaceuticals Inc ICPT is scheduled to report fourth quarter 2016 results on Feb 23 before the market opens In the last reported quarter the company recorded a positive surprise of 3 49 Let s see how things are shaping up for this announcement Intercept s share
EXEL,EXEL:UW,BBG000BQ56F4,Patterson Companies (PDCO) Q3 Earnings: What's in Store?,2017-02-21 14:54:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/85XU7PaT-rs/patterson-companies-pdco-q3-earnings-whats-in-store-cm750484,Patterson Companies Inc PDCO is set to report fiscal third quarter 2017 results on Feb 23 before the opening bell Patterson Companies does not have an impressive track of beating estimates in the trailing four quarters In the last reported quarter it recorded a negative earnings
EXEL,EXEL:UW,BBG000BQ56F4,Patterson Companies (PDCO) Q3 Earnings: What's in Store?,2017-02-21 13:46:01 +0000,http://finance.yahoo.com/news/patterson-companies-pdco-q3-earnings-134601284.html,Patterson Companies (PDCO) Q3 Earnings: What's in Store?
EXEL,EXEL:UW,BBG000BQ56F4,"Forget Alexion, Buy these 4 Biotech Stocks Instead",2017-02-20 14:53:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wCRPpf18LR0/forget-alexion-buy-these-4-biotech-stocks-instead-cm750186,New Haven CT based Alexion Pharmaceuticals Inc s ALXN fourth quarter results were mixed with the company reporting in line earnings while revenues were just shy of expectations Alexion s guidance for 2017 also fell short of expectations Although flagship drug Soliris will continue
EXEL,EXEL:UW,BBG000BQ56F4,"Forget Alexion, Buy these 4 Biotech Stocks Instead",2017-02-20 12:52:12 +0000,http://finance.yahoo.com/news/forget-alexion-buy-4-biotech-125212478.html,"Forget Alexion, Buy these 4 Biotech Stocks Instead"
EXEL,EXEL:UW,BBG000BQ56F4,Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?,2017-02-20 11:51:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ri8Hy5981YU/medtronic-mdt-q3-earnings-disappointment-in-the-cards-cm750158,Ireland based medical device major 160 Medtronic plc MDT is slated to report its third quarter fiscal 2017 earnings on Feb 21 before the opening bell Last quarter the company posted earnings of 1 12 per share surpassing the Zacks Consensus Estimate by a penny In fact Medtronic
EXEL,EXEL:UW,BBG000BQ56F4,Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?,2017-02-20 10:15:10 +0000,http://finance.yahoo.com/news/medtronic-mdt-q3-earnings-disappointment-101510102.html,Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,2017-02-17 22:02:00 +0000,http://finance.yahoo.com/news/exelixis-announces-phase-1-trial-220200818.html,"[Business Wire] - Exelixis, Inc. today announced results from a phase 1 trial of cabozantinib in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory genitourinary tumors."
EXEL,EXEL:UW,BBG000BQ56F4,Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?,2017-02-17 21:52:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4dUCIFDSRIE/radius-health-rdus-q4-earnings-will-the-stock-disappoint-cm749839,Radius Health Inc RDUS is scheduled to report fourth quarter 2016 financial results on Feb 23 Radius shares have underperformed the Medical Drugs industry in the last three months The stock lost 14 7 during this time period as compared to a gain of 4 4 for the industry
EXEL,EXEL:UW,BBG000BQ56F4,Merrimack (MACK): What Awaits the Stock in Q4 Earnings?,2017-02-17 21:51:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p6mayfa5Oa8/merrimack-mack-what-awaits-the-stock-in-q4-earnings-cm749823,Merrimack Pharmaceuticals Inc MACK is scheduled to report fourth quarter 2016 results in the next week Last quarter Merrimack delivered a positive earnings surprise of 23 33 Merrimack s share price decreased 21 9 year to date compared with the Zacks classified Medical Biomedical
EXEL,EXEL:UW,BBG000BQ56F4,Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?,2017-02-17 19:30:07 +0000,http://finance.yahoo.com/news/radius-health-rdus-q4-earnings-193007590.html,Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?
EXEL,EXEL:UW,BBG000BQ56F4,BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?,2017-02-17 14:58:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qTP1yu0rxU4/biomarin-bmrn-q4-earnings-will-it-post-a-beat-again-cm749441,We expect BioMarin Pharmaceutical Inc BMRN to beat expectations when it reports fourth quarter and full year 2016 results on Feb 23 after the market closes BioMarin had delivered a positive earnings surprise of 66 67 in the last quarter BioMarin s shares are up 9 2 so far this
EXEL,EXEL:UW,BBG000BQ56F4,Easier Regulatory Environment Could Send Biotech Industry Skyrocketing in 2017: Today's Reports on Neuralstem and Exelixis,2017-02-17 14:30:00 +0000,http://finance.yahoo.com/news/easier-regulatory-environment-could-send-143000190.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 17, 2017 / Biotech stocks have continued to outperform the broader markets in 2017 as an expectation of easier regulatory environment and growing speculation of mergers ..."
EXEL,EXEL:UW,BBG000BQ56F4,Two Great Stock Ideas in the IBB Biotech ETF,2017-02-15 19:44:00 +0000,http://www.investopedia.com/articles/investing/021517/looking-best-stock-ideas-ibb-acad-exel.asp?partner=YahooSA,Two Great Stock Ideas in the IBB Biotech ETF
EXEL,EXEL:UW,BBG000BQ56F4,"The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics",2017-02-14 16:21:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/08J0bT5Z2kI/the-zacks-analyst-blog-highlights-gilead-sciences-celgene-fate-therapeutics-exelixis-and-akebia-therapeutics-cm747617,For Immediate Release Chicago IL February 14 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
EXEL,EXEL:UW,BBG000BQ56F4,"The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics",2017-02-14 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-gilead-143002852.html,"The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics"
EXEL,EXEL:UW,BBG000BQ56F4,"Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb",2017-02-13 23:18:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mCtM39MPWUM/better-buy-exelixis-inc-vs-bristol-myers-squibb-cm747327,Two hot cancer drugs are being marketed by two very different companies Cabometyx is Exelixis NASDAQ EXEL crown jewel Opdivo is Bristol Myers Squibb s NYSE BMY rising star But Bristol Myers Squibb s stock is down over the last 12 months while Exelixis shares
EXEL,EXEL:UW,BBG000BQ56F4,"Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb",2017-02-13 22:17:17 +0000,http://www.fool.com/investing/2017/02/13/better-buy-exelixis-inc-vs-bristol-myers-squibb.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb"
EXEL,EXEL:UW,BBG000BQ56F4,ITT Inc. (ITT) Q4 Earnings: What's in Store for the Stock?,2017-02-13 16:22:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7ztc8gzoCeQ/itt-inc-itt-q4-earnings-whats-in-store-for-the-stock-cm747024,ITT Inc ITT is slated to report fourth quarter 2016 results before the opening bell on Feb 14 Last quarter the company s earnings came in line with the Zacks Consensus Estimate ITT Inc has a positive earnings surprise of 4 3 with earnings meeting estimates twice and beating in the
EXEL,EXEL:UW,BBG000BQ56F4,"Forget Gilead, Buy These 5 Biotech Stocks Instead",2017-02-13 16:22:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aPXypYElVcA/forget-gilead-buy-these-5-biotech-stocks-instead-cm747021,Biotech major Gilead Sciences Inc GILD reported better than expected results for the fourth quarter of 2016 however shares were down 8 6 immediately after the company reported results Overall Gilead s shares are down 9 3 ever since 4Q results were announced Moreover over
EXEL,EXEL:UW,BBG000BQ56F4,"Forget Gilead, Buy These 5 Biotech Stocks Instead",2017-02-13 14:14:02 +0000,http://finance.yahoo.com/news/forget-gilead-buy-5-biotech-141402577.html,"Forget Gilead, Buy These 5 Biotech Stocks Instead"
EXEL,EXEL:UW,BBG000BQ56F4,Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?,2017-02-10 17:19:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DqjSkTvxQO8/can-allscripts-mdrx-surprise-investors-in-q4-earnings-cm746376,Allscripts Healthcare Solutions Inc MDRX is scheduled to release fourth quarter 2016 results on Feb 16 Allscripts Healthcare has an impressive track of beating estimates in all the four trailing quarters In the last reported quarter it recorded a positive earnings surprise of 10
EXEL,EXEL:UW,BBG000BQ56F4,"Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors",2017-02-10 16:20:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hWpPYATCUmw/zackscom-featured-highlights-exelixis-rpc-unit-and-fortress-transportation-and-infrastructure-investors-cm746226,For Immediate Release Chicago IL February 10 2017 Stocks in this week s article include 160 Exelixis Inc NASDAQ EXEL Free Report RPC Inc NYSE RES Free Report Unit Corporation NYSE UNT Free Report and Fortress Transportation and Infrastructure
EXEL,EXEL:UW,BBG000BQ56F4,Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?,2017-02-10 14:42:02 +0000,http://finance.yahoo.com/news/allscripts-mdrx-surprise-investors-q4-144202028.html,Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?
EXEL,EXEL:UW,BBG000BQ56F4,"Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors",2017-02-10 14:30:02 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-exelixis-143002866.html,"Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors"
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis (EXEL) Shares March Higher, Can It Continue?",2017-02-10 11:19:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M2SnmO7y5xg/exelixis-exel-shares-march-higher-can-it-continue-cm746014,As of late it has definitely been a great time to be an investor in Exelixis Inc EXEL The stock has moved higher by 18 5 in the past month while it is also above its 20 Day SMA too This combination of strong price performance and favorable technical could suggest that the stock may be
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis (EXEL) Shares March Higher, Can It Continue?",2017-02-10 09:10:09 +0000,http://finance.yahoo.com/news/exelixis-exel-shares-march-higher-091009656.html,"Exelixis (EXEL) Shares March Higher, Can It Continue?"
EXEL,EXEL:UW,BBG000BQ56F4,Can Nutrisystem (NTRI) Surprise Investors in Q4 Earnings?,2017-02-09 18:19:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SHQVPQKyMoQ/can-nutrisystem-ntri-surprise-investors-in-q4-earnings-cm745671,Weight management products and service provider Nutrisystem Inc NTRI is scheduled to release fourth quarter 2016 results on Feb 27 Nutrisystem has an impressive track of beating estimates in three of the four trailing quarters However in the last reported quarter it earnings missed
EXEL,EXEL:UW,BBG000BQ56F4,Harry Boxer’s stocks to watch: biotechnology and technology,2017-02-09 17:37:44 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=7E5A804A-EEE4-11E6-866B-46BCFEE06D29&siteid=yhoof2,Harry Boxer’s stocks to watch: biotechnology and technology
EXEL,EXEL:UW,BBG000BQ56F4,Ecolab (ECL): What's in the Cards this Earnings Season?,2017-02-09 17:21:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-zSYMsqvaho/ecolab-ecl-whats-in-the-cards-this-earnings-season-cm745579,St Paul MN based Ecolab Inc ECL a leading provider of water hygiene and energy technologies and services is expected to report fourth quarter 2016 results on Feb 21 Last quarter the company reported earnings of 1 22 per share which missed the Zacks Consensus Estimate of 1
EXEL,EXEL:UW,BBG000BQ56F4,Buy 4 Stocks Riding High on Superb Earnings Acceleration,2017-02-09 16:22:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ulcmaefdW8w/buy-4-stocks-riding-high-on-superb-earnings-acceleration-cm745457,As we are in the thick of the Q4 earnings season investors should ideally scoop up stocks that are ready to make a big move Better than expected earnings results mostly lead to an uptick in the share price Right from the top brass to research analysts earnings growth captivates all This
EXEL,EXEL:UW,BBG000BQ56F4,Ecolab (ECL): What's in the Cards this Earnings Season?,2017-02-09 15:15:03 +0000,http://finance.yahoo.com/news/ecolab-ecl-whats-cards-earnings-151503568.html,Ecolab (ECL): What's in the Cards this Earnings Season?
EXEL,EXEL:UW,BBG000BQ56F4,Buy 4 Stocks Riding High on Superb Earnings Acceleration,2017-02-09 14:27:02 +0000,http://finance.yahoo.com/news/buy-4-stocks-riding-high-142702181.html,Buy 4 Stocks Riding High on Superb Earnings Acceleration
EXEL,EXEL:UW,BBG000BQ56F4,5 Drug Stocks Poised to Beat Earnings Estimates in Q4,2017-02-09 14:20:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R733SkOwjzs/5-drug-stocks-poised-to-beat-earnings-estimates-in-q4-cm745419,A positive earnings picture continues to emerge from the fourth quarter earnings season with both earnings and revenue growth improving compared to recent quarters As of Feb 8 319 S amp P 500 members or 76 3 of the index s total market capitalization had reported results the numbers show
EXEL,EXEL:UW,BBG000BQ56F4,5 Drug Stocks Poised to Beat Earnings Estimates in Q4,2017-02-09 12:39:12 +0000,http://finance.yahoo.com/news/5-drug-stocks-poised-beat-123912751.html,5 Drug Stocks Poised to Beat Earnings Estimates in Q4
EXEL,EXEL:UW,BBG000BQ56F4,3 Scorching Hot Biotech Stocks -- Are They Buys?,2017-02-08 23:18:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lpKiuq-DIDA/3-scorching-hot-biotech-stocks-are-they-buys-cm745212,Making a 70 return in only three months sounds pretty good Three biotech stocks have done just that and more Shares of Clovis Oncology NASDAQ CLVS soared over 120 during the last three months Bluebird bio s NASDAQ BLUE stock jumped more than 80 during the period
EXEL,EXEL:UW,BBG000BQ56F4,3 Scorching Hot Biotech Stocks -- Are They Buys?,2017-02-08 21:53:03 +0000,http://www.fool.com/investing/2017/02/08/3-scorching-hot-biotech-stocks-are-they-buys.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Scorching Hot Biotech Stocks -- Are They Buys?
EXEL,EXEL:UW,BBG000BQ56F4,"4 Stocks to Watch, Led by Biotech",2017-02-08 18:57:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4dNHW5mwHUM/4-stocks-to-watch-led-by-biotech-cm745073,"By Harry Boxer,  TheTechTrader.com    Biotech stocks continue to dominate our charts to watch.  Achaogen, Inc. ( AKAO ), which exploded in December on positive late-stage data on its lead antibiotic, has been working its way higher since.  The stock flagged in the second half of December, broke out, and then flagged"
EXEL,EXEL:UW,BBG000BQ56F4,Four Biotech Stocks Breaking Out,2017-02-08 18:49:00 +0000,http://www.forbes.com/sites/greatspeculations/2017/02/08/four-biotech-stocks-breaking-out/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Four Biotech Stocks Breaking Out
EXEL,EXEL:UW,BBG000BQ56F4,DENTSPLY (XRAY) Q4 Earnings: Is Disappointment in Store?,2017-02-08 17:20:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bhUd_R3fUaQ/dentsply-xray-q4-earnings-is-disappointment-in-store-cm744947,York PA based DENTSPLY Sirona Inc XRAY a dental solutions company is expected to report fourth quarter 2016 results on Feb 10 Last quarter the company reported earnings of 66 cents per share which beat the Zacks Consensus Estimate of 63 cents Meanwhile over the last four
EXEL,EXEL:UW,BBG000BQ56F4,DENTSPLY (XRAY) Q4 Earnings: Is Disappointment in Store?,2017-02-08 15:10:03 +0000,http://finance.yahoo.com/news/dentsply-xray-q4-earnings-disappointment-151003751.html,DENTSPLY (XRAY) Q4 Earnings: Is Disappointment in Store?
EXEL,EXEL:UW,BBG000BQ56F4,"The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals",2017-02-08 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-celgene-143002432.html,"The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals"
EXEL,EXEL:UW,BBG000BQ56F4,"The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma",2017-02-08 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-celgene-143002999.html,"The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 15,2017-02-07 21:05:00 +0000,http://finance.yahoo.com/news/exelixis-present-leerink-partners-global-210500159.html,"[Business Wire] - Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at Leerink’s Global Healthcare Conference taking place February 15-16 in New York, NY."
EXEL,EXEL:UW,BBG000BQ56F4,5 Great Biotech Stocks to Buy Now,2017-02-07 20:26:08 +0000,http://finance.yahoo.com/news/5-great-biotech-stocks-buy-202608361.html,5 Great Biotech Stocks to Buy Now
EXEL,EXEL:UW,BBG000BQ56F4,4 Drug Stocks that are Broker Favorites,2017-02-07 12:41:12 +0000,http://finance.yahoo.com/news/4-drug-stocks-broker-favorites-124112242.html,4 Drug Stocks that are Broker Favorites
EXEL,EXEL:UW,BBG000BQ56F4,"Hopes for Tax Reform, Less Regulation Lift Indices",2017-02-03 16:17:00 +0000,http://realmoney.thestreet.com/articles/02/03/2017/hopes-tax-reform-less-regulation-lift-indices?puc=yahoo&cm_ven=YAHOO,"Hopes for Tax Reform, Less Regulation Lift Indices"
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis to Release Fourth Quarter and Full Year 2016 Financial Results on Monday, February 27, 2017",2017-02-02 21:05:00 +0000,http://finance.yahoo.com/news/exelixis-release-fourth-quarter-full-210500794.html,"[Business Wire] - Exelixis, Inc. announced today that its fourth quarter and full year 2016 financial results will be released on Monday, February 27, 2017 after the markets close. At 5:00 p.m."
EXEL,EXEL:UW,BBG000BQ56F4,"2 Big Reasons Exelixis, Inc. Soared 22% in January",2017-02-02 14:35:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oZ9l2_p0H8k/2-big-reasons-exelixis-inc-soared-22-in-january-cm742015,Image source Getty Images What happened Shares of Exelixis NASDAQ EXEL a biopharmaceutical company focused on the development of therapies to treat cancer surged 22 in January according to data from S amp P Global Market Intelligence Two factors can
EXEL,EXEL:UW,BBG000BQ56F4,"2 Big Reasons Exelixis, Inc. Soared 22% in January",2017-02-02 12:37:13 +0000,http://www.fool.com/investing/2017/02/02/2-big-reasons-exelixis-inc-soared-22-in-january.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"2 Big Reasons Exelixis, Inc. Soared 22% in January"
EXEL,EXEL:UW,BBG000BQ56F4,Blog Coverage Exelixis Partners with Takeda to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan,2017-02-01 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-exelixis-partners-takeda-131500280.html,"[Accesswire] - Upcoming AWS Coverage on ARIAD Pharmaceuticals LONDON, UK / ACCESSWIRE / February 1, 2017 / Active Wall St. blog coverage looks at the headline from Exelixis, Inc. (NASDAQ: EXEL ) as the Company and Japan ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2017-01-31 21:05:00 +0000,http://finance.yahoo.com/news/exelixis-reports-inducement-grants-under-210500713.html,"[Business Wire] - Exelixis, Inc. announced that today it granted restricted stock unit awards representing an aggregate of 61,750 shares of Exelixis common stock and stock options to purchase an aggregate of 123,500 shares of Exelixis common stock to 13 new employees."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Takeda Sign Japanese Cancer Drug Deal",2017-01-31 16:24:00 +0000,http://www.investopedia.com/news/exelixis-takeda-ink-145m-cancer-license-pact-exel/?partner=YahooSA,"Exelixis, Takeda Sign Japanese Cancer Drug Deal"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Inks Partnership with Takeda for Cabometyx in Japan,2017-01-31 13:33:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tqBmhDVLf-g/exelixis-inks-partnership-with-takeda-for-cabometyx-in-japan-cm740668,Exelixis Inc EXEL announced that it has entered into an exclusive licensing agreement with Japan based Takeda Pharmaceutical Company Limited TKPYY for the commercialization and clinical development of Cabometyx cabozantinib in the country A look at Exelixis share price movement
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Inks Partnership with Takeda for Cabometyx in Japan,2017-01-31 12:00:12 +0000,http://finance.yahoo.com/news/exelixis-inks-partnership-takeda-cabometyx-120012119.html,Exelixis Inks Partnership with Takeda for Cabometyx in Japan
EXEL,EXEL:UW,BBG000BQ56F4,"EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement",2017-01-31 11:03:32 +0000,http://biz.yahoo.com/e/170131/exel8-k.html,"EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement"
EXEL,EXEL:UW,BBG000BQ56F4,"AEZS Inches Closer To D-Day, EYEG Catches Investors' Eyes, MCRB On Watch",2017-01-31 03:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gUAgYE_P7wI/aezs-inches-closer-to-dday-eyeg-catches-investors-eyes-mcrb-on-watch-20170131-00111,"AEZS Inches Closer To D-Day, EYEG Catches Investors' Eyes, MCRB On Watch"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan,2017-01-30 23:00:00 +0000,http://au.finance.yahoo.com/news/exelixis-takeda-enter-exclusive-licensing-230000709.html,"[Business Wire] - SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESSWIRE)-- Exelixis, Inc. (NASDAQ:EXEL - News) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced an exclusive licensing agreement for the commercialization and further clinical development in Japan of cabozantinib, Exelixis’ lead oncology medicine. With the signing of the agreement, Takeda gains exclusive commercial rights for all potential future cabozantinib indications in Japan, including advanced renal cell carcinoma (RCC), for which cabozantinib is marketed in the United States and European Union as CABOMETYX™ tablets."
EXEL,EXEL:UW,BBG000BQ56F4,3 Mid-Cap Biotech Stocks to Buy in February,2017-01-30 12:27:46 +0000,http://www.fool.com/investing/2017/01/29/3-mid-cap-biotech-stocks-to-buy-in-february.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Mid-Cap Biotech Stocks to Buy in February
EXEL,EXEL:UW,BBG000BQ56F4,3 Mid-Cap Biotech Stocks to Buy in February,2017-01-29 13:31:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yKUzag6Rxiw/3-mid-cap-biotech-stocks-to-buy-in-february-cm739849,Many small cap biotech stocks are super risky with no products on the market yet Some big cap biotech stocks on the other hand aren t growing like they used to Mid cap biotech stocks could meet Goldilocks criteria of finding what is just right Three mid cap biotechs in
EXEL,EXEL:UW,BBG000BQ56F4,Biotech M&A Activity Expected to Rise in 2017: Latest Reports on Exelixis and Vertex Pharmaceuticals,2017-01-27 14:45:00 +0000,http://finance.yahoo.com/news/biotech-m-activity-expected-rise-144500106.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 27, 2017 / The Biotech Industry witnessed a drop in mergers and acquisitions (M&A) activity amidst a slump in 2016. The Nasdaq Biotech Index declined roughly 22 percent ..."
EXEL,EXEL:UW,BBG000BQ56F4,"Better Buy: Exelixis, Inc. vs. Novartis",2017-01-23 22:27:21 +0000,http://www.fool.com/investing/2017/01/23/better-buy-exelixis-inc-vs-novartis.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Exelixis, Inc. vs. Novartis"
EXEL,EXEL:UW,BBG000BQ56F4,"Better Buy: Exelixis, Inc. vs. Novartis",2017-01-23 18:33:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tP4xP9L8oJI/better-buy-exelixis-inc-vs-novartis-cm736868,Last year Exelixis Inc NASDAQ EXEL was one of the best performing stocks in biotech notching a 164 gain With essentially one drug driving growth though it looks a bit risky Conversely shares of the diverse pharma giant Novartis NYSE NVS sank about 15 last year Yet
EXEL,EXEL:UW,BBG000BQ56F4,4 Momentum Charts to Watch This Week,2017-01-11 16:08:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FxkS9sxrlEU/4-momentum-charts-to-watch-this-week-cm732259,"Here are four stocks to watch in biotech and technology that have strong technical patterns.  Achaogen, Inc. ( AKAO ), which exploded on positive phase 3 news in December, has since been consolidating in a slightly declining coil. It recently broke out of the coil, but on low volume, and hasn't yet followed through."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. – Value Analysis (NASDAQ:EXEL) : January 11, 2017",2017-01-11 15:49:33 +0000,http://www.capitalcube.com/blog/index.php/exelixis-inc-value-analysis-nasdaqexel-january-11-2017/,"Exelixis, Inc. – Value Analysis (NASDAQ:EXEL) : January 11, 2017"
EXEL,EXEL:UW,BBG000BQ56F4,"After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next",2017-01-10 18:52:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E305Mk4Dbx0/after-ariads-acquisition-these-3-cancer-drug-stocks-could-be-next-cm731788,Japanese drugmaker Takeda Pharmaceutical Company NASDAQOTH TKPYY 160 announced yesterday that it s acquiring ARIAD Pharmaceuticals NASDAQ ARIA 160 for 24 per share or 5 2 billion The deal removes yet another commercial stage cancer drugmaker from the market and
EXEL,EXEL:UW,BBG000BQ56F4,"After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next",2017-01-10 17:21:07 +0000,http://www.fool.com/investing/2017/01/10/3-cancer-stocks-that-could-be-next-to-get-acquired.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next"
EXEL,EXEL:UW,BBG000BQ56F4,4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal,2017-01-10 16:55:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FtgRdTy4lhk/4-stocks-in-focus-as-biotech-ma-hopes-surge-on-takeda-ariad-deal-cm731695,Quite a few deals and licensing agreements were announced yesterday by pharma and biotech stocks but the one that stood out is the Takeda Pharmaceutical Company Limited TKPYY ARIAD Pharmaceuticals Inc ARIA announcement Japanese firm Takeda will be acquiring cancer focused ARIAD for
EXEL,EXEL:UW,BBG000BQ56F4,4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal,2017-01-10 14:27:02 +0000,http://finance.yahoo.com/news/4-stocks-focus-biotech-m-142702106.html,4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal
EXEL,EXEL:UW,BBG000BQ56F4,Genentech Withdraws Cost Claims Against Exelixis,2017-01-10 14:20:00 +0000,http://www.investopedia.com/news/exelixis-spikes-after-genentech-withdraws-claim-exel/?partner=YahooSA,Genentech Withdraws Cost Claims Against Exelixis
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : January 10, 2017",2017-01-10 12:23:16 +0000,http://www.capitalcube.com/blog/index.php/exelixis-inc-breached-its-50-day-moving-average-in-a-bullish-manner-exel-us-january-10-2017/,"Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : January 10, 2017"
EXEL,EXEL:UW,BBG000BQ56F4,"Why Exelixis, Inc. Stock Zoomed Higher Today",2017-01-09 22:49:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ELABRUa5yrk/why-exelixis-inc-stock-zoomed-higher-today-cm731333,Image source Getty Images What happened Shares of Exelixis NASDAQ EXEL ended the day up almost 15 after the company announced that its partner Genentech agreed to stop charging the biotech for some expenses under their collaboration agreement So what The two
EXEL,EXEL:UW,BBG000BQ56F4,"Why Exelixis, Inc. Stock Zoomed Higher Today",2017-01-09 21:14:46 +0000,http://www.fool.com/investing/2017/01/09/why-exelixis-inc-zoomed-higher-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Exelixis, Inc. Stock Zoomed Higher Today"
EXEL,EXEL:UW,BBG000BQ56F4,3 Stocks Expected to More Than Double Their Earnings in 2017,2017-01-09 12:25:11 +0000,http://www.fool.com/investing/2017/01/08/3-stocks-expected-to-more-than-double-their-earnin.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Stocks Expected to More Than Double Their Earnings in 2017
EXEL,EXEL:UW,BBG000BQ56F4,"Update on Dispute between Exelixis and Genentech, a Member of the Roche Group",2017-01-09 10:13:00 +0000,http://finance.yahoo.com/news/dispute-between-exelixis-genentech-member-101300221.html,"[Business Wire] - Exelixis, Inc. announced today that Genentech, Inc. has withdrawn its counterclaim against Exelixis in the ongoing JAMS arbitration concerning alleged breaches of the parties’ collaboration agreement."
EXEL,EXEL:UW,BBG000BQ56F4,Genentech Withdraws Counterclaim Against Exelixis In JAMS Arbitration,2017-01-09 05:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zkrQmfuthu0/genentech-withdraws-counterclaim-against-exelixis-in-jams-arbitration-20170109-00104,Genentech Withdraws Counterclaim Against Exelixis In JAMS Arbitration
EXEL,EXEL:UW,BBG000BQ56F4,3 Stocks Expected to More Than Double Their Earnings in 2017,2017-01-08 13:49:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gmYAYq0nPTo/3-stocks-expected-to-more-than-double-their-earnings-in-2017-cm730785,Most investors idea of impressive earnings growth is say 20 or more per year So what does that say about companies that grow their earnings by more than 100 in a year That s what Wall Street expects three biotechs to achieve over the next year Here s how Corcept
EXEL,EXEL:UW,BBG000BQ56F4,"The 4 Building Blocks That Pushed Exelixis, Inc. Higher by 164% in 2016",2017-01-05 16:44:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8ZaocuxPYdk/the-4-building-blocks-that-pushed-exelixis-inc-higher-by-164-in-2016-cm729849,Image source Getty Images What happened Shares of Exelixis NASDAQ EXEL a mid cap biotech company primarily focused on developing therapies to treat cancer surged 164 during 2016 according to S amp P Global Market Intelligence There appear to be four key reasons
EXEL,EXEL:UW,BBG000BQ56F4,"The 4 Building Blocks That Pushed Exelixis, Inc. Higher by 164% in 2016",2017-01-05 14:43:06 +0000,http://www.fool.com/investing/2017/01/05/the-4-building-blocks-that-pushed-exelixis-inc-hig.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"The 4 Building Blocks That Pushed Exelixis, Inc. Higher by 164% in 2016"
EXEL,EXEL:UW,BBG000BQ56F4,Biotech Stocks to Watch in 2017 ACADIA Pharmaceuticals and Exelixis,2017-01-04 14:15:00 +0000,http://finance.yahoo.com/news/biotech-stocks-watch-2017-acadia-141500730.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 4, 2017 / The Biotech Industry posted a sharp loss in 2016 as concerns over price gouging plagued the Industry. The iShares NASDAQ Biotechnology Index ETF (IBB) fell ..."
EXEL,EXEL:UW,BBG000BQ56F4,How calls are looking for Exelixis rally,2017-01-04 13:49:54 +0000,http://finance.yahoo.com/news/calls-looking-exelixis-rally-134954547.html,How calls are looking for Exelixis rally
EXEL,EXEL:UW,BBG000BQ56F4,Is It Too Late to Buy Exelixis Stock?,2017-01-04 12:24:26 +0000,http://www.fool.com/investing/2017/01/03/is-it-too-late-to-buy-exelixis-stock.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is It Too Late to Buy Exelixis Stock?
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2017-01-03 23:23:05 +0000,http://www.publicnow.com/view/5D1A21C55E73F00F05FAA76308E1F5ECA3D4C746,"[at noodls] - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 3, 2017-- Exelixis, Inc. (NASDAQ:EXEL) announced that today it granted restricted stock unit awards (RSUs) representing an aggregate of 17,750 shares ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2017-01-03 23:07:00 +0000,http://finance.yahoo.com/news/exelixis-reports-inducement-grants-under-230700690.html,"[Business Wire] - Exelixis, Inc. announced that today it granted restricted stock unit awards representing an aggregate of 17,750 shares of Exelixis common stock, and stock options to purchase an aggregate of 35,500 shares of Exelixis common stock to 11 new employees."
EXEL,EXEL:UW,BBG000BQ56F4,"ETFs with exposure to Exelixis, Inc. : January 3, 2017",2017-01-03 19:04:38 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-exelixis-inc-january-3-2017/,"ETFs with exposure to Exelixis, Inc. : January 3, 2017"
EXEL,EXEL:UW,BBG000BQ56F4,Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year,2017-01-03 15:08:01 +0000,http://www.fool.com/investing/2017/01/02/forget-gilead-sciences-inc-these-2-stocks-doubled.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year
EXEL,EXEL:UW,BBG000BQ56F4,Is It Too Late to Buy Exelixis Stock?,2017-01-03 13:57:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dos3Pb2JKJs/is-it-too-late-to-buy-exelixis-stock-cm728467,In just two years shares of Exelixis NASDAQ EXEL have soared more than 800 The stock s 2016 performance made it one of the best performing biotech stocks of the year That s great news for investors who jumped aboard the fast moving Exelixis train early But is it now too
EXEL,EXEL:UW,BBG000BQ56F4,Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year,2017-01-02 16:58:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RCGqfx5p3RM/forget-gilead-sciences-inc-these-2-stocks-doubled-last-year-cm728387,Long term holders of Gilead Sciences NASDAQ GILD enjoyed some market thumping gains in years past but concern over sagging hepatitis C antiviral sales caused the stock to slide about 26 5 in 2016 Despite a generally bleak year for Gilead and for biotech stocks in general
EXEL,EXEL:UW,BBG000BQ56F4,Biotech Stocks: What to Watch in 2017,2016-12-30 21:22:32 +0000,http://www.fool.com/investing/2016/12/29/biotech-stocks-what-to-watch-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Biotech Stocks: What to Watch in 2017
EXEL,EXEL:UW,BBG000BQ56F4,4 Biotech Stocks with Bright Prospects in 2017,2016-12-30 15:31:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BGi-iwi1xt0/4-biotech-stocks-with-bright-prospects-in-2017-cm727700,Biotech a happening but highly volatile sector again found itself in rough waters this year due to the drug pricing issue This is evident from the 20 8 decline witnessed by the NASDAQ Biotechnology Index in the year to date period Besides strained balance sheets and macroeconomic woes are
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : December 30, 2016",2016-12-30 13:25:48 +0000,http://www.capitalcube.com/blog/index.php/exelixis-inc-breached-its-50-day-moving-average-in-a-bearish-manner-exel-us-december-30-2016/,"Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : December 30, 2016"
EXEL,EXEL:UW,BBG000BQ56F4,Biotech Stocks: What to Watch in 2017,2016-12-29 22:57:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r53fbZDbezo/biotech-stocks-what-to-watch-in-2017-cm727678,This year has been a little rocky for biotech stocks In fact it s on pace to be the first decline for the sector in quite a few years But despite this year s decline for the sector there are plenty of individual biotech stocks with potential catalysts to help them rocket higher in
EXEL,EXEL:UW,BBG000BQ56F4,4 Biotech Stocks with Bright Prospects in 2017,2016-12-29 22:29:10 +0000,http://finance.yahoo.com/news/4-biotech-stocks-bright-prospects-222910692.html,4 Biotech Stocks with Bright Prospects in 2017
EXEL,EXEL:UW,BBG000BQ56F4,The 3 Biggest Risks for Pfizer in 2017,2016-12-28 12:23:22 +0000,http://www.fool.com/investing/2016/12/27/3-biggest-risks-for-pfizer-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The 3 Biggest Risks for Pfizer in 2017
EXEL,EXEL:UW,BBG000BQ56F4,The 3 Biggest Risks for Pfizer in 2017,2016-12-27 13:57:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BfG7UnLCm8k/the-3-biggest-risks-for-pfizer-in-2017-cm726141,Pfizer NYSE PFE appears to be on track to end 2016 with its stock price at roughly the same level as it began the year Could the new year present better opportunities for the big pharma Yes but challenges remain Here are three of Pfizer s biggest risks in
EXEL,EXEL:UW,BBG000BQ56F4,"Better Buy: Celldex Therapeutics, Inc. vs. Exelixis",2016-12-24 19:52:00 +0000,http://www.fool.com/investing/2016/12/23/better-buy-celldex-therapeutics-inc-vs-exelixis.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Celldex Therapeutics, Inc. vs. Exelixis"
EXEL,EXEL:UW,BBG000BQ56F4,"Better Buy: Celldex Therapeutics, Inc. vs. Exelixis",2016-12-23 20:57:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/258AzTIpRuQ/better-buy-celldex-therapeutics-inc-vs-exelixis-cm725842,Two oncology focused biotech stocks began 2016 with a dip but have diverged a great deal ever since A successful label expansion made Exelixis Inc NASDAQ EXEL a top industry performer this year and a surprising clinical trial failure made it a year Celldex
EXEL,EXEL:UW,BBG000BQ56F4,"The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen",2016-12-23 16:58:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Yr0VXQSPsBE/the-zacks-analyst-blog-highlights-colucid-pharmaceuticals-exelixis-tesaro-and-achaogen-cm725714,For Immediate Release Chicago IL December 23 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
EXEL,EXEL:UW,BBG000BQ56F4,"The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen",2016-12-23 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-colucid-143002218.html,"The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen"
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Ipsen Amend Exclusive Agreement for Cabometyx",2016-12-23 00:56:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MVmNsMXHYFw/exelixis-ipsen-amend-exclusive-agreement-for-cabometyx-cm725449,Exelixis Inc EXEL announced that it has amended the exclusive collaboration and licensing agreement with its European partner Ipsen Exelixis s year to date share price performance has been much better than that of the Zacks classified Medical Biomed Genetics industry The company
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Ipsen Amend Exclusive Agreement for Cabometyx",2016-12-22 23:18:11 +0000,http://finance.yahoo.com/news/exelixis-ipsen-amend-exclusive-agreement-231811790.html,"Exelixis, Ipsen Amend Exclusive Agreement for Cabometyx"
EXEL,EXEL:UW,BBG000BQ56F4,4 Biotech Stocks that More than Doubled in 2016,2016-12-22 17:01:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f97Na7O0HQY/4-biotech-stocks-that-more-than-doubled-in-2016-cm725153,2016 has not been a great year for biotech stocks which were under intense pressure with issues like increasing political and media focus on high price tags for drugs and the changing competitive scenario weighing on the sector While there has always been dissatisfaction about the high
EXEL,EXEL:UW,BBG000BQ56F4,4 Biotech Stocks that More than Doubled in 2016,2016-12-22 14:28:02 +0000,http://finance.yahoo.com/news/4-biotech-stocks-more-doubled-142802878.html,4 Biotech Stocks that More than Doubled in 2016
EXEL,EXEL:UW,BBG000BQ56F4,"EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement",2016-12-21 11:06:06 +0000,http://biz.yahoo.com/e/161221/exel8-k.html,"EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Stock Is Up 203% in 2016 -- Is There Still More Upside Ahead?,2016-12-21 06:22:05 +0000,http://www.fool.com/investing/2016/12/20/exelixis-stock-is-up-203-in-2016-is-there-still-mo.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Exelixis Stock Is Up 203% in 2016 -- Is There Still More Upside Ahead?
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada,2016-12-21 06:12:15 +0000,http://www.publicnow.com/view/F9BB44C824C8CB771AD136FDE3D67E3D233AF8DE,"[at noodls] - -- Amendment enhances productive year with CABOMETYXregulatory approvals and commercial launches in the United States and European Union -- Exelixis to receive $10 million upfront payment, with subsequent ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada,2016-12-21 06:00:00 +0000,http://au.finance.yahoo.com/news/exelixis-ipsen-amend-exclusive-licensing-060000856.html,"[Business Wire] - ADR: IPSEY) today jointly announced an amendment to the exclusive collaboration and licensing agreement for the commercialization and continued development of cabozantinib, to include commercialization rights in Canada for Ipsen where Ipsen has an established business (Mississauga, Ontario). Signed in February 2016, the original agreement gave Ipsen exclusive commercialization rights for current and potential future cabozantinib indications outside of the United States, Canada and Japan."
EXEL,EXEL:UW,BBG000BQ56F4,Interesting EXEL Put And Call Options For August 2017,2016-12-20 15:59:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qFELMfnqs4w/interesting-exel-put-and-call-options-for-august-2017-cm724005,Investors in Exelixis Inc Symbol EXEL saw new options begin trading this week for the August 2017 expiration One of the key inputs that goes into the price an option buyer is willing to pay is the time value so with 241 days until expiration the newly trading contracts represent a
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Stock Is Up 203% in 2016 -- Is There Still More Upside Ahead?,2016-12-20 15:57:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3c-FhuqtssM/exelixis-stock-is-up-203-in-2016-is-there-still-more-upside-ahead-cm723879,While most of its biotechnology peers floundered in 2016 Cinderella stock Exelixis NASDAQ EXEL has treated investors to a stunning 200 gain so far this year Its lead drug Cabometyx also branded as Cometriq spent years generating lackluster sales as a rare thyroid
EXEL,EXEL:UW,BBG000BQ56F4,Forget Marijuana Stocks: Buy These 3 Biotech Stocks Instead,2016-12-19 19:06:59 +0000,http://www.fool.com/investing/2016/12/18/forget-marijuana-stocks-buy-these-3-biotech-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Forget Marijuana Stocks: Buy These 3 Biotech Stocks Instead
EXEL,EXEL:UW,BBG000BQ56F4,7 Top Stocks We're Excited About Headed Into 2017,2016-12-19 16:00:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dey9qp2mHG4/7-top-stocks-were-excited-about-headed-into-2017-cm723223,The new year is rapidly approaching which means it s a great time to give your portfolio a fresh look To help you find a few stocks that could go on to be big winners in 2017 we asked a team of our Motley Fool contributors to highlight one of their top ideas Read on to see why
EXEL,EXEL:UW,BBG000BQ56F4,7 Top Stocks We're Excited About Headed Into 2017,2016-12-19 14:28:00 +0000,http://www.fool.com/investing/2016/12/19/7-top-stocks-were-excited-about-headed-into-2017.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,7 Top Stocks We're Excited About Headed Into 2017
EXEL,EXEL:UW,BBG000BQ56F4,The Best Biopharma CEOs of 2016 Are...,2016-12-19 14:10:00 +0000,https://www.thestreet.com/story/13930531/1/the-best-biopharma-ceos-of-2016-are.html?puc=yahoo&cm_ven=YAHOO,The Best Biopharma CEOs of 2016 Are...
EXEL,EXEL:UW,BBG000BQ56F4,Forget Marijuana Stocks: Buy These 3 Biotech Stocks Instead,2016-12-18 20:56:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iQpCYh7GFrs/forget-marijuana-stocks-buy-these-3-biotech-stocks-instead-cm723015,Why are investors so excited and intrigued by marijuana stocks Some want to ride the wave of growing acceptance of cannabis based products Others like the momentum I think though that investors can find better risk versus reward potential in three biotech stocks Organovo
EXEL,EXEL:UW,BBG000BQ56F4,"XT, EXEL, S, MRVL: Large Inflows Detected at ETF",2016-12-16 17:58:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hlhmt7mlHBo/xt-exel-s-mrvl-large-inflows-detected-at-etf-cm722635,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Exponential Technologies ETF Symbol XT where we have detected an approximate 145 6 million dollar inflow that s a 17 8 increase week over week
EXEL,EXEL:UW,BBG000BQ56F4,"ETFs with exposure to Exelixis, Inc. : December 14, 2016",2016-12-14 18:02:00 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-exelixis-inc-december-14-2016/,"ETFs with exposure to Exelixis, Inc. : December 14, 2016"
EXEL,EXEL:UW,BBG000BQ56F4,"The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis",2016-12-14 17:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NhU-h4RWqmw/the-zacks-analyst-blog-highlights-celgene-regeneron-pharmaceuticals-ophthotech-and-exelixis-cm721403,For Immediate Release Chicago IL December 14 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
EXEL,EXEL:UW,BBG000BQ56F4,"The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis",2016-12-14 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-celgene-143002936.html,"The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis"
EXEL,EXEL:UW,BBG000BQ56F4,Here's Why Trump's Pledge to Lower Drug Prices Is All Bark and No Bite,2016-12-13 18:19:19 +0000,http://www.fool.com/investing/2016/12/12/heres-why-trumps-pledge-to-lower-drug-prices-is-al.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Here's Why Trump's Pledge to Lower Drug Prices Is All Bark and No Bite
EXEL,EXEL:UW,BBG000BQ56F4,3 Great Stocks to Beat the Biotech Blues,2016-12-13 14:59:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FvOeEBkdu7U/3-great-stocks-to-beat-the-biotech-blues-cm720567,There is no doubt that 2016 has been a pretty tumultuous year for biotech stocks with the sector facing a lot of flak for rising drug prices The sector has been under pressure for more than a year now though shares did rally post elections in November Immediately after election results
EXEL,EXEL:UW,BBG000BQ56F4,3 Great Stocks to Beat the Biotech Blues,2016-12-13 13:09:01 +0000,http://finance.yahoo.com/news/3-great-stocks-beat-biotech-130901414.html,3 Great Stocks to Beat the Biotech Blues
EXEL,EXEL:UW,BBG000BQ56F4,Here's Why Trump's Pledge to Lower Drug Prices Is All Bark and No Bite,2016-12-12 19:56:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZD9DMGOrvgk/heres-why-trumps-pledge-to-lower-drug-prices-is-all-bark-and-no-bite-cm720317,Image source Disney ABC Television Group via Flickr In less than six weeks President elect Donald Trump will be inaugurated and become the 45th president of the United States Shortly after winning the Nov 8 election Trump and his team released his 100 day action plan which
EXEL,EXEL:UW,BBG000BQ56F4,2 Companies I Wish I'd Bought in 2016,2016-12-12 15:59:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/80fmY96w17E/2-companies-i-wish-id-bought-in-2016-cm720077,We Fools are firm believers that successful investing 160 requires patience but we also recognize that waiting too long can sometimes be a costly decision I learned this lesson the hard way in 2016 as my patience caused me to miss out on buying a few companies that I believed could
EXEL,EXEL:UW,BBG000BQ56F4,2 Companies I Wish I'd Bought in 2016,2016-12-12 14:03:06 +0000,http://www.fool.com/investing/2016/12/12/2-companies-i-wish-id-bought-in-2016.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,2 Companies I Wish I'd Bought in 2016
EXEL,EXEL:UW,BBG000BQ56F4,"Wednesday Sector Laggards: Drugs, Biotechnology Stocks",2016-12-07 18:56:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NfceRJdoDV4/wednesday-sector-laggards-drugs-biotechnology-stocks-cm718164,In trading on Wednesday drugs shares were relative laggards down on the day by about 2 7 Helping drag down the group were shares of Repros Therapeutics RPRX down about 10 5 and shares of Blueprint Medicines BPMC down about 9 6 on the day Also lagging the market Wednesday
EXEL,EXEL:UW,BBG000BQ56F4,"Wednesday's ETF Movers: GDXJ, XBI",2016-12-07 18:56:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jffro8m8QT0/wednesdays-etf-movers-gdxj-xbi-cm718160,In trading on Wednesday the Junior Gold Miners ETF GDXJ is outperforming other ETFs up about 2 6 on the day Components of that ETF showing particular strength include shares of Asanko Gold AKG CA up about 6 8 and shares of B2gold BTG up about 5 4 on the day
EXEL,EXEL:UW,BBG000BQ56F4,Mid-Day Market Update: Dave & Buster's Climbs On Upbeat Results; Sigma Designs Shares Slide,2016-12-07 18:35:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WLTiUDPVurM/mid-day-market-update-dave-busters-climbs-on-upbeat-results-sigma-designs-shares-slide-cm718199,Midway through trading Wednesday the Dow traded up 0 30 percent to 19 308 81 while the NASDAQ gained 0 01 percent to 5 333 19 The S amp P also rose gaining 0 21 percent to 2 216 83 Leading and Lagging Sectors On Wednesday basic materials shares gained by 1 12 percent
EXEL,EXEL:UW,BBG000BQ56F4,Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?,2016-12-07 13:38:01 +0000,http://finance.yahoo.com/news/earnings-estimates-moving-higher-exelixis-133801010.html,Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and Pipeline,2016-12-07 13:00:00 +0000,http://finance.yahoo.com/news/exelixis-announces-leadership-hires-public-130000720.html,"[Business Wire] - Exelixis, Inc. today announced two high-level appointments designed to further strengthen the company’s public affairs and business development capabilities following the launch of its newest medicine, CABOMETYX™, earlier this year."
EXEL,EXEL:UW,BBG000BQ56F4,"This Dynamic Duo of Catalysts Sent Exelixis, Inc. Higher by 60% in November",2016-12-05 23:11:41 +0000,http://www.fool.com/investing/2016/12/04/this-dynamic-duo-of-catalysts-sent-exelixis-inc-hi.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"This Dynamic Duo of Catalysts Sent Exelixis, Inc. Higher by 60% in November"
EXEL,EXEL:UW,BBG000BQ56F4,Hedge Funds Aren’t Crazy About John Bean Technologies Corp (JBT) Anymore,2016-12-05 08:15:54 +0000,http://www.insidermonkey.com/blog/hedge-funds-arent-crazy-about-john-bean-technologies-corp-jbt-anymore-498097/,Hedge Funds Aren’t Crazy About John Bean Technologies Corp (JBT) Anymore
EXEL,EXEL:UW,BBG000BQ56F4,Why Exelixis Was a Top Stock in 2016 So Far,2016-12-02 18:03:49 +0000,http://www.fool.com/investing/2016/12/02/why-exelixis-was-a-top-stock-in-2016-so-far.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Exelixis Was a Top Stock in 2016 So Far
EXEL,EXEL:UW,BBG000BQ56F4,3 Biotech Stocks to Buy in December,2016-12-02 14:21:09 +0000,http://www.fool.com/investing/2016/12/01/3-biotech-stocks-to-buy-in-december.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotech Stocks to Buy in December
EXEL,EXEL:UW,BBG000BQ56F4,5 Top Performing Biotechnology Stocks of November,2016-12-01 23:35:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iRErIMJJE-w/5-top-performing-biotechnology-stocks-of-november-cm716722,November was a great month for pharma biotech stocks after a rather difficult year when the industry struggled with media and political focus on high drug prices The pharma biotech industry responded favorably to Donald Trump s victory in the Presidential election last month on anticipation
EXEL,EXEL:UW,BBG000BQ56F4,5 Top Performing Biotechnology Stocks of November,2016-12-01 21:20:09 +0000,http://finance.yahoo.com/news/5-top-performing-biotechnology-stocks-212009162.html,5 Top Performing Biotechnology Stocks of November
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis (EXEL): Strong Industry, Solid Earnings Estimate Revisions",2016-12-01 18:19:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TJmagQeCUWQ/exelixis-exel-strong-industry-solid-earnings-estimate-revisions-cm716486,One stock that might be an intriguing choice for investors right now is Exelixis Inc EXEL This is because this security in the Medical Biomedical and Genetics space is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective This
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis (EXEL): Strong Industry, Solid Earnings Estimate Revisions",2016-12-01 16:08:04 +0000,http://finance.yahoo.com/news/exelixis-exel-strong-industry-solid-160804033.html,"Exelixis (EXEL): Strong Industry, Solid Earnings Estimate Revisions"
EXEL,EXEL:UW,BBG000BQ56F4,3 Biotech Stocks to Buy in December,2016-12-01 15:19:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XNV973yfpJ4/3-biotech-stocks-to-buy-in-december-cm716237,Image source Getty Images It has been a wild year to be a biotech investor Shares of the SPDR S amp P Biotech ETF NYSEMKT XBI a popular ETF that holds several dozen individual biotech companies cratered and recovered multiple times in 2016 based on the political
EXEL,EXEL:UW,BBG000BQ56F4,5 Stocks Up 100% or More This Year,2016-12-01 02:16:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HsLBstg8vYg/5-stocks-up-100-or-more-this-year-cm716124,The stock market has been on a bullish run this year thanks in part to the recent rise following the U S election and encouraging numbers for U S GDP growth and jobs creation Year to date the S amp P 500 and Nasdaq are each up around 7 5 hitting all time highs within the
EXEL,EXEL:UW,BBG000BQ56F4,5 Stocks Up 100% or More This Year,2016-12-01 00:43:00 +0000,http://www.fool.com/investing/2016/11/30/5-stocks-up-100-or-more-this-year.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,5 Stocks Up 100% or More This Year
EXEL,EXEL:UW,BBG000BQ56F4,What's Pfizer's Excuse for Not Buying Exelixis?,2016-11-30 23:18:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bCXPOLmgFgk/whats-pfizers-excuse-for-not-buying-exelixis-cm716068,Exelixis Inc NASDAQ EXEL 160 reported in October that its kidney cancer drug Cabometyx outperformed Pfizer Inc s NYSE PFE 160 top selling Sutent in first line advanced kidney cancer patients Exelixis management plans to use this data to convince regulators to
EXEL,EXEL:UW,BBG000BQ56F4,Is Wright Medical Group Inc (WMGI) a Good Stock for Your Portfolio?,2016-11-30 22:36:01 +0000,http://www.insidermonkey.com/blog/is-wright-medical-group-inc-wmgi-a-good-stock-for-your-portfolio-491846/,Is Wright Medical Group Inc (WMGI) a Good Stock for Your Portfolio?
EXEL,EXEL:UW,BBG000BQ56F4,What's Pfizer's Excuse for Not Buying Exelixis?,2016-11-30 21:41:08 +0000,http://www.fool.com/investing/2016/11/30/whats-pfizers-excuse-for-not-buying-exelixis.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,What's Pfizer's Excuse for Not Buying Exelixis?
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis to Present at the BMO Prescription for Success Healthcare Conference on December 14,2016-11-30 21:15:00 +0000,http://finance.yahoo.com/news/exelixis-present-bmo-prescription-success-211500589.html,"[Business Wire] - Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at BMO Capital Markets’ Prescription for Success Healthcare Conference taking place December 14 in New York."
EXEL,EXEL:UW,BBG000BQ56F4,"Hedge Funds Are Buying RealPage, Inc. (RP)",2016-11-30 15:40:41 +0000,http://www.insidermonkey.com/blog/hedge-funds-are-buying-realpage-inc-rp-492914/,"Hedge Funds Are Buying RealPage, Inc. (RP)"
EXEL,EXEL:UW,BBG000BQ56F4,The 5 Best Biotech Stocks of 2016,2016-11-30 15:02:23 +0000,http://www.fool.com/investing/2016/11/29/the-best-biotech-stocks-of-2016.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The 5 Best Biotech Stocks of 2016
EXEL,EXEL:UW,BBG000BQ56F4,"Should You Buy Exelixis, Inc. (EXEL)?",2016-11-30 14:46:01 +0000,http://www.insidermonkey.com/blog/should-you-buy-exelixis-inc-exel-491691/,"Should You Buy Exelixis, Inc. (EXEL)?"
EXEL,EXEL:UW,BBG000BQ56F4,The 5 Best Biotech Stocks of 2016,2016-11-29 21:54:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nxr66jvKvn0/the-5-best-biotech-stocks-of-2016-cm715355,There have been better years for biotech stocks than 2016 has turned out to be Concerns about a potential crackdown on excessive drug pricing cast a dark cloud over most drugmakers However despite headwinds for the broader industry some biotech stocks performed very well Here s
EXEL,EXEL:UW,BBG000BQ56F4,Shark Bites: Eager Buyers Pounce on Pullback,2016-11-29 18:52:00 +0000,http://realmoney.thestreet.com/articles/11/29/2016/shark-bites-eager-buyers-pounce-pullback?puc=yahoo&cm_ven=YAHOO,Shark Bites: Eager Buyers Pounce on Pullback
EXEL,EXEL:UW,BBG000BQ56F4,3 Healthcare Stocks Investors Have Been Thankful for This Year,2016-11-29 00:32:35 +0000,http://www.fool.com/investing/2016/11/28/3-healthcare-stocks-investors-have-been-thankful-f.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Healthcare Stocks Investors Have Been Thankful for This Year
EXEL,EXEL:UW,BBG000BQ56F4,3 Healthcare Stocks Investors Have Been Thankful for This Year,2016-11-28 19:55:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HgU-4LMATT4/3-healthcare-stocks-investors-have-been-thankful-for-this-year-cm714647,Happy holidays 160 What do a cancer drugmaker a medical marijuana play and an insurer have in common They re among the best performing healthcare stocks on the planet this year Exelixis NASDAQ EXEL GW Pharmaceuticals NASDAQ GWPH and UnitedHealth Group
EXEL,EXEL:UW,BBG000BQ56F4,The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3,2016-11-24 22:48:40 +0000,http://www.insidermonkey.com/blog/the-healthcare-gurus-at-baker-bros-advisors-were-buying-these-stocks-in-q3-491116/,The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3
EXEL,EXEL:UW,BBG000BQ56F4,4 stocks to watch,2016-11-23 14:30:56 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=9801B360-14C5-4CEF-BB3F-DB2D35B26488&siteid=yhoof2,4 stocks to watch
EXEL,EXEL:UW,BBG000BQ56F4,"EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits",2016-11-22 22:09:19 +0000,http://biz.yahoo.com/e/161122/exel8-k.html,"EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits"
EXEL,EXEL:UW,BBG000BQ56F4,Sanofi (SNY) Soliqua Approved for Type 2 Diabetes in Adults,2016-11-22 18:21:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pBga_NaEpn4/sanofi-sny-soliqua-approved-for-type-2-diabetes-in-adults-cm712687,Sanofi SNY announced that the FDA has approved its once daily injection Soliqua 100 33 a combination of its diabetes drugs Lantus and lixisenatide EU trade name Lyxumia for the treatment of type 2 diabetes in adults who have inadequately controlled their disease with basal insulin
EXEL,EXEL:UW,BBG000BQ56F4,"4 Stocks Breaking Out: Week Of November 22, 2016",2016-11-22 16:02:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M30f_mzU3iE/4-stocks-breaking-out-week-of-november-22-2016-cm712695,"Advanced Micro Devices, Inc. ( AMD ) has been up seven sessions in a row, gaining almost 50% during that time. On Monday it closed up 23 cents to 8.94, getting as high as 9.22 intraday. With big volume and strong OBV, watch for a move to 10 next, followed by the channel top above 13.  Amkor Technology, Inc. ( AMKR )"
EXEL,EXEL:UW,BBG000BQ56F4,Sanofi (SNY) Soliqua Approved for Type 2 Diabetes in Adults,2016-11-22 13:54:01 +0000,http://finance.yahoo.com/news/sanofi-sny-soliqua-approved-type-135401923.html,Sanofi (SNY) Soliqua Approved for Type 2 Diabetes in Adults
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis to Present at the Piper Jaffray 28th Annual Healthcare Conference on November 29,2016-11-21 21:17:00 +0000,http://finance.yahoo.com/news/exelixis-present-piper-jaffray-28th-211700784.html,"[Business Wire] - Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at Piper Jaffray’s 28th Annual Healthcare Conference taking place November 29 – 30 in New York."
EXEL,EXEL:UW,BBG000BQ56F4,Is Exelixis the Best Small-Cap Biotech Stock?,2016-11-18 23:50:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hFf7J3ueGvU/is-exelixis-the-best-small-cap-biotech-stock-cm711507,What stock is best is undeniably subjective but Exelixis NASDAQ EXEL 196 return this year certainly makes it worthy of consideration Shares in the once maligned cancer drug developer have enjoyed a resurgence this year following the successful launch of its new kidney
EXEL,EXEL:UW,BBG000BQ56F4,7 A-Rated Healthcare Stocks to Buy Before Trump Takes Office,2016-11-18 22:51:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A5dreGhRHAU/7-a-rated-healthcare-stocks-to-buy-before-trump-takes-office-cm711495,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips There is no doubt change is in the air across the U S after our recent historic election And one of the likely first changes or at least one of the first to be discussed will be how to modify
EXEL,EXEL:UW,BBG000BQ56F4,Is Exelixis the Best Small-Cap Biotech Stock?,2016-11-18 21:40:06 +0000,http://www.fool.com/investing/2016/11/18/is-exelixis-the-best-small-cap-biotech-stock.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Exelixis the Best Small-Cap Biotech Stock?
EXEL,EXEL:UW,BBG000BQ56F4,"New Oriental Education & Technology Group, BJ's Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day",2016-11-18 16:52:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QzxZPgB8cwk/new-oriental-education-technology-group-bjs-restaurants-ariad-pharmaceuticals-incyte-and-exelixis-highlighted-as-zacks-bull-and-bear-of-the-day-cm711226,For Immediate Release Chicago IL November 18 2016 Zacks Equity Research highlights 160 New Oriental Education amp Technology Group NYSE EDU Free Report as the Bull of the Day and BJ s Restaurants NASDAQ BJRI Free Report as the Bear of the Day In
EXEL,EXEL:UW,BBG000BQ56F4,Endo Reports Positive Cellulite Treatment Data on Xiaflex,2016-11-18 15:51:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HAtr2pSNNEs/endo-reports-positive-cellulite-treatment-data-on-xiaflex-cm711173,Endo International plc ENDP announced positive data from a phase IIb study on Xiaflex collagenase clostridium histolyticum for the treatment of patients suffering from edematous fibrosclerotic panniculopathy also known as cellulite Data showed that patients treated with
EXEL,EXEL:UW,BBG000BQ56F4,"New Oriental Education & Technology Group, BJ's Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day",2016-11-18 14:30:02 +0000,http://finance.yahoo.com/news/oriental-education-technology-group-bjs-143002240.html,"New Oriental Education & Technology Group, BJ's Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day"
EXEL,EXEL:UW,BBG000BQ56F4,Endo Reports Positive Cellulite Treatment Data on Xiaflex,2016-11-18 13:48:01 +0000,http://finance.yahoo.com/news/endo-reports-positive-cellulite-treatment-134801246.html,Endo Reports Positive Cellulite Treatment Data on Xiaflex
EXEL,EXEL:UW,BBG000BQ56F4,Shire Launches Cuvitru in U.S. for Primary Immunodeficiency,2016-11-18 06:51:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C-7ODevpLyA/shire-launches-cuvitru-in-us-for-primary-immunodeficiency-cm710973,Shire plc SHPG announced the launch of Cuvitru in the U S Cuvitru an immune globulin subcutaneous 20 solution gained FDA approval for primary humoral immunodeficiency in adult and pediatric patients aged two years and older in Sep 2016 According to the press release issued by
EXEL,EXEL:UW,BBG000BQ56F4,"Bristol-Myers, Enterome Ink Immuno-Oncology Collaboration",2016-11-17 15:53:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GF6gcq9h1Io/bristol-myers-enterome-ink-immuno-oncology-collaboration-cm710586,Bristol Myers Squibb Company BMY announced an immuno oncology focused collaboration agreement with Enterome for the discovery and development of microbiome derived biomarkers drug targets and bioactive molecules as potential companion diagnostics and therapeutics for cancer The partnership
EXEL,EXEL:UW,BBG000BQ56F4,3 Things Exelixis Must Do to Survive and Thrive in 2017,2016-11-17 15:52:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FPpwwYqZXB8/3-things-exelixis-must-do-to-survive-and-thrive-in-2017-cm710577,Few stocks have performed as well as Exelixis NASDAQ EXEL has in 2016 The biotech s share price has nearly tripled this year Will Exelixis be able to carry this tremendous momentum in to 2017 Mike Morrissey Exelixis CEO spoke at the Stifel Healthcare Conference this week
EXEL,EXEL:UW,BBG000BQ56F4,3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise,2016-11-17 15:51:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/haGDFsP1dtc/3-stocks-to-add-to-your-portfolio-as-biotech-ma-hopes-rise-cm710528,2016 has not been a great year for mergers and acquisitions M amp As in the pharma and biotech sector although some headline deals like the Pfizer PFE Medivation and the Teva Actavis Generics acquisitions were completed this year While expectations were high that this year too the pharma
EXEL,EXEL:UW,BBG000BQ56F4,3 Things Exelixis Must Do to Survive and Thrive in 2017,2016-11-17 14:29:41 +0000,http://www.fool.com/investing/2016/11/17/3-keys-for-exelixis-to-survive-and-thrive-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Things Exelixis Must Do to Survive and Thrive in 2017
EXEL,EXEL:UW,BBG000BQ56F4,3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise,2016-11-17 13:56:01 +0000,http://finance.yahoo.com/news/3-stocks-add-portfolio-biotech-135601225.html,3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise
EXEL,EXEL:UW,BBG000BQ56F4,"Bristol-Myers, Enterome Ink Immuno-Oncology Collaboration",2016-11-17 13:17:01 +0000,http://finance.yahoo.com/news/bristol-myers-enterome-ink-immuno-131701115.html,"Bristol-Myers, Enterome Ink Immuno-Oncology Collaboration"
EXEL,EXEL:UW,BBG000BQ56F4,Surging Earnings Estimates Signal Good News for Exelixis (EXEL),2016-11-16 17:52:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NGNhIuYy0Z4/surging-earnings-estimates-signal-good-news-for-exelixis-exel-cm710157,Exelixis Inc EXEL is a California based biopharmaceutical company that could be an interesting play for investors That is because not only does the stock have decent short term momentum but it is seeing solid activity on the earnings estimate revision front as well These positive
EXEL,EXEL:UW,BBG000BQ56F4,Pfizer Reports Phase III Psoriatic Arthritis Data on Xeljanz,2016-11-16 15:53:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fODPPtQOSeI/pfizer-reports-phase-iii-psoriatic-arthritis-data-on-xeljanz-cm710017,Pfizer Inc PFE announced detailed data from the two phase III OPAL O ral P soriatic A rthritis Tria L studies Broaden and Beyond on Xeljanz The data will be presented at the ACR ARHP annual meeting OPAL Broaden and OPAL Beyond evaluated the efficacy and safety of Xeljanz in
EXEL,EXEL:UW,BBG000BQ56F4,Ionis (IONS) Offers Positive Interim Data on Lipid Candidate,2016-11-16 15:52:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OOI8xK6V860/ionis-ions-offers-positive-interim-data-on-lipid-candidate-cm710015,Ionis Pharmaceuticals Inc s IONS wholly owned subsidiary Akcea Therapeutics announced positive data from an interim analysis of a phase I IIa study on its pipeline candidate IONIS ANGPTL3 L RX Data were presented at the American Heart Association Meeting In the study patients
EXEL,EXEL:UW,BBG000BQ56F4,Surging Earnings Estimates Signal Good News for Exelixis (EXEL),2016-11-16 15:27:03 +0000,http://finance.yahoo.com/news/surging-earnings-estimates-signal-good-152703120.html,Surging Earnings Estimates Signal Good News for Exelixis (EXEL)
EXEL,EXEL:UW,BBG000BQ56F4,Pfizer Reports Phase III Psoriatic Arthritis Data on Xeljanz,2016-11-16 13:20:01 +0000,http://finance.yahoo.com/news/pfizer-reports-phase-iii-psoriatic-132001729.html,Pfizer Reports Phase III Psoriatic Arthritis Data on Xeljanz
EXEL,EXEL:UW,BBG000BQ56F4,4 Breakout Charts to Watch This Week,2016-11-15 18:18:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2xNmrZBN-1Y/4-breakout-charts-to-watch-this-week-cm709570,"Exelixis, Inc. ( EXEL ) broke down last month out of a rising channel, but has exploded recently, up seven sessions in a row, from just above 10 to yesterday's close of 16.76.  The stock is a bit overextended, and got up to our initial target of 17 intraday yesterday.  Watch for a break of that, followed by 19 next."
EXEL,EXEL:UW,BBG000BQ56F4,Repros (RPRX) Reports Positive Top-Line Data on Proellex,2016-11-15 14:31:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-vQP28NyJ-g/repros-rprx-reports-positive-top-line-data-on-proellex-cm709172,Repros Therapeutics Inc RPRX reported top line results from two phase II studies on its lead pipeline candidate Proellex when delivered orally and vaginally for the treatment of uterine fibroids The company s shares were up 3 87 on the news The studies enrolled women with
EXEL,EXEL:UW,BBG000BQ56F4,Celldex Stock Up on Positive Data on New Cancer Candidate,2016-11-15 14:30:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OVg81-W7KfQ/celldex-stock-up-on-positive-data-on-new-cancer-candidate-cm709357,Celldex Therapeutics Inc CLDX presented pre clinical data on a new candidate CDX 1140 a fully human antibody that targets CD40 and demonstrated potent agonist activity The data was presented at the Society for Immunotherapy of Cancer Annual Meeting Importantly the company said that
EXEL,EXEL:UW,BBG000BQ56F4,Celldex Stock Up on Positive Data on New Cancer Candidate,2016-11-15 13:03:01 +0000,http://finance.yahoo.com/news/celldex-stock-positive-data-cancer-130301911.html,Celldex Stock Up on Positive Data on New Cancer Candidate
EXEL,EXEL:UW,BBG000BQ56F4,Alexion (ALXN) Offers Long-Term Phase III Data on Kanuma,2016-11-14 13:35:01 +0000,http://finance.yahoo.com/news/alexion-alxn-offers-long-term-133501635.html,Alexion (ALXN) Offers Long-Term Phase III Data on Kanuma
EXEL,EXEL:UW,BBG000BQ56F4,Gilead (GILD) HBV Drug Vemlidy Gets Positive CHMP Opinion,2016-11-14 13:04:01 +0000,http://finance.yahoo.com/news/gilead-gild-hbv-drug-vemlidy-130401624.html,Gilead (GILD) HBV Drug Vemlidy Gets Positive CHMP Opinion
EXEL,EXEL:UW,BBG000BQ56F4,Election 2016's Healthcare Winners and Losers,2016-11-12 17:16:47 +0000,http://www.fool.com/investing/2016/11/11/election-2016s-healthcare-winners-and-losers.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Election 2016's Healthcare Winners and Losers
EXEL,EXEL:UW,BBG000BQ56F4,VIVUS (VVUS) Reports Narrower-than-Expected Loss in Q3,2016-11-11 19:51:07 +0000,http://finance.yahoo.com/news/vivus-vvus-reports-narrower-expected-195107472.html,VIVUS (VVUS) Reports Narrower-than-Expected Loss in Q3
EXEL,EXEL:UW,BBG000BQ56F4,Election 2016's Healthcare Winners and Losers,2016-11-11 18:29:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kK7vwsa6ZS4/election-2016s-healthcare-winners-and-losers-cm707998,Following Donald Trump s shocking victory and California Proposition 61 s defeat drug pricing policy fears stoked by Hillary Clinton s campaign practically evaporated overnight This helped send biotech stocks Ionis Pharmaceuticals Inc NASDAQ IONS 160 and Exelixis
EXEL,EXEL:UW,BBG000BQ56F4,"Allscripts (MDRX) Beats on Earnings in Q3, Revenues Miss",2016-11-11 16:16:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O6J9drmyuTo/allscripts-mdrx-beats-on-earnings-in-q3-revenues-miss-cm707781,Allscripts Healthcare Solutions Inc MDRX reported third quarter 2016 earnings of 11 cents per share a penny above the Zacks Consensus Estimate The figure also improved from 10 cents in the year ago quarter Revenues increased from 355 million in the year ago period to 404
EXEL,EXEL:UW,BBG000BQ56F4,Endocyte (ECYT) Stock Up on Lower-than-Expected Q3 Loss,2016-11-11 15:16:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3Hgh0rSSP94/endocyte-ecyt-stock-up-on-lower-than-expected-q3-loss-cm707715,Endocyte Inc ECYT reported a third quarter 2016 loss of 21 cents per share narrower than both the Zacks Consensus Estimate of a loss of 27 cents and the year ago loss of 24 cents The company s shares gained 3 following the release of its quarterly results
EXEL,EXEL:UW,BBG000BQ56F4,"The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte",2016-11-11 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-enzo-143002423.html,"The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte"
EXEL,EXEL:UW,BBG000BQ56F4,Mylan (MYL) Q3 Earnings & Revenues Miss on EpiPen Woes,2016-11-10 14:56:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vpiLMYsvuXs/mylan-myl-q3-earnings-revenues-miss-on-epipen-woes-cm706987,Mylan N V s MYL third quarter 2016 earnings of 1 38 per share missed the Zacks Consensus Estimate of 1 50 and declined 3 from the year ago quarter reflecting significant contribution from new products in the prior year period FindTheCompany Graphiq In the
EXEL,EXEL:UW,BBG000BQ56F4,Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q3,2016-11-10 13:09:01 +0000,http://finance.yahoo.com/news/catalyst-cprx-reports-narrower-expected-130901606.html,Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q3
EXEL,EXEL:UW,BBG000BQ56F4,"Repros (RPRX) Loss Narrower Y/Y in Q3, Pipeline in Focus",2016-11-09 22:54:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TDxUcInJ4dI/repros-rprx-loss-narrower-yy-in-q3-pipeline-in-focus-cm706824,Repros Therapeutics Inc RPRX reported a loss of 17 cents per share in the third quarter of 2016 significantly narrower than the year ago loss of 27 cents primarily due to lower expenses related to the development of the company s pipeline candidates enclomiphene and Proellex as well as
EXEL,EXEL:UW,BBG000BQ56F4,Why These Biotechs Saw Double-Digit Gains Today,2016-11-09 19:25:20 +0000,http://www.fool.com/investing/2016/11/09/why-these-biotechs-saw-double-digit-gains-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why These Biotechs Saw Double-Digit Gains Today
EXEL,EXEL:UW,BBG000BQ56F4,Conatus (CNAT) Reports Narrower-than-Expected Loss in Q3,2016-11-09 14:56:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DgPLQ_a7sH8/conatus-cnat-reports-narrower-than-expected-loss-in-q3-cm706267,Conatus Pharmaceuticals Inc CNAT reported third quarter 2016 loss of 31 cents per share narrower than the Zacks Consensus Estimate of a loss of 33 cents The reported loss was however in line with the year ago figure FindTheCompany Graphiq With no approved product
EXEL,EXEL:UW,BBG000BQ56F4,Endo (ENDP) Q3 Earnings & Revenues Beat; View Intact,2016-11-08 21:39:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ojz-pV_uZGc/endo-endp-q3-earnings-revenues-beat-view-intact-cm705869,Endo International plc s ENDP third quarter 2016 earnings of 1 01 per share were significantly above the Zacks Consensus Estimate of 81 cents However reported earnings slipped 1 from the year ago figure The company s shares were up around 7 in the pre market trading Revenues came
EXEL,EXEL:UW,BBG000BQ56F4,"PerkinElmer (PKI) Beats on Earnings, Misses Revenue in Q3",2016-11-08 21:34:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ACMpK-NJG0c/perkinelmer-pki-beats-on-earnings-misses-revenue-in-q3-cm705850,Waltham MA based PerkinElmer Inc PKI a worldwide provider of products services and solutions to the diagnostics research and laboratory services markets reported third quarter 2016 earnings of 68 cents per share which beat the Zacks Consensus Estimate by 2 cents Additionally the
EXEL,EXEL:UW,BBG000BQ56F4,Wright Medical (WMGI) Q3 Loss Narrower than Expected,2016-11-08 20:46:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B3HSSU82jPI/wright-medical-wmgi-q3-loss-narrower-than-expected-cm705629,Wright Medical Group N V WMGI reported adjusted loss of 19 cents per share way narrower than the loss of 51 cents reported in the year ago quarter and the Zacks Consensus Estimate of a loss of 20 cents Net sales increased 96 3 year over year to 157 3 million but missed the
EXEL,EXEL:UW,BBG000BQ56F4,"Horizon (HZNP) Stock Up Despite Q3 Earnings, Revenue Miss",2016-11-08 18:42:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CU8A4o_MwKI/horizon-hznp-stock-up-despite-q3-earnings-revenue-miss-cm705472,Horizon Pharma plc HZNP reported third quarter 2016 earnings of 56 cents per share including the impact of share based compensation expense and tax adjustments which surged approximately 85 from the year ago period Reported earnings however missed the Zacks Consensus Estimate of 63
EXEL,EXEL:UW,BBG000BQ56F4,"Arena (ARNA) Q3 Loss Lower than Expected, Revenues Rise",2016-11-08 18:24:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PwEXdjZ4fGs/arena-arna-q3-loss-lower-than-expected-revenues-rise-cm705442,Arena Pharmaceuticals Inc ARNA reported a loss of 5 cents per share in the third quarter of 2016 narrower than both the year ago loss of 11 cents and the Zacks Consensus Estimate of a loss of 7 cents Total revenue surged 110 year over year to 19 2 million which includes 11 million
EXEL,EXEL:UW,BBG000BQ56F4,"ETF’s with exposure to Exelixis, Inc. : November 8, 2016",2016-11-08 17:02:01 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-exelixis-inc-november-8-2016/,"ETF’s with exposure to Exelixis, Inc. : November 8, 2016"
EXEL,EXEL:UW,BBG000BQ56F4,"2 Reasons Exelixis, Inc. Dove 17% in October, and 1 Excuse to Be Excited",2016-11-08 16:06:40 +0000,http://www.fool.com/investing/2016/11/07/2-reasons-exelixis-inc-dove-17-in-october-and-1-ex.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"2 Reasons Exelixis, Inc. Dove 17% in October, and 1 Excuse to Be Excited"
EXEL,EXEL:UW,BBG000BQ56F4,"PerkinElmer (PKI) Beats on Earnings, Misses Revenue in Q3",2016-11-08 15:07:03 +0000,http://finance.yahoo.com/news/perkinelmer-pki-beats-earnings-misses-150703348.html,"PerkinElmer (PKI) Beats on Earnings, Misses Revenue in Q3"
EXEL,EXEL:UW,BBG000BQ56F4,Wright Medical (WMGI) Q3 Loss Narrower than Expected,2016-11-08 13:54:01 +0000,http://finance.yahoo.com/news/wright-medical-wmgi-q3-loss-135401151.html,Wright Medical (WMGI) Q3 Loss Narrower than Expected
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : November 8, 2016",2016-11-08 12:57:26 +0000,http://www.capitalcube.com/blog/index.php/exelixis-inc-breached-its-50-day-moving-average-in-a-bullish-manner-exel-us-november-8-2016/,"Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : November 8, 2016"
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. Continues Its Solid Launch",2016-11-07 21:08:10 +0000,http://www.fool.com/investing/2016/11/07/premium-exelixis-inc-continues-its-solid-launch.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Exelixis, Inc. Continues Its Solid Launch"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis to Present at the Stifel 2016 Healthcare Conference on November 15,2016-11-07 21:05:00 +0000,http://finance.yahoo.com/news/exelixis-present-stifel-2016-healthcare-210500979.html,"[Business Wire] - Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at Stifel’s 2016 Healthcare Conference taking place November 15-16 in New York."
EXEL,EXEL:UW,BBG000BQ56F4,"Masimo (MASI) Beats on Q3 Earnings, Revenues; Guides Up",2016-11-07 15:20:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NGd2dI3g3n8/masimo-masi-beats-on-q3-earnings-revenues-guides-up-cm704938,Masimo Corp MASI reported earnings of 47 cents per share in the third quarter of 2016 which increased from 36 cents in the year ago quarter The figure also came above the Zacks Consensus Estimate of 42 cents Revenues improved almost 9 9 year over year to 167 6 million well ahead of
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. :EXEL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016",2016-11-07 14:50:50 +0000,http://www.capitalcube.com/blog/index.php/exelixis-inc-exel-us-earnings-analysis-q3-2016-by-the-numbers-november-7-2016/,"Exelixis, Inc. :EXEL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016"
EXEL,EXEL:UW,BBG000BQ56F4,Pacific Biosciences (PACB) Q3 Loss Narrower than Expected,2016-11-07 13:21:01 +0000,http://finance.yahoo.com/news/pacific-biosciences-pacb-q3-loss-132101802.html,Pacific Biosciences (PACB) Q3 Loss Narrower than Expected
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Presentation of Cobimetinib Combination Therapy Data at the Society for Melanoma Research 2016 Congress That Support Genentech’s Planned Phase 3 Pivotal Trials,2016-11-07 06:00:00 +0000,http://finance.yahoo.com/news/exelixis-announces-presentation-cobimetinib-combination-060000074.html,"[Business Wire] - Exelixis, Inc. today announced the presentation of new data from clinical trials of cobimetinib in combination with other therapies to treat forms of advanced melanoma."
EXEL,EXEL:UW,BBG000BQ56F4,Why We're Excited About These 5 Top Stocks,2016-11-05 18:04:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2r78rGbg1cw/why-were-excited-about-these-5-top-stocks-cm704525,Image source Getty Images It s pretty exciting when you find a stock idea you can really get behind We reached out to some of our top Motley Fool contributors to ask them what stocks have them jumping for joy right now They came back with an eclectic list of intriguing stocks
EXEL,EXEL:UW,BBG000BQ56F4,Why We're Excited About These 5 Top Stocks,2016-11-05 16:01:06 +0000,http://www.fool.com/investing/2016/11/05/why-were-excited-about-these-5-top-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why We're Excited About These 5 Top Stocks
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis (EXEL) Q3 Loss Narrower than Expected, Sales Beat",2016-11-04 20:37:08 +0000,http://finance.yahoo.com/news/exelixis-exel-q3-loss-narrower-193707594.html,"Exelixis (EXEL) Q3 Loss Narrower than Expected, Sales Beat"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis (EXEL) Stock Gains on Q3 Results,2016-11-04 19:12:00 +0000,https://www.thestreet.com/story/13882006/1/exelixis-exel-stock-gains-on-q3-results.html?puc=yahoo&cm_ven=YAHOO,Exelixis (EXEL) Stock Gains on Q3 Results
EXEL,EXEL:UW,BBG000BQ56F4,"Friday's ETF Movers: XBI, GDXJ",2016-11-04 18:49:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G4SJtucLq30/fridays-etf-movers-xbi-gdxj-cm704306,In trading on Friday the SPDR S amp P Biotech ETF XBI is outperforming other ETFs up about 3 on the day Components of that ETF showing particular strength include shares of Novavax NVAX up about 20 9 and shares of Exelixis EXEL up about 12 9 on the day
EXEL,EXEL:UW,BBG000BQ56F4,"Why Exelixis, Inc. Reported Higher Today",2016-11-04 18:48:20 +0000,http://www.fool.com/investing/2016/11/04/why-exelixis-inc-reported-higher-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Exelixis, Inc. Reported Higher Today"
EXEL,EXEL:UW,BBG000BQ56F4,"DENTSPLY (XRAY) Beats on Earnings in Q3, Misses Revenue",2016-11-04 17:11:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VYgH_6PBeMo/dentsply-xray-beats-on-earnings-in-q3-misses-revenue-cm704219,DENTSPLY SIRONA Inc XRAY reported adjusted earnings per share EPS of 66 cents in the third quarter of 2016 beating the Zacks Consensus Estimate by 3 cents Earnings were flat on a year over year basis Notably DENTSPLY repurchased an additional 100 million of shares and paid 18
EXEL,EXEL:UW,BBG000BQ56F4,Geron (GERN) Reports Narrower-than-Expected Loss in Q3,2016-11-04 15:13:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VR70PPAnRbc/geron-gern-reports-narrower-than-expected-loss-in-q3-cm704008,Geron Corporation GERN reported a loss of 2 cents per share in the third quarter of 2016 narrower than the Zacks Consensus Estimate of a loss of 6 cents The company had reported earnings of 17 cents in the year ago quarter FindTheCompany Graphiq Quarterly revenues came
EXEL,EXEL:UW,BBG000BQ56F4,Aduro (ADRO) Stock Down on Wider-than-Expected Q3 Loss,2016-11-04 15:12:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DGWtx11pTkU/aduro-adro-stock-down-on-wider-than-expected-q3-loss-cm703964,Aduro BioTech Inc ADRO reported third quarter 2016 loss of 54 cents per share wider than the Zacks Consensus Estimate of a loss of 49 cents The company had reported earnings of a penny in the year ago quarter Aduro s shares were down almost 8 since the release of its third quarter
EXEL,EXEL:UW,BBG000BQ56F4,"Acadia Healthcare (ACHC) Misses Q3 Earnings, Cuts View",2016-11-04 15:12:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AxvMXJxWkQc/acadia-healthcare-achc-misses-q3-earnings-cuts-view-cm703954,Acadia Healthcare Company Inc ACHC reported third quarter 2016 adjusted earnings of 58 cents per share which missed the Zacks Consensus Estimate by a penny Further earnings deteriorated 6 5 on a year over year basis thanks to lower than expected same facility revenues from U K
EXEL,EXEL:UW,BBG000BQ56F4,Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3,2016-11-04 14:15:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qkk5q6vE7Bo/epizyme-epzm-reports-narrower-than-expected-loss-in-q3-cm704067,Epizyme Inc EPZM reported a loss of 42 cents per share in the third quarter of 2016 narrower than both the Zacks Consensus Estimate and the year ago loss of 56 cents FindTheCompany Graphiq Quarter in Detail The company earned collaboration revenues of 6 6 million
EXEL,EXEL:UW,BBG000BQ56F4,Community Health (CYH) Q3 Loss in Line with Estimates,2016-11-04 14:14:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qVk1N2A3EEA/community-health-cyh-q3-loss-in-line-with-estimates-cm704059,Franklin TN based Community Health CYH reported adjusted loss of 35 cents per share in the third quarter of 2016 in line with the Zacks Consensus Estimate However the figure deteriorated a massive 162 5 from the year ago quarter on revenue decline as well as higher operating expenses
EXEL,EXEL:UW,BBG000BQ56F4,"Radius Health (RDUS) Q3 Loss Match Estimates, Wider Y/Y",2016-11-04 14:14:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uzCuo9Bh2ps/radius-health-rdus-q3-loss-match-estimates-wider-yy-cm704058,Radius Health Inc RDUS posted a loss of 1 07 per share in the third quarter of 2016 in line with the Zacks Consensus Estimate but wider than the year ago loss of 68 cents With no approved product in its portfolio the company has not generated any revenue yet In this scenario
EXEL,EXEL:UW,BBG000BQ56F4,"Intercept (ICPT) Q3 Loss Narrower than Expected, Sales Miss",2016-11-04 13:35:01 +0000,http://finance.yahoo.com/news/intercept-icpt-q3-loss-narrower-133501756.html,"Intercept (ICPT) Q3 Loss Narrower than Expected, Sales Miss"
EXEL,EXEL:UW,BBG000BQ56F4,Aegerion (AEGR) Reports Narrower-than-Expected Loss in Q3,2016-11-04 13:32:01 +0000,http://finance.yahoo.com/news/aegerion-aegr-reports-narrower-expected-133201391.html,Aegerion (AEGR) Reports Narrower-than-Expected Loss in Q3
EXEL,EXEL:UW,BBG000BQ56F4,Edited Transcript of EXEL earnings conference call or presentation 3-Nov-16 9:00pm GMT,2016-11-03 23:10:10 +0000,http://finance.yahoo.com/news/edited-transcript-exel-earnings-conference-231010338.html,Edited Transcript of EXEL earnings conference call or presentation 3-Nov-16 9:00pm GMT
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis reports 3Q loss,2016-11-03 22:50:53 +0000,http://sg.finance.yahoo.com/news/exelixis-reports-3q-loss-225053382.html,Exelixis reports 3Q loss
EXEL,EXEL:UW,BBG000BQ56F4,"Pacira (PCRX) Misses Q3 Earnings Estimates, Beats on Sales",2016-11-03 22:08:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e6QS_nieB_g/pacira-pcrx-misses-q3-earnings-estimates-beats-on-sales-cm703694,Pacira Pharmaceuticals Inc PCRX reported third quarter 2016 earnings of 2 cents including the impact of stock based compensation missing the Zacks Consensus Estimate of 3 cents and declining from the year ago quarter figure of 10 cents Revenues on the other hand surged 10 year
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Enters Oversold Territory (EXEL),2016-11-03 22:07:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rdu5LEtDBJ8/exelixis-enters-oversold-territory-exel-cm703683,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Third Quarter and Year to Date 2016 Financial Results and Provides Corporate Update,2016-11-03 20:21:38 +0000,http://www.publicnow.com/view/4CAA76A94929EA5EA5F2DF8F581986439ED48280,[at noodls] - Exelixis Announces Third Quarter and Year to Date 2016 Financial Results and Provides Corporate Update The text version of this document is not available at the moment. The original content was posted ...
EXEL,EXEL:UW,BBG000BQ56F4,"EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition",2016-11-03 20:13:52 +0000,http://biz.yahoo.com/e/161103/exel8-k.html,"EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition"
EXEL,EXEL:UW,BBG000BQ56F4,"EXELIXIS, INC. Files SEC form 10-Q, Quarterly Report",2016-11-03 20:06:02 +0000,http://biz.yahoo.com/e/161103/exel10-q.html,"EXELIXIS, INC. Files SEC form 10-Q, Quarterly Report"
EXEL,EXEL:UW,BBG000BQ56F4,"Aerie (AERI) Q3 Loss Wider than Expected, Pipeline in Focus",2016-11-03 17:09:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4ndHu1giosA/aerie-aeri-q3-loss-wider-than-expected-pipeline-in-focus-cm703371,Aerie Pharmaceuticals Inc AERI posted third quarter 2016 loss of 81 cents per share including stock based compensation wider than both the Zacks Consensus Estimate of a loss of 70 cents and the year ago loss of 69 cents FindTheCompany Graphiq Being a development
EXEL,EXEL:UW,BBG000BQ56F4,"Alkermes (ALKS) Q3 Loss in Line, Sales Miss; '16 View Intact",2016-11-03 15:10:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w0nv3FditPg/alkermes-alks-q3-loss-in-line-sales-miss-16-view-intact-cm703228,Alkermes plc ALKS reported a loss of 25 cents per share including the impact of share based compensation expense in the third quarter of 2016 in line with the Zacks Consensus Estimate The reported loss was however narrower than the year ago tally of 43 cents Alkermes reported revenues
EXEL,EXEL:UW,BBG000BQ56F4,"Aerie (AERI) Q3 Loss Wider than Expected, Pipeline in Focus",2016-11-03 15:08:03 +0000,http://finance.yahoo.com/news/aerie-aeri-q3-loss-wider-150803672.html,"Aerie (AERI) Q3 Loss Wider than Expected, Pipeline in Focus"
EXEL,EXEL:UW,BBG000BQ56F4,Q3 2016 Exelixis Inc Earnings Release - After Market Close,2016-11-03 11:07:08 +0000,http://biz.yahoo.com/research/earncal/20161103.html?t=exel,Q3 2016 Exelixis Inc Earnings Release - After Market Close
EXEL,EXEL:UW,BBG000BQ56F4,4 stocks to watch,2016-11-02 18:37:53 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=C2E1D926-A94C-49DC-8129-F84F76F34346&siteid=yhoof2,4 stocks to watch
EXEL,EXEL:UW,BBG000BQ56F4,Four Medical And Biotech Stock Charts To Watch,2016-11-02 17:25:00 +0000,http://www.forbes.com/sites/greatspeculations/2016/11/02/four-medical-and-biotech-stock-charts-to-watch/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Four Medical And Biotech Stock Charts To Watch
EXEL,EXEL:UW,BBG000BQ56F4,"QLT's (QLTI) Reports In-Line Q3 Loss, Merger in Focus",2016-11-02 17:10:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D_Z3M4yWkTE/qlts-qlti-reports-in-line-q3-loss-merger-in-focus-cm702646,QLT Inc QLTI reported a loss of 11 cents per share in the third quarter of 2016 in line with the Zacks Consensus Estimate but wider than the year ago loss of 5 cents The company did not report any revenues during the quarter as was the case a year ago The company s research
EXEL,EXEL:UW,BBG000BQ56F4,"Zoetis (ZTS) Tops Q3 Earnings Estimates, Updates Outlook",2016-11-02 16:12:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jzCJq0cvOic/zoetis-zts-tops-q3-earnings-estimates-updates-outlook-cm702524,Zoetis Inc s ZTS third quarter 2016 earnings of 52 cents per share comfortably surpassed the Zacks Consensus Estimate of 46 cents Earnings were also up 4 from the year ago period FindTheCompany Graphiq Total revenue increased 4 year over year to 1 24 billion in
EXEL,EXEL:UW,BBG000BQ56F4,"Gilead (GILD) Misses Q3 Earnings Estimates, Retains View",2016-11-02 16:11:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bg2Xb8JhRi8/gilead-gild-misses-q3-earnings-estimates-retains-view-cm702472,Gilead Sciences Inc s GILD third quarter 2016 earnings including the impact of stock based compensation expenses of 2 70 per share missed the Zacks Consensus Estimate of 2 74 and were down 15 4 from the year ago quarter figure Moreover total revenue in the reported quarter came in
EXEL,EXEL:UW,BBG000BQ56F4,4 Medical And Biotech Stocks to Watch,2016-11-02 14:48:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_w1gwupOUDI/4-medical-and-biotech-stocks-to-watch-cm702453,"By Harry Boxer   Here are 4 bullish charts in the medical and biotech arena, which is starting to heat up again.  Exelixis, Inc. ( EXEL ), which has been in a declining wedge off its September top, made a new low for the move intraday on Tuesday before snapping back to close up 39 cents, or 3.68%, to 10.98, on 4.6"
EXEL,EXEL:UW,BBG000BQ56F4,"AmerisourceBergen (ABC) Q4 Earnings Top, Revenues Lag",2016-11-02 14:48:02 +0000,http://finance.yahoo.com/news/amerisourcebergen-abc-q4-earnings-top-144802530.html,"AmerisourceBergen (ABC) Q4 Earnings Top, Revenues Lag"
EXEL,EXEL:UW,BBG000BQ56F4,Shire (SHPG) Misses Q3 Earnings & Revenue Estimates,2016-11-02 13:16:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pAd0YjyyWWY/shire-shpg-misses-q3-earnings-revenue-estimates-cm702303,Shire plc SHPG reported third quarter 2016 earnings of 3 17 per American Depositary Share ADS missing the Zacks Consensus Estimate of 3 18 and down from the year ago tally of 3 24 Revenues on the other hand surged 109 to 3 45 billion but lagged the Zacks Consensus Estimate
EXEL,EXEL:UW,BBG000BQ56F4,Prothena (PRTA) Reports Wider-than-Expected Loss in Q3,2016-11-02 12:14:12 +0000,http://finance.yahoo.com/news/prothena-prta-reports-wider-expected-121412371.html,Prothena (PRTA) Reports Wider-than-Expected Loss in Q3
EXEL,EXEL:UW,BBG000BQ56F4,Shire (SHPG) Misses Q3 Earnings & Revenue Estimates,2016-11-02 12:13:12 +0000,http://finance.yahoo.com/news/shire-shpg-misses-q3-earnings-121312238.html,Shire (SHPG) Misses Q3 Earnings & Revenue Estimates
EXEL,EXEL:UW,BBG000BQ56F4,"Drug Stocks Q3 Earnings Roster for Nov 3; ICPT, EXEL, AKRX",2016-11-02 12:03:12 +0000,http://finance.yahoo.com/news/drug-stocks-q3-earnings-roster-120312449.html,"Drug Stocks Q3 Earnings Roster for Nov 3; ICPT, EXEL, AKRX"
EXEL,EXEL:UW,BBG000BQ56F4,"Novo Nordisk (NVO) Tops Q3 Earnings, Revenues Up Y/Y",2016-10-31 18:15:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IeBZPeLf2wc/novo-nordisk-nvo-tops-q3-earnings-revenues-up-yy-cm701243,Novo Nordisk A S NVO reported third quarter 2016 earnings of 58 cents per American Depository Receipt ADR above the Zacks Consensus Estimate of 56 cents and up from the year ago figure of 49 cents Quarterly revenues were also up 3 4 year over year to 4 1 billion Reported
EXEL,EXEL:UW,BBG000BQ56F4,ImmunoGen (IMGN) Reports Wider-than-Expected Loss,2016-10-31 16:19:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WcFiUFlb2F8/immunogen-imgn-reports-wider-than-expected-loss-cm701083,ImmunoGen Inc IMGN reported a loss of 46 cents per share excluding restructuring charge in the three months ended Sep 30 wider than both the Zacks Consensus Estimate of a loss of 38 cents and the year ago loss of 39 cents We note that ImmunoGen is transitioning to a fiscal year ending
EXEL,EXEL:UW,BBG000BQ56F4,"Novo Nordisk (NVO) Tops Q3 Earnings, Revenues Up Y/Y",2016-10-31 15:38:03 +0000,http://finance.yahoo.com/news/novo-nordisk-nvo-tops-q3-153803073.html,"Novo Nordisk (NVO) Tops Q3 Earnings, Revenues Up Y/Y"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis (EXEL) Q3 Earnings: What's in Store for the Stock?,2016-10-31 14:16:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ny3mYZ728cM/exelixis-exel-q3-earnings-whats-in-store-for-the-stock-cm700963,Exelixis Inc EXEL is scheduled to report third quarter 2016 results on Nov 3 after the market closes Exelixis had a mixed track record over the last four quarters The company surpassed expectations twice in the four trailing quarters and missed the same in the remaining two with
EXEL,EXEL:UW,BBG000BQ56F4,ImmunoGen (IMGN) Reports Wider-than-Expected Loss,2016-10-31 14:16:02 +0000,http://finance.yahoo.com/news/immunogen-imgn-reports-wider-expected-141602741.html,ImmunoGen (IMGN) Reports Wider-than-Expected Loss
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis (EXEL) Q3 Earnings: What's in Store for the Stock?,2016-10-31 13:22:01 +0000,http://finance.yahoo.com/news/exelixis-exel-q3-earnings-whats-132201550.html,Exelixis (EXEL) Q3 Earnings: What's in Store for the Stock?
EXEL,EXEL:UW,BBG000BQ56F4,"AbbVie (ABBV) Q3 Earnings in Line, Revenues Lag Estimates",2016-10-28 17:33:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0rQZXDRYDiE/abbvie-abbv-q3-earnings-in-line-revenues-lag-estimates-cm700410,AbbVie Inc ABBV reported third quarter 2016 earnings of 1 21 per share in line with the Zacks Consensus Estimate but up 7 1 from the year ago quarter FindTheCompany Graphiq Revenues increased 8 2 to 6 43 billion in the third quarter but missed the Zacks
EXEL,EXEL:UW,BBG000BQ56F4,"BioMarin (BMRN) Q3 Loss Narrows Y/Y, Pipeline in Focus",2016-10-28 16:35:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/74q6bQBXFaY/biomarin-bmrn-q3-loss-narrows-yy-pipeline-in-focus-cm700295,BioMarin Pharmaceutical Inc BMRN reported a loss of 18 cents per share in the third quarter of 2016 including stock based compensation expense narrower than the year ago loss of 44 cents The Zacks Consensus Estimate was of a loss of 39 cents per share Total revenue came in at
EXEL,EXEL:UW,BBG000BQ56F4,"United Therapeutics (UTHR) Beats Q3 Earnings, Sales Miss",2016-10-28 15:35:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jF0NKpmW6hc/united-therapeutics-uthr-beats-q3-earnings-sales-miss-cm700153,United Therapeutics Corporation UTHR reported adjusted earnings of 3 63 per share including after tax impact of stock based compensation expense for third quarter 2016 which beat the Zacks Consensus Estimate of 3 47 by 4 61 Revenues for the reported quarter increased 5 6 year over year
EXEL,EXEL:UW,BBG000BQ56F4,"AbbVie (ABBV) Q3 Earnings in Line, Revenues Lag Estimates",2016-10-28 15:23:03 +0000,http://finance.yahoo.com/news/abbvie-abbv-q3-earnings-line-152303035.html,"AbbVie (ABBV) Q3 Earnings in Line, Revenues Lag Estimates"
EXEL,EXEL:UW,BBG000BQ56F4,"McKesson (MCK) Misses on Q2 Earnings & Sales, Cuts View",2016-10-28 13:44:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2SMUsErOyl8/mckesson-mck-misses-on-q2-earnings-sales-cuts-view-cm700128,McKesson Corporation MCK reported second quarter fiscal 2017 ended Sep 30 2016 earnings of 2 94 per share missing the Zacks Consensus Estimate of 3 05 and declining from the year ago figure of 3 17 FindTheCompany Graphiq Revenues on the other hand improved 2 5 to
EXEL,EXEL:UW,BBG000BQ56F4,Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3,2016-10-28 13:35:01 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-srpt-incurs-narrower-133501322.html,Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3
EXEL,EXEL:UW,BBG000BQ56F4,"McKesson (MCK) Misses on Q2 Earnings & Sales, Cuts View",2016-10-28 12:24:12 +0000,http://finance.yahoo.com/news/mckesson-mck-misses-q2-earnings-122412874.html,"McKesson (MCK) Misses on Q2 Earnings & Sales, Cuts View"
EXEL,EXEL:UW,BBG000BQ56F4,"Celgene (CELG) Beats on Q3 Earnings, Raises '16 Outlook",2016-10-27 17:42:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NShLezeq-80/celgene-celg-beats-on-q3-earnings-raises-16-outlook-cm699542,Celgene Corporation CELG reported third quarter 2016 earnings of 1 39 per share including share based compensation expense and tax adjustments beating the Zacks Consensus Estimate of 1 31 and surging almost 28 from the year ago period Excluding share based compensation expense Celgene
EXEL,EXEL:UW,BBG000BQ56F4,The Medicines Co. (MDCO) Q3 Loss Narrower than Expected,2016-10-27 16:46:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hoa1kLrNVSw/the-medicines-co-mdco-q3-loss-narrower-than-expected-cm699494,The Medicines Company MDCO reported a loss of 75 cents per share including the impact of share based compensation expenses in the third quarter of 2016 significantly narrower than both the Zacks Consensus Estimate of a loss of 1 38 and the year ago loss of 94 cents Meanwhile
EXEL,EXEL:UW,BBG000BQ56F4,"Celgene (CELG) Beats on Q3 Earnings, Raises '16 Outlook",2016-10-27 15:45:03 +0000,http://finance.yahoo.com/news/celgene-celg-beats-q3-earnings-154503140.html,"Celgene (CELG) Beats on Q3 Earnings, Raises '16 Outlook"
EXEL,EXEL:UW,BBG000BQ56F4,The Medicines Co. (MDCO) Q3 Loss Narrower than Expected,2016-10-27 14:33:02 +0000,http://finance.yahoo.com/news/medicines-co-mdco-q3-loss-143302841.html,The Medicines Co. (MDCO) Q3 Loss Narrower than Expected
EXEL,EXEL:UW,BBG000BQ56F4,Cardinal Health (CAH) Q1 Earnings: Disappointment in Store?,2016-10-26 15:53:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qGXl4sDS240/cardinal-health-cah-q1-earnings-disappointment-in-store-cm698530,Cardinal Health Inc CAH is set to report first quarter fiscal 2017 earnings results on Oct 31 Last quarter the company reported earnings of 1 14 per share which beat the Zacks Consensus Estimate by a penny Notably Cardinal Health posted a positive earnings surprise of 9 46 on
EXEL,EXEL:UW,BBG000BQ56F4,"Express Scripts (ESRX) Q3 Earnings in Line, Revenues Lag",2016-10-26 14:53:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HLdl7KafoLY/express-scripts-esrx-q3-earnings-in-line-revenues-lag-cm698574,Pharmacy benefit manager Express Scripts Holding Company ESRX posted third quarter 2016 earnings per share excluding special items of 1 74 in line with the Zacks Consensus Estimate Reported earnings were up 20 from the year ago period FindTheCompany Graphiq On a
EXEL,EXEL:UW,BBG000BQ56F4,"Zacks.com featured highlights: Incyte, LegacyTexas Financial Group, Exelixis, Bayerische Motoren Werke Aktiengesellschaft and EQT Midstream Partners",2016-10-26 14:52:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BIzcQfX3rcI/zackscom-featured-highlights-incyte-legacytexas-financial-group-exelixis-bayerische-motoren-werke-aktiengesellschaft-and-eqt-midstream-partners-cm698555,For Immediate Release Chicago IL October 26 2016 Stocks in this week s article include Incyte Corporation NASDAQ INCY Free Report LegacyTexas Financial Group Inc NASDAQ LTXB Free Report Exelixis Inc NASDAQ EXEL Free Report Bayerische Motoren
EXEL,EXEL:UW,BBG000BQ56F4,"Vertex's (VRTX) Q3 Loss Wider than Expected, Sales Miss",2016-10-26 13:50:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ynaMS2__G10/vertexs-vrtx-q3-loss-wider-than-expected-sales-miss-cm698458,Vertex Pharmaceuticals Inc VRTX reported third quarter 2016 loss of 8 cents per share including the impact of stock based compensation expense wider than the Zacks Consensus Estimate of a loss of 6 cents However the loss was narrower than a loss of 40 cents reported in the year ago
EXEL,EXEL:UW,BBG000BQ56F4,"Zacks.com featured highlights: Incyte, LegacyTexas Financial Group, Exelixis, Bayerische Motoren Werke Aktiengesellschaft and EQT Midstream Partners",2016-10-26 13:30:01 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-incyte-133001138.html,"Zacks.com featured highlights: Incyte, LegacyTexas Financial Group, Exelixis, Bayerische Motoren Werke Aktiengesellschaft and EQT Midstream Partners"
EXEL,EXEL:UW,BBG000BQ56F4,"Express Scripts (ESRX) Q3 Earnings in Line, Revenues Lag",2016-10-26 13:17:01 +0000,http://finance.yahoo.com/news/express-scripts-esrx-q3-earnings-131701657.html,"Express Scripts (ESRX) Q3 Earnings in Line, Revenues Lag"
EXEL,EXEL:UW,BBG000BQ56F4,Ligand Partner Melinta Therapeutics Submits NDA for Baxdela,2016-10-25 22:24:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HNlZ2OxTG5Q/ligand-partner-melinta-therapeutics-submits-nda-for-baxdela-cm698250,Ligand Pharmaceuticals Incorporated LGND said its partner Melinta Therapeutics a private pharma company has submitted New Drug Applications NDAs to the FDA for its pipeline candidate Baxdela delafloxacin to treat serious bacterial infections Ligand Pharma and Melinta Therapeutics
EXEL,EXEL:UW,BBG000BQ56F4,Ligand Partner Melinta Therapeutics Submits NDA for Baxdela,2016-10-25 20:32:08 +0000,http://finance.yahoo.com/news/ligand-partner-melinta-therapeutics-submits-203208669.html,Ligand Partner Melinta Therapeutics Submits NDA for Baxdela
EXEL,EXEL:UW,BBG000BQ56F4,"Lilly (LLY) Misses on Q3 Earnings, Sales; Animal Health Hurts",2016-10-25 16:28:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fLETdGBg3aA/lilly-lly-misses-on-q3-earnings-sales-animal-health-hurts-cm697939,Eli Lilly and Company s LLY third quarter results were below expectations with both earnings and sales missing the Zacks Consensus Estimate The company revised certain elements of its 2016 outlook Shares declined 1 in pre market trading Earnings Miss Third quarter 2016
EXEL,EXEL:UW,BBG000BQ56F4,"Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View",2016-10-25 16:28:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UIXvyQoplXI/merck-mrk-beats-on-q3-earnings-revenues-lifts-view-cm697925,Merck amp Co Inc MRK reported third quarter 2016 earnings of 1 07 per share comfortably surpassing the Zacks Consensus Estimate of 98 cents and increasing approximately 12 from the year ago period FindTheCompany Graphiq Again revenues for the quarter were up 5
EXEL,EXEL:UW,BBG000BQ56F4,5 Profitable Stocks for Outstanding Returns,2016-10-25 15:28:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l3uB9jvLrmg/5-profitable-stocks-for-outstanding-returns-cm697956,One of the most widely used tools to measure the potential of stocks is profitability analysis It helps in evaluating whether a company can generate ample sales revenue not only to meet all its business operations but also to offer stable returns to investors There is no guarantee that the
EXEL,EXEL:UW,BBG000BQ56F4,What's in Store for Stryker (SYK) this Earnings Season?,2016-10-25 14:25:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lRfRZrI3syY/whats-in-store-for-stryker-syk-this-earnings-season-cm697808,Headquartered in Kalamazoo MI Stryker Corporation SYK is set to report third quarter 2016 results on Oct 27 Last quarter the company posted earnings of 1 39 per share which surpassed the Zacks Consensus Estimate by 3 cents Notably on an average Stryker beat the Zacks Consensus
EXEL,EXEL:UW,BBG000BQ56F4,Inovio Stock Down on FDA Hold on VGX-3100 Phase III Study,2016-10-25 14:25:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/idUNRrGc11A/inovio-stock-down-on-fda-hold-on-vgx-3100-phase-iii-study-cm697806,Inovio Pharmaceuticals Inc s INO shares plunged 16 4 after the company announced that the FDA has placed a clinical hold on the proposed phase III program on its lead pipeline candidate VGX 3100 We note that a clinical hold is a notification issued by the FDA to a sponsor of the
EXEL,EXEL:UW,BBG000BQ56F4,Aduro Stock Down on Partial Clinical Hold on LADD Studies,2016-10-25 14:25:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fgr6As9rnhM/aduro-stock-down-on-partial-clinical-hold-on-ladd-studies-cm697793,Aduro BioTech Inc s ADRO shares were down 4 5 after the company announced that the FDA has placed a partial clinical hold on studies evaluating investigational agents based on its LADD Listeria based immunotherapy construct platform The partial clinical hold was implemented after a
EXEL,EXEL:UW,BBG000BQ56F4,"Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View",2016-10-25 14:04:02 +0000,http://finance.yahoo.com/news/merck-mrk-beats-q3-earnings-140402772.html,"Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View"
EXEL,EXEL:UW,BBG000BQ56F4,5 Profitable Stocks for Outstanding Returns,2016-10-25 13:48:01 +0000,http://finance.yahoo.com/news/5-profitable-stocks-outstanding-returns-134801903.html,5 Profitable Stocks for Outstanding Returns
EXEL,EXEL:UW,BBG000BQ56F4,What's in Store for Merit Medical (MMSI) in Q3 Earnings?,2016-10-25 13:27:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_F6s19yOtSM/whats-in-store-for-merit-medical-mmsi-in-q3-earnings-cm697749,Headquartered in South Jordan Utah Merit Medical Systems Inc MMSI is set to report third quarter 2016 results on Oct 26 Last quarter the company posted earnings of 26 cents per share which surpassed the Zacks Consensus Estimate by 2 cents Notably on an average Merit Medical beat
EXEL,EXEL:UW,BBG000BQ56F4,Aduro Stock Down on Partial Clinical Hold on LADD Studies,2016-10-25 13:27:01 +0000,http://finance.yahoo.com/news/aduro-stock-down-partial-clinical-132701863.html,Aduro Stock Down on Partial Clinical Hold on LADD Studies
EXEL,EXEL:UW,BBG000BQ56F4,C.R. Bard (BCR) to Report Q3 Earnings: What's in the Cards?,2016-10-24 22:25:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3Rx7sg2KGmI/cr-bard-bcr-to-report-q3-earnings-whats-in-the-cards-cm697503,CR Bard Inc BCR is scheduled to report third quarter 2016 earnings on Oct 25 Last quarter the company reported earnings of 2 56 per share which beat the Zacks Consensus Estimate of 2 46 by 4 07 Notably the company s earnings topped the Zacks Consensus Estimate in the last
EXEL,EXEL:UW,BBG000BQ56F4,C.R. Bard (BCR) to Report Q3 Earnings: What's in the Cards?,2016-10-24 20:19:08 +0000,http://finance.yahoo.com/news/c-r-bard-bcr-report-201908079.html,C.R. Bard (BCR) to Report Q3 Earnings: What's in the Cards?
EXEL,EXEL:UW,BBG000BQ56F4,Bristol-Myers's (BMY) Opdivo Under Priority Review by FDA,2016-10-24 16:27:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tEbTnB-ytRA/bristol-myerss-bmy-opdivo-under-priority-review-by-fda-cm697211,Bristol Myers Squibb Company BMY announced that its supplemental biologics license application sBLA for immuno oncology drug Opdivo has been accepted for priority review by the FDA The company is looking to expand Opdivo s label to include the treatment of locally advanced unresectable
EXEL,EXEL:UW,BBG000BQ56F4,Can Nutrisystem (NTRI) Surprise Investors in Q3 Earnings?,2016-10-24 15:04:03 +0000,http://finance.yahoo.com/news/nutrisystem-ntri-surprise-investors-q3-150403114.html,Can Nutrisystem (NTRI) Surprise Investors in Q3 Earnings?
EXEL,EXEL:UW,BBG000BQ56F4,Merck Gets FDA Approval for Investigational Drug Zinplava,2016-10-24 13:35:01 +0000,http://finance.yahoo.com/news/merck-gets-fda-approval-investigational-133501578.html,Merck Gets FDA Approval for Investigational Drug Zinplava
EXEL,EXEL:UW,BBG000BQ56F4,Varian Medical (VAR) Q4 Earnings: What's in the Cards?,2016-10-24 13:25:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X_f0r9Yy5N4/varian-medical-var-q4-earnings-whats-in-the-cards-cm697043,Varian Medical Systems Inc VAR is set to report results for the fourth quarter of fiscal 2016 after the closing bell Last quarter the company reported earnings of 1 22 per share which beat the Zacks Consensus Estimate by a nickel Notably the figure improved 6 1 on a year over
EXEL,EXEL:UW,BBG000BQ56F4,United Health (UHS): What's in Store this Earnings Season?,2016-10-24 13:25:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iMu9dwqOZeg/united-health-uhs-whats-in-store-this-earnings-season-cm697040,Universal Health Services Inc UHS is set to report third quarter fiscal 2016 results on Oct 26 after the closing bell Last quarter the company reported earnings of 1 94 per share in line with the Zacks Consensus Estimate Meanwhile the figure improved 4 9 on a year over year
EXEL,EXEL:UW,BBG000BQ56F4,Alkermes Depression Candidate Positive in Phase III Study,2016-10-21 15:27:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bj_k-93xFEs/alkermes-depression-candidate-positive-in-phase-iii-study-cm696597,Alkermes plc ALKS announced positive top line data from the third phase III efficacy study FORWARD 5 Focused On Results With A Rethinking of Depression on its pipeline candidate ALKS 5461 The company is evaluating ALKS 5461 for the adjunctive treatment of major depressive disorder MDD
EXEL,EXEL:UW,BBG000BQ56F4,Amgen's (AMGN) Xgeva Meets Endpoint in Phase III Study,2016-10-21 15:25:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iFuyBL-KXCY/amgens-amgn-xgeva-meets-endpoint-in-phase-iii-study-cm696538,Amgen Inc AMGN announced that a phase III study on its marketed drug Xgeva for the prevention of skeletal related events SRE in patients with multiple myeloma met the primary endpoint Xgevais is approved in the U S and the EU for the prevention of SREs in patients with bone metastases
EXEL,EXEL:UW,BBG000BQ56F4,XBI's Underlying Holdings Could Mean 43% Gain Potential,2016-10-21 14:01:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o8DiHJuzuxQ/xbis-underlying-holdings-could-mean-43-gain-potential-cm696423,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
EXEL,EXEL:UW,BBG000BQ56F4,Amgen's (AMGN) Xgeva Meets Endpoint in Phase III Study,2016-10-21 14:00:02 +0000,http://finance.yahoo.com/news/amgens-amgn-xgeva-meets-endpoint-140002460.html,Amgen's (AMGN) Xgeva Meets Endpoint in Phase III Study
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis to Release Third Quarter 2016 Financial Results on Thursday, November 3, 2016",2016-10-20 20:49:06 +0000,http://www.publicnow.com/view/EF01F01053BCFB21FCDFC32E88CEE1D3D597509E,"[at noodls] - - Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m. PDT - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 20, 2016-- Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter ..."
EXEL,EXEL:UW,BBG000BQ56F4,41 Billion Reasons Why Gilead Sciences Might Need New Management,2016-10-20 19:52:32 +0000,http://www.fool.com/investing/2016/10/19/41-billion-reasons-why-gilead-sciences-might-need.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,41 Billion Reasons Why Gilead Sciences Might Need New Management
EXEL,EXEL:UW,BBG000BQ56F4,Alexion Graft-Versus-Host Disease Drug Wins Orphan Status,2016-10-20 17:27:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b4VrFi1OLFQ/alexion-graft-versus-host-disease-drug-wins-orphan-status-cm696084,Alexion Pharmaceuticals Inc ALXN announced that the FDA has granted orphan drug designation ODD to its pipeline candidate ALXN1007 for the treatment of acute graft versus host disease GVHD The FDA through its Office of Orphan Products Development grants this status to candidates
EXEL,EXEL:UW,BBG000BQ56F4,Merck's Antiviral Medicine Meets Endpoint in Phase III,2016-10-20 15:28:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jdm6JkTXvxU/mercks-antiviral-medicine-meets-endpoint-in-phase-iii-cm695924,Merck amp Co Inc MRK announced that a phase III study on its antiviral pipeline candidate letermovir met the primary endpoint Letermovir is being developed for the treatment of cytomegalovirus CVM infections The study assessed the safety and efficacy of letermovir in
EXEL,EXEL:UW,BBG000BQ56F4,Merck's Antiviral Medicine Meets Endpoint in Phase III,2016-10-20 13:58:01 +0000,http://finance.yahoo.com/news/mercks-antiviral-medicine-meets-endpoint-135801819.html,Merck's Antiviral Medicine Meets Endpoint in Phase III
EXEL,EXEL:UW,BBG000BQ56F4,Eli Lilly Lartruvo Gets FDA Approval for Soft Tissue Sarcoma,2016-10-20 13:51:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3CwzFCuosCg/eli-lilly-lartruvo-gets-fda-approval-for-soft-tissue-sarcoma-cm695769,Eli Lilly and Company LLY announced that the FDA has granted accelerated approval to its pipeline candidate Lartruvo olaratumab injection 10 mg mL in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma STS not amenable to curative
EXEL,EXEL:UW,BBG000BQ56F4,41 Billion Reasons Why Gilead Sciences Might Need New Management,2016-10-19 21:47:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1P7LkyVKK6s/41-billion-reasons-why-gilead-sciences-might-need-new-management-cm695624,Gilead Sciences NASDAQ GILD may have a management problem at least if the market s sentiment toward this top biotech is a reliable indicator After all ever since 160 John Milligan replaced John Martin as Chief Executive Officer last March Gilead s shares have
EXEL,EXEL:UW,BBG000BQ56F4,What's in Store for athenahealth (ATHN) in Q3 Earnings?,2016-10-19 15:51:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_oq3X3XuUXE/whats-in-store-for-athenahealth-athn-in-q3-earnings-cm695371,athenahealth Inc ATHN is set to report third quarter 2016 results on Oct 21 Last quarter the company posted earnings of 6 cents per share which missed the Zacks Consensus Estimate of 16 cents Notably on an average athenahealth beat the Zacks Consensus Estimate by almost 189 6 over
EXEL,EXEL:UW,BBG000BQ56F4,AstraZeneca's Hyperkalemia Drug NDA Resubmission Accepted,2016-10-19 15:49:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/28CHthdi4rA/astrazenecas-hyperkalemia-drug-nda-resubmission-accepted-cm695337,AstraZeneca plc AZN announced that the FDA has accepted for review its complete re submission of the new drug application NDA for ZS 9 sodium zirconium cyclosilicate The company is looking to get ZS 9 approved for the treatment of hyperkalemia high potassium level in the blood
EXEL,EXEL:UW,BBG000BQ56F4,AstraZeneca's Hyperkalemia Drug NDA Resubmission Accepted,2016-10-19 13:56:01 +0000,http://finance.yahoo.com/news/astrazenecas-hyperkalemia-drug-nda-resubmission-135601402.html,AstraZeneca's Hyperkalemia Drug NDA Resubmission Accepted
EXEL,EXEL:UW,BBG000BQ56F4,Shire Cancer Drug Onivyde Receives EU Marketing Approval,2016-10-19 13:50:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lFWBMk5Cr9U/shire-cancer-drug-onivyde-receives-eu-marketing-approval-cm695203,Shire plc SHPG announced that the European Commission has granted marketing authorization to Onivyde in combination with fluorouracil 5 FU and leucovorin for the treatment of metastatic adenocarcinoma of the pancreas after disease progression following treatment with Eli Lilly and Company
EXEL,EXEL:UW,BBG000BQ56F4,The Medicines Co. Reports Positive Phase II Data on PCSK9si,2016-10-19 13:50:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XHtPaNtTCpE/the-medicines-co-reports-positive-phase-ii-data-on-pcsk9si-cm695305,The Medicines Company MDCO announced positive top line results from a Day 90 interim analysis of the ongoing ORION 1 phase II study of its pipeline candidate PCSK9si for the treatment of hypercholesterolemia PCSK9si earlier known as ALN PCSsc is a first in class
EXEL,EXEL:UW,BBG000BQ56F4,Shire Cancer Drug Onivyde Receives EU Marketing Approval,2016-10-19 11:55:11 +0000,http://finance.yahoo.com/news/shire-cancer-drug-onivyde-receives-115511567.html,Shire Cancer Drug Onivyde Receives EU Marketing Approval
EXEL,EXEL:UW,BBG000BQ56F4,Teva Trisenox Wins CHMP Nod for Expanded Use in Leukemia,2016-10-18 15:51:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fL0RKd9hzrU/teva-trisenox-wins-chmp-nod-for-expanded-use-in-leukemia-cm694767,Teva Pharmaceutical Industries Ltd TEVA announced that the European Medicines Agency s EMA Committee for Medicinal Products for Human Use CHMP has recommended expanding Trisenox s label in the EU The company is looking to get Trisenox approved in combination with retinoic acid for
EXEL,EXEL:UW,BBG000BQ56F4,J&J (JNJ) Outshines in Q3 Earnings on Strong Pharma Sales,2016-10-18 15:50:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ir8EQZrt_0A/jj-jnj-outshines-in-q3-earnings-on-strong-pharma-sales-cm694705,Johnson amp Johnson JNJ reported another strong quarter with both earnings and sales beating expectations Moreover the company raised the lower end of its earnings outlook for the year The healthcare giant s third quarter 2016 earnings came in at 1 68 per share beating the Zacks
EXEL,EXEL:UW,BBG000BQ56F4,PTC Therapeutics Falls on FDA Denial of DMD Drug Appeal,2016-10-18 14:50:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LBmxdRBP8-g/ptc-therapeutics-falls-on-fda-denial-of-dmd-drug-appeal-cm694642,PTC Therapeutics Inc s PTCT shares fell almost 40 after it provided a regulatory update on its lead pipeline candidate Translarna ataluren for the treatment of patients with nonsense genetic mutation Duchenne muscular dystrophy nmDMD PTC Therapeutics declared that its first appeal
EXEL,EXEL:UW,BBG000BQ56F4,J&J (JNJ) Outshines in Q3 Earnings on Strong Pharma Sales,2016-10-18 14:05:02 +0000,http://finance.yahoo.com/news/j-j-jnj-outshines-q3-140502774.html,J&J (JNJ) Outshines in Q3 Earnings on Strong Pharma Sales
EXEL,EXEL:UW,BBG000BQ56F4,Shire (SHPG) Updates Vyvanse Label with New Efficacy Data,2016-10-18 13:49:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lqbVhPHvX-c/shire-shpg-updates-vyvanse-label-with-new-efficacy-data-cm694669,Shire plc SHPG announced that it has updated Vyvanse s label to include data associated with its supplemental New Drug Application sNDA for the treatment of adults with moderate to severe binge eating disorder B E D The updated label includes data from a phase III study SPD489
EXEL,EXEL:UW,BBG000BQ56F4,Teva Trisenox Wins CHMP Nod for Expanded Use in Leukemia,2016-10-18 13:23:01 +0000,http://finance.yahoo.com/news/teva-trisenox-wins-chmp-nod-132301590.html,Teva Trisenox Wins CHMP Nod for Expanded Use in Leukemia
EXEL,EXEL:UW,BBG000BQ56F4,"Biotech Review DVAX Vaccine Faces Crucial PDUFA Date, CLDX Seeks Fast-Track Orphan Drug Status",2016-10-18 13:23:00 +0000,http://finance.yahoo.com/news/biotech-review-dvax-vaccine-faces-132300364.html,"[CNW Group] - Biotech Review DVAX Vaccine Faces Crucial PDUFA Date, CLDX Seeks Fast-Track Orphan Drug Status"
EXEL,EXEL:UW,BBG000BQ56F4,PTC Therapeutics Falls on FDA Denial of DMD Drug Appeal,2016-10-18 12:59:12 +0000,http://finance.yahoo.com/news/ptc-therapeutics-falls-fda-denial-125912250.html,PTC Therapeutics Falls on FDA Denial of DMD Drug Appeal
EXEL,EXEL:UW,BBG000BQ56F4,Interesting EXEL Put And Call Options For January 2019,2016-10-17 16:41:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N2xR-A7SvGY/interesting-exel-put-and-call-options-for-january-2019-cm694185,Investors in Exelixis Inc Symbol EXEL saw new options become available today for the January 2019 expiration One of the key data points that goes into the price an option buyer is willing to pay is the time value so with 823 days until expiration the newly available contracts represent
EXEL,EXEL:UW,BBG000BQ56F4,Intercept (ICPT) Ocaliva Wins Positive CHMP Opinion for PBC,2016-10-17 15:42:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qml6Lbl8o6I/intercept-icpt-ocaliva-wins-positive-chmp-opinion-for-pbc-cm694108,Intercept Pharmaceuticals Inc ICPT announced that that the European Medicines Agency s EMA Committee for Medicinal Products for Human Use CHMP has recommended a conditional approval of Ocaliva obeticholic acid OCA for the treatment of primary biliary cholangitis PBC Note that
EXEL,EXEL:UW,BBG000BQ56F4,Tetraphase Begins Phase III Dosing of Antibiotic Candidate,2016-10-17 15:42:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZgvIc9PgEhc/tetraphase-begins-phase-iii-dosing-of-antibiotic-candidate-cm694100,Tetraphase Pharmaceuticals TTPH announced that it has begun dosing in the phase III IGNITE4 study on its lead antibiotic candidate eravacycline IGNITE4 is evaluating the efficacy and safety of twice daily intravenous IV eravacycline compared to meropenem for the treatment of
EXEL,EXEL:UW,BBG000BQ56F4,Allergan's Belkyra Gets Swedish Approval for Double Chin,2016-10-17 14:44:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kJi3sB9iMvo/allergans-belkyra-gets-swedish-approval-for-double-chin-cm694040,Allergan plc AGN announced that its prescription medicine Belkyra deoxycholic acid has been granted marketing approval in Sweden for the treatment of moderate to severe fullness under the chin in adults commonly referred to as double chin Belkyra was added to Allergan s portfolio
EXEL,EXEL:UW,BBG000BQ56F4,Enzo Biochem (ENZ) Looks Good: Stock Adds 11% in Session,2016-10-17 13:43:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t2Qnc7bSQI0/enzo-biochem-enz-looks-good-stock-adds-11-in-session-cm694081,Enzo Biochem Inc ENZ was a big mover last session as its shares rose a little more than 11 on the day The move came after the company reported strong results for the fourth quarter and fiscal year ended July 31 2016 This led to far more shares changing hands than in a normal session
EXEL,EXEL:UW,BBG000BQ56F4,Natus Medical (BABY) Q3 Earnings: What's in the Cards?,2016-10-17 13:43:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3B6p_V9kf2k/natus-medical-baby-q3-earnings-whats-in-the-cards-cm694062,Natus Medical Inc BABY is set to report third quarter 2016 results on Oct 19 before market opens Last quarter the company reported earnings of 39 cents which exceeded the Zacks Consensus Estimate by 3 cents We note that on an average Natus Medical posted a positive earnings
EXEL,EXEL:UW,BBG000BQ56F4,Allergan (AGN) Gains Rights to RTGel from UroGen Pharma,2016-10-17 13:14:01 +0000,http://finance.yahoo.com/news/allergan-agn-gains-rights-rtgel-131401585.html,Allergan (AGN) Gains Rights to RTGel from UroGen Pharma
EXEL,EXEL:UW,BBG000BQ56F4,Allergan's Belkyra Gets Swedish Approval for Double Chin,2016-10-17 12:57:12 +0000,http://finance.yahoo.com/news/allergans-belkyra-gets-swedish-approval-125712395.html,Allergan's Belkyra Gets Swedish Approval for Double Chin
EXEL,EXEL:UW,BBG000BQ56F4,Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis,2016-10-17 12:36:56 +0000,http://www.fool.com/investing/2016/10/17/pfizer-faces-a-big-threat-from-small-biotech-exeli.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis
EXEL,EXEL:UW,BBG000BQ56F4,Intuitive Surgical (ISRG) Q3 Earnings: What's in Store?,2016-10-14 14:43:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iu2QfVtUHNo/intuitive-surgical-isrg-q3-earnings-whats-in-store-cm693342,Intuitive Surgical Inc ISRG is set to report third quarter 2016 results on Oct 18 after the closing bell Last quarter the company reported earnings of 4 86 per share which exceeded the Zacks Consensus Estimate by 65 cents We note that on an average Intuitive Surgical posted a
EXEL,EXEL:UW,BBG000BQ56F4,Sunesis Submits Response to Questions on Leukemia Drug,2016-10-14 14:03:02 +0000,http://finance.yahoo.com/news/sunesis-submits-response-questions-leukemia-140302689.html,Sunesis Submits Response to Questions on Leukemia Drug
EXEL,EXEL:UW,BBG000BQ56F4,"OncoGenex Cancer Drug Fails in Phase III Study, Stock Down",2016-10-14 13:59:01 +0000,http://finance.yahoo.com/news/oncogenex-cancer-drug-fails-phase-135901809.html,"OncoGenex Cancer Drug Fails in Phase III Study, Stock Down"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Goes for It,2016-10-13 21:00:03 +0000,http://www.fool.com/investing/2016/10/13/exelixis-goes-for-it.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Exelixis Goes for It
EXEL,EXEL:UW,BBG000BQ56F4,Supernus (SUPN) Reports Encouraging Data from ADHD Study,2016-10-13 18:25:06 +0000,http://finance.yahoo.com/news/supernus-supn-reports-encouraging-data-182506855.html,Supernus (SUPN) Reports Encouraging Data from ADHD Study
EXEL,EXEL:UW,BBG000BQ56F4,AMAG Issues Encouraging Updates on Makena & Feraheme,2016-10-13 15:43:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6Lp6BDxnNfY/amag-issues-encouraging-updates-on-makena-feraheme-cm692801,AMAG Pharmaceuticals Inc AMAG announced the achievement of key milestones with respect to its next generation development programs on Makena and Feraheme The company announced that it has initiated a randomized open label parallel definitive pharmacokinetic and the comparative pain
EXEL,EXEL:UW,BBG000BQ56F4,AMAG Issues Encouraging Updates on Makena & Feraheme,2016-10-13 13:59:01 +0000,http://finance.yahoo.com/news/amag-issues-encouraging-updates-makena-135901072.html,AMAG Issues Encouraging Updates on Makena & Feraheme
EXEL,EXEL:UW,BBG000BQ56F4,Will These 5 Drug Stocks Be Big Winners This Earnings Season?,2016-10-13 13:46:01 +0000,http://finance.yahoo.com/news/5-drug-stocks-big-winners-134601176.html,Will These 5 Drug Stocks Be Big Winners This Earnings Season?
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : October 13, 2016",2016-10-13 12:28:47 +0000,http://www.capitalcube.com/blog/index.php/exelixis-inc-breached-its-50-day-moving-average-in-a-bearish-manner-exel-us-october-13-2016/,"Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : October 13, 2016"
EXEL,EXEL:UW,BBG000BQ56F4,Momenta Pharmaceuticals (MNTA) Jumps: Stock Up 12.7%,2016-10-12 14:21:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jVS5_62Y4gU/momenta-pharmaceuticals-mnta-jumps-stock-up-127-cm692309,Momenta Pharmaceuticals Inc MNTA was a big mover last session as its shares rose almost 13 on the day The move came after the stock s rating was upped to overweight from equal weight at Barclays This led to far more shares changing hands than in a normal session This breaks the
EXEL,EXEL:UW,BBG000BQ56F4,These 3 Little Biotechs Just Scored Big,2016-10-11 20:30:11 +0000,http://www.fool.com/investing/2016/10/11/these-3-little-biotechs-just-scored-big.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,These 3 Little Biotechs Just Scored Big
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Finds Success with Cabozantinib (EXEL),2016-10-11 00:41:00 +0000,http://www.investopedia.com/news/exelixis-finds-success-cabozantinib-exel/?partner=YahooSA,Exelixis Finds Success with Cabozantinib (EXEL)
EXEL,EXEL:UW,BBG000BQ56F4,"Deere & Company (DE), Gas Natural Inc. (EGAS) & More: Why These Stocks are Trending Today",2016-10-10 15:47:48 +0000,http://www.insidermonkey.com/blog/deere-company-de-gas-natural-inc-egas-more-why-these-stocks-are-trending-today-480003/,"Deere & Company (DE), Gas Natural Inc. (EGAS) & More: Why These Stocks are Trending Today"
EXEL,EXEL:UW,BBG000BQ56F4,Traders bet Exelixis will hold gains,2016-10-10 15:43:10 +0000,http://finance.yahoo.com/news/exelixis-gets-vote-confidence-163955594.html,Traders bet Exelixis will hold gains
EXEL,EXEL:UW,BBG000BQ56F4,"Stocks to Watch: Mylan, Twitter, Dover",2016-10-10 14:12:34 +0000,http://blogs.wsj.com/moneybeat/2016/10/10/stocks-to-watch-mylan-twitter-dover/?mod=yahoo_hs,"Stocks to Watch: Mylan, Twitter, Dover"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Continues Massive Run With Positive Cabosun Results,2016-10-10 12:40:39 +0000,http://247wallst.com/healthcare-business/2016/10/10/exelixis-continues-massive-run-with-positive-cabosun-results/,Exelixis Continues Massive Run With Positive Cabosun Results
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Investor Conference Call At 1:00 PM ET,2016-10-10 08:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M-BBasJdFbo/exelixis-investor-conference-call-at-100-pm-et-20161010-00248,Exelixis Investor Conference Call At 1:00 PM ET
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Investor Conference Call At 1:00 PM ET,2016-10-10 08:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xEb0yc15WNE/exelixis-investor-conference-call-at-100-pm-et-20161010-00249,Exelixis Investor Conference Call At 1:00 PM ET
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis and Pfizer drugs compete in kidney cancer trial,2016-10-10 07:32:33 +0000,http://uk.finance.yahoo.com/news/exelixis-pfizer-drugs-compete-kidney-073233035.html,Exelixis and Pfizer drugs compete in kidney cancer trial
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016,2016-10-10 06:33:05 +0000,http://www.publicnow.com/view/246332DA39D9DAE65B2B5701CAFB0D6A18FE87A5,"[at noodls] - - Cabozantinib met the primary endpoint of improving progression-free survival as compared to sunitinib, decreasing the rate of disease progression or death by 31 percent - - Objective response rate significantly ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis and Pfizer drugs face off in kidney cancer,2016-10-10 06:15:01 +0000,http://uk.finance.yahoo.com/news/exelixis-pfizer-drugs-face-off-061501472.html,Exelixis and Pfizer drugs face off in kidney cancer
EXEL,EXEL:UW,BBG000BQ56F4,"Better Buy: Exelixis, Inc. vs. Roche",2016-10-09 01:12:57 +0000,http://www.fool.com/investing/2016/10/08/better-buy-exelixis-inc-vs-roche.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Exelixis, Inc. vs. Roche"
EXEL,EXEL:UW,BBG000BQ56F4,"Better Buy: Exelixis, Inc. vs. Roche",2016-10-08 12:43:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HNfjSwXtgmQ/better-buy-exelixis-inc-vs-roche-cm690655,Image source Getty Images Recently approved cancer therapies from Exelixis NASDAQ EXEL and Roche NASDAQOTH RHHBY have oncologists fizzing with excitement but the two drugmakers have more differences than similarities While Roche has been profitable for decades
EXEL,EXEL:UW,BBG000BQ56F4,"These 2 Big Catalysts Pushed Exelixis, Inc. Higher By 15% in September",2016-10-07 18:44:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uW0HML5aqZc/these-2-big-catalysts-pushed-exelixis-inc-higher-by-15-in-september-cm690481,Image source Getty Images What happened Shares of Exelixis NASDAQ EXEL a biopharmaceutical company focused on the development of therapies to treat cancer surged another 15 during the month of September according to data from S amp P Global Market
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Reports Genitourinary Results (EXEL),2016-10-07 17:38:00 +0000,http://www.investopedia.com/news/exelixis-reports-genitourinary-results-exel/?partner=YahooSA,Exelixis Reports Genitourinary Results (EXEL)
EXEL,EXEL:UW,BBG000BQ56F4,"These 2 Big Catalysts Pushed Exelixis, Inc. Higher By 15% in September",2016-10-07 16:56:42 +0000,http://www.fool.com/investing/2016/10/07/these-2-big-catalysts-pushed-exelixis-inc-higher-b.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"These 2 Big Catalysts Pushed Exelixis, Inc. Higher By 15% in September"
EXEL,EXEL:UW,BBG000BQ56F4,"FEX, FYX: Big ETF Inflows",2016-10-07 16:44:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IavC_zzpPWE/fex-fyx-big-etf-inflows-cm690405,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the First Trust Large Cap Core AlphaDEX Fund which added 4 600 000 units or a 15 2 increase week over week Among the largest underlying components of FEX in
EXEL,EXEL:UW,BBG000BQ56F4,"Ipsens’ partner, Exelixis, Announced Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors",2016-10-07 14:39:05 +0000,http://www.publicnow.com/view/2408BADFDD71FD97F8F529DB2C2E3661F259C563,"[at noodls] - Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors October 07, 2016 Read the press release >... This is an abstract of the original ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors,2016-10-07 08:19:00 +0000,http://www.publicnow.com/view/662C04B300222B52A62820F2431A0A96A46CC1E6,[at noodls] - Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors The text version of this document is not available at the moment. The original content ...
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis Announces Genentech Presentation of Preliminary Phase 1b Results for the Combination of Cobimetinib, Vemurafenib and Atezolizumab at ESMO 2016 Congress",2016-10-07 08:01:00 +0000,http://finance.yahoo.com/news/exelixis-announces-genentech-presentation-preliminary-080100341.html,"[Business Wire] - Exelixis, Inc. today announced that its collaborator Genentech, a member of the Roche Group, will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of the triple combination of cobimetinib, vemurafenib, and atezolizumab in patients with previously untreated BRAF V600 mutation-positive advanced melanoma."
EXEL,EXEL:UW,BBG000BQ56F4,Key FDA Decisions and Trial Results Expected in October,2016-10-04 13:15:55 +0000,http://247wallst.com/healthcare-business/2016/10/04/key-fda-decisions-and-trial-results-expected-in-october-2/,Key FDA Decisions and Trial Results Expected in October
EXEL,EXEL:UW,BBG000BQ56F4,"Forget Celldex Therapeutics, Inc.: These 2 Stocks Doubled Last Year",2016-10-04 12:56:38 +0000,http://www.fool.com/investing/2016/10/03/forget-celldex-therapeutics-inc-these-2-stocks-dou.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Forget Celldex Therapeutics, Inc.: These 2 Stocks Doubled Last Year"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis and Ipsen to Host Investor and Media Briefing to Discuss Data Presented at the ESMO 2016 Congress,2016-10-03 20:05:00 +0000,http://finance.yahoo.com/news/exelixis-ipsen-host-investor-media-200500590.html,"[Business Wire] - Exelixis, Inc. today announced that the company and its partner Ipsen will jointly host a live investor and media briefing at the European Society for Medical Oncology 2016 Congress."
EXEL,EXEL:UW,BBG000BQ56F4,Fitbit Inc (FIT) Trapped in Middle of Several Extreme Opinions,2016-10-03 18:44:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CBctry3gCNE/fitbit-inc-fit-trapped-in-middle-of-several-extreme-opinions-cm688005,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Not so fast Pacific Crest Mizuho and Gizmodo both disagree with your recent assessments of how well Fitbit Inc NYSE FIT is doing with the recently debuted Charge 2 and how it stacks up against
EXEL,EXEL:UW,BBG000BQ56F4,"Forget Celldex Therapeutics, Inc.: These 2 Stocks Doubled Last Year",2016-10-03 14:46:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jo1a_ZX4lug/forget-celldex-therapeutics-inc-these-2-stocks-doubled-last-year-cm687705,Image source Getty Images The embattled biotech Celldex Therapeutics Inc NASDAQ CLDX may seem like a compelling bargain at the moment in light of its diverse oncology oriented pipeline and meager market cap of 382 million Even so the market has shown far more interest
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Reaches Analyst Target Price,2016-10-03 14:45:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ErsgmIHU24U/exelixis-reaches-analyst-target-price-cm687668,In recent trading shares of Exelixis Inc Symbol EXEL have crossed above the average analyst 12 month target price of 12 67 changing hands for 12 79 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation or re
EXEL,EXEL:UW,BBG000BQ56F4,"Total System Services, Inc (TSS) Lost Its Momentum",2016-09-30 17:23:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CKtvqt7jEFA/total-system-services-inc-tss-lost-its-momentum-cm687237,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Editor s note This column is part of our Best Stocks for 2016 contest Louis Navellier s pick for the contest is Total System Services Inc
EXEL,EXEL:UW,BBG000BQ56F4,Goldman Sachs Group Inc (GS): Are We Entering the Next Recession?,2016-09-30 17:23:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UDvzMEpw_Js/goldman-sachs-group-inc-gs-are-we-entering-the-next-recession-cm687236,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Every recession has a cause usually seen only in retrospect 160 The Great Recession was caused by the mortgage insurance crisis The 2001 recession was the result of the Dot Com bubble crashing The
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. (EXEL) Crushed on CaboNivo Drug Trial Results",2016-09-30 16:24:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MCZ95b0VkVg/exelixis-inc-exel-crushed-on-cabonivo-drug-trial-results-cm687199,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Look up the term volatility and you re likely to find several biotech stocks that have posted wild price swings over the past several weeks Among them Exelixis Inc
EXEL,EXEL:UW,BBG000BQ56F4,Piecing your biotech together again — BioFlash podcast,2016-09-30 14:55:11 +0000,http://www.bizjournals.com/sanfrancisco/blog/biotech/2016/09/exelixis-exel-cabozantinib-cancer-bioflash-podcast.html?ana=yahoo,Piecing your biotech together again — BioFlash podcast
EXEL,EXEL:UW,BBG000BQ56F4,Call buyers looking for more in Exelixis,2016-09-30 12:45:30 +0000,http://finance.yahoo.com/news/call-buyers-looking-more-exelixis-124530136.html,Call buyers looking for more in Exelixis
EXEL,EXEL:UW,BBG000BQ56F4,"Why Exelixis, Inc. Continued Its Downfall Today",2016-09-29 23:22:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wxlEGT9125U/why-exelixis-inc-continued-its-downfall-today-cm686882,Image source Getty Images What happened Exelixis NASDAQ EXEL continued its fall today down as much as 12 and ending the day down 8 after falling 14 yesterday So what Today s move seems to be a continuation of yesterday The momentum down shouldn t come as
EXEL,EXEL:UW,BBG000BQ56F4,"Why Exelixis, Inc. Continued Its Downfall Today",2016-09-29 21:20:45 +0000,http://www.fool.com/investing/2016/09/29/why-exelixis-inc-continued-its-downfall-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Exelixis, Inc. Continued Its Downfall Today"
EXEL,EXEL:UW,BBG000BQ56F4,"Why Exelixis, Inc. Got Hammered Today",2016-09-29 20:21:04 +0000,http://www.fool.com/investing/2016/09/28/why-exelixis-inc-got-hammered-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Exelixis, Inc. Got Hammered Today"
EXEL,EXEL:UW,BBG000BQ56F4,Mid-Afternoon Market Update: Dow Falls Over 200 Points; Catabasis Shares Spike Higher,2016-09-29 19:51:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/s0yiYoiL5TM/mid-afternoon-market-update-dow-falls-over-200-points-catabasis-shares-spike-higher-cm686768,Toward the end of trading Thursday the Dow traded down 1 14 percent to 18 130 13 while the NASDAQ declined 0 97 percent to 5 266 87 The S amp P also fell dropping 0 98 percent to 2 150 00 Leading and Lagging Sectors Thursday afternoon energy shares slipped by just 0 1
EXEL,EXEL:UW,BBG000BQ56F4,Mid-Day Market Update:  Crude Oil Rises Over 2%; Intra-Cellular Therapies Shares Slide,2016-09-29 17:51:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3nCc9fu5HQQ/mid-day-market-update-crude-oil-rises-over-2-intra-cellular-therapies-shares-slide-cm686716,Midway through trading Thursday the Dow traded down 0 10 percent to 18 321 30 while the NASDAQ declined 0 31 percent to 5 302 09 The S amp P also fell dropping 0 11 percent to 2 169 00 Leading and Lagging Sectors On Thursday energy shares gained 1 37 percent Meanwhile
EXEL,EXEL:UW,BBG000BQ56F4,Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations,2016-09-29 15:22:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H8WiNTJOkZs/mid-morning-market-update-markets-edge-lower-pepsico-beats-q3-expectations-cm686545,Following the market opening Thursday the Dow traded down 0 06 percent to 18 329 07 while the NASDAQ declined 0 16 percent to 5 310 17 The S amp P also fell dropping 0 11 percent to 2 169 03 Leading and Lagging Sectors Thursday morning energy shares gained 0 52
EXEL,EXEL:UW,BBG000BQ56F4,"Why Exelixis, Inc. Got Hammered Today",2016-09-28 22:21:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J6ZVYPUa1gQ/why-exelixis-inc-got-hammered-today-cm686251,Image source Getty Images What happened Exelixis NASDAQ EXEL fell 14 today after abstracts from the European Society for Medical Oncology ESMO meeting were released today So what Data from Exelixis s most important clinical trial the CABOSUN trial testing
EXEL,EXEL:UW,BBG000BQ56F4,"Why Exelixis, Inc. Got Hammered Today",2016-09-28 20:48:00 +0000,http://www.fool.com/investing/2016/09/28/why-exelixis-inc-got-hammered-today.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,"Why Exelixis, Inc. Got Hammered Today"
EXEL,EXEL:UW,BBG000BQ56F4,"Wednesday's ETF Movers: XOP, XBI",2016-09-28 20:21:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kfuo1YKSeQU/wednesdays-etf-movers-xop-xbi-cm686187,In trading on Wednesday the SPDR S amp P Oil amp Gas Exploration amp Production ETF XOP is outperforming other ETFs up about 4 2 on the day Components of that ETF showing particular strength include shares of Oasis Petroleum OAS up about 11 3 and shares of Denbury
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis (EXEL) Stock Plummets on Cancer Drug Trial Results, Leerink: Selloff Overdone",2016-09-28 18:21:00 +0000,https://www.thestreet.com/story/13755511/1/exelixis-exel-stock-plummets-on-cancer-drug-trial-results-leerink-selloff-overdone.html?puc=yahoo&cm_ven=YAHOO,"Exelixis (EXEL) Stock Plummets on Cancer Drug Trial Results, Leerink: Selloff Overdone"
EXEL,EXEL:UW,BBG000BQ56F4,"EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers",2016-09-26 20:36:30 +0000,http://biz.yahoo.com/e/160926/exel8-k.html,"EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers"
EXEL,EXEL:UW,BBG000BQ56F4,Surging Earnings Estimates Signal Good News for Exelixis (EXEL),2016-09-26 14:23:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/49Qyf9bnABM/surging-earnings-estimates-signal-good-news-for-exelixis-exel-cm684388,Exelixis Inc EXEL is a genomics based drug discovery company that could be an interesting play for investors That is because not only does the stock have decent short term momentum but it is seeing solid activity on the earnings estimate revision front as well These positive
EXEL,EXEL:UW,BBG000BQ56F4,4 Biopharma Companies Moving on Monday Ahead of the Presidential Debate,2016-09-26 14:15:44 +0000,http://247wallst.com/healthcare-business/2016/09/26/4-biopharma-companies-moving-on-monday-ahead-of-the-presidential-debate/,4 Biopharma Companies Moving on Monday Ahead of the Presidential Debate
EXEL,EXEL:UW,BBG000BQ56F4,Surging Earnings Estimates Signal Good News for Exelixis (EXEL),2016-09-26 12:33:12 +0000,http://finance.yahoo.com/news/surging-earnings-estimates-signal-good-123312004.html,Surging Earnings Estimates Signal Good News for Exelixis (EXEL)
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist",2016-09-26 10:19:06 +0000,http://www.publicnow.com/view/2686A92011397B500BAF90D835C639D5AEFCCAAE,[at noodls] - -- Daiichi Sankyo-sponsored development program includes phase 3 pivotal trial in Japanese hypertensive patients and six supportive studies - -- Enrollment of first patient in phase 3 pivotal trial triggers ...
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Elects Julie Anne Smith to Its Board of Directors,2016-09-26 10:19:06 +0000,http://www.publicnow.com/view/FF0515016788513AB1B6C6CDC9CE0AB7C5EB29AA,"[at noodls] - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 26, 2016-- Exelixis, Inc. (NASDAQ: EXEL) today announced that accomplished biopharmaceutical executive Julie Anne Smith has been elected to the company's ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Elects Julie Anne Smith to Its Board of Directors,2016-09-26 10:02:00 +0000,http://finance.yahoo.com/news/exelixis-elects-julie-anne-smith-100200597.html,"[Business Wire] - Exelixis, Inc. today announced that accomplished biopharmaceutical executive Julie Anne Smith has been elected to the company’s Board of Directors. Ms. Smith’s appointment took effect on September 22, 2016."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist",2016-09-26 10:00:00 +0000,http://au.finance.yahoo.com/news/exelixis-announces-collaborator-daiichi-sankyo-100000540.html,"[Business Wire] - SOUTH SAN FRANCISCO, Calif.--(BUSINESSWIRE)-- Exelixis, Inc. (NASDAQ:EXEL - News) today announced that its partner Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) has initiated a phase 3 pivotal trial to evaluate CS-3150 (esaxerenone (r-INN)), an oral, non-steroidal, selective mineralocorticoid receptor antagonist, as a treatment for essential hypertension in Japanese patients. As a result of Daiichi Sankyo enrolling the first patient in the program’s phase 3 pivotal trial, Exelixis is eligible for a $15 million milestone payment, which it expects to receive in the fourth quarter of 2016. In March 2006, Daiichi Sankyo and Exelixis entered into a research collaboration agreement to discover, develop and commercialize novel therapies targeting the mineralocorticoid receptor."
EXEL,EXEL:UW,BBG000BQ56F4,First Week of May 2017 Options Trading For Exelixis (EXEL),2016-09-21 16:21:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gTljnUYBt8k/first-week-of-may-2017-options-trading-for-exelixis-exel-cm682659,Investors in Exelixis Inc Symbol EXEL saw new options begin trading this week for the May 2017 expiration One of the key data points that goes into the price an option buyer is willing to pay is the time value so with 240 days until expiration the newly trading contracts represent
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress,2016-09-20 20:55:00 +0000,http://finance.yahoo.com/news/exelixis-provides-timing-key-cabozantinib-205500920.html,"[Business Wire] - Exelixis, Inc. today provided an update on the timing of a key data presentation for cabozantinib at the European Society for Medical Oncology 2016 Congress, which is being held October 7-11, 2016 in Copenhagen, Denmark."
EXEL,EXEL:UW,BBG000BQ56F4,3 Longs And 1 Short to Watch,2016-09-20 16:58:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pkoNH223dKo/3-longs-and-1-short-to-watch-cm682153,"Here are three stocks with strong technical momentum and one that appears to be headed lower.  Avon Products Inc. ( AVP ) is in a bullish consolidation after breaking out in early August.  The stock bounced off lateral support on Monday, closing up 27 cents to $5.54 on 5 million shares.  As long as the stock remains"
EXEL,EXEL:UW,BBG000BQ56F4,2 Bullish Stock Picks and 2 Stocks to Sell Short,2016-09-20 15:59:00 +0000,https://www.thestreet.com/story/13746034/1/2-bullish-stock-picks-and-2-stocks-to-sell-short.html?puc=yahoo&cm_ven=YAHOO,2 Bullish Stock Picks and 2 Stocks to Sell Short
EXEL,EXEL:UW,BBG000BQ56F4,3 Reasons Momentum Stock Investors Will Love Exelixis (EXEL),2016-09-20 14:24:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NvShEmBjC2Y/3-reasons-momentum-stock-investors-will-love-exelixis-exel-cm681859,Many investors like to look for momentum in stocks but this can be very tough to define There is great debate regarding which metrics are the best to focus on in this regard and which are not really quality indicators of future performance Fortunately with our new style score system we
EXEL,EXEL:UW,BBG000BQ56F4,3 Reasons Momentum Stock Investors Will Love Exelixis (EXEL),2016-09-20 12:37:12 +0000,http://finance.yahoo.com/news/3-reasons-momentum-stock-investors-123712623.html,3 Reasons Momentum Stock Investors Will Love Exelixis (EXEL)
EXEL,EXEL:UW,BBG000BQ56F4,These 3 Stocks Have Doubled Their Investors' Money,2016-09-17 16:20:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Rs4t08V4E1E/these-3-stocks-have-doubled-their-investors-money-cm680932,Image source Getty Images There s more than one way to skin a cat and more than one path a company can follow to double an investor s money in the course of a year These three companies have managed to do just that despite blazing different paths to the same end Going their
EXEL,EXEL:UW,BBG000BQ56F4,These 3 Stocks Have Doubled Their Investors' Money,2016-09-17 15:13:17 +0000,http://www.fool.com/investing/2016/09/17/these-3-stocks-have-doubled-their-investors-money.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,These 3 Stocks Have Doubled Their Investors' Money
EXEL,EXEL:UW,BBG000BQ56F4,"Forget Novavax, Buy These 4 Biotech Stocks Instead",2016-09-16 22:18:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J58VFJ7gzxU/forget-novavax-buy-these-4-biotech-stocks-instead-cm680788,Shares of Novavax Inc NVAX plunged around 82 in pre market trading on Friday after the biopharmaceutical company announced a day before that its key vaccine candidate unexpectedly failed to meet the primary endpoint in a phase III trial What Went Wrong at Novavax Top line
EXEL,EXEL:UW,BBG000BQ56F4,Will Exelixis (EXEL) Continue to Surge Higher?,2016-09-15 15:11:03 +0000,http://finance.yahoo.com/news/exelixis-exel-continue-surge-higher-151103531.html,Will Exelixis (EXEL) Continue to Surge Higher?
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Wins EU Approval for Cabometyx RCC Treatment (EXEL),2016-09-14 23:50:00 +0000,http://www.investopedia.com/news/exelixis-wins-eu-approval-cabometyx-rcc-treatment-exel/?partner=YahooSA,Exelixis Wins EU Approval for Cabometyx RCC Treatment (EXEL)
EXEL,EXEL:UW,BBG000BQ56F4,"Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar",2016-09-14 20:27:26 +0000,http://www.investors.com/research/ibd-industry-themes/bevy-of-biotech-stocks-healthy-sarepta-bluebird-exelixis-soar/,"Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar"
EXEL,EXEL:UW,BBG000BQ56F4,"Wednesday's ETF Movers: XBI, XOP",2016-09-14 17:45:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p9CB9WPSnDQ/wednesdays-etf-movers-xbi-xop-cm679523,In trading on Wednesday the SPDR S amp P Biotech ETF is outperforming other ETFs up about 1 9 on the day Components of that ETF showing particular strength include shares of Sarepta Therapeutics up about 24 7 and shares of Exelixis up about 5 5 on the day And underperforming
EXEL,EXEL:UW,BBG000BQ56F4,"3 Stocks to Watch Wednesday: Monsanto Company (MON), Herbalife Ltd. (HLF) and Exelixis, Inc. (EXEL)",2016-09-14 14:47:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3MIVkx30EpQ/3-stocks-to-watch-wednesday-monsanto-company-mon-herbalife-ltd-hlf-and-exelixis-inc-exel-cm679316,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Tuesday proved to be the 160 ebb to Monday s flow The major indices cracked amid a drop in oil prices with the 160 S amp P 500 off 1 5 the 160 Dow Jones Industrial
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis (EXEL) Stock Advances, EC Approves Kidney Cancer Drug",2016-09-14 14:03:00 +0000,https://www.thestreet.com/story/13728579/1/exelixis-exel-stock-advances-ec-approves-kidney-cancer-drug.html?puc=yahoo&cm_ven=YAHOO,"Exelixis (EXEL) Stock Advances, EC Approves Kidney Cancer Drug"
EXEL,EXEL:UW,BBG000BQ56F4,4 stocks to watch,2016-09-14 13:34:33 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=C0CFD741-F9D3-4FAC-8CD0-AB43DD606B57&siteid=yhoof2,4 stocks to watch
EXEL,EXEL:UW,BBG000BQ56F4,Key FDA Decisions and Trial Results Coming in the Next 2 Months,2016-09-14 12:20:11 +0000,http://247wallst.com/healthcare-business/2016/09/14/key-fda-decisions-and-trial-results-coming-in-the-next-2-months/,Key FDA Decisions and Trial Results Coming in the Next 2 Months
EXEL,EXEL:UW,BBG000BQ56F4,European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy,2016-09-14 05:28:04 +0000,http://www.publicnow.com/view/244AC348ED7A86E9757B8597573222F485DA3C7F,"[at noodls] - - CABOMETYX is the first and only therapy approved in the European Union to demonstrate improved overall survival, progression-free survival and objective response rate in a large, randomized phase 3 trial ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Shares Soar on Cancer Therapies (EXEL),2016-09-13 15:25:00 +0000,http://www.investopedia.com/news/exelixis-shares-soar-cancer-therapies-exel/?partner=YahooSA,Exelixis Shares Soar on Cancer Therapies (EXEL)
EXEL,EXEL:UW,BBG000BQ56F4,4 Momentum Stocks to Watch,2016-09-13 15:12:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dZFdV7kL0Sg/4-momentum-stocks-to-watch-cm678803,"By Harry Boxer   These four stocks have strong technical momentum.   Clovis Oncology, Inc.  ( CLVS ), which poppped nearly 30% three weeks ago and then flagged, broke out of the flag last week and looks to be consolidating ahead of its next up-move.  On Monday it gained 40 cents to 28.05 on strong volume of 2.8"
EXEL,EXEL:UW,BBG000BQ56F4,"The Clear Reason Behind Exelixis, Inc.'s 21% Gain in August",2016-09-08 13:19:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/39BrYV68t9k/the-clear-reason-behind-exelixis-incs-21-gain-in-august-cm676080,Image source Getty Images What happened Shares of Exelixis NASDAQ EXEL a midcap biotech company focused on the development of cancer therapeutics surged 21 in August based on data from S amp P Global Market Intelligence The clear reason for the strong
EXEL,EXEL:UW,BBG000BQ56F4,"The Clear Reason Behind Exelixis, Inc.'s 21% Gain in August",2016-09-08 12:08:12 +0000,http://www.fool.com/investing/2016/09/08/the-clear-reason-behind-exelixis-incs-21-gain-in-a.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"The Clear Reason Behind Exelixis, Inc.'s 21% Gain in August"
EXEL,EXEL:UW,BBG000BQ56F4,Key FDA Decisions and Trial Results Expected in October,2016-09-08 12:05:52 +0000,http://247wallst.com/healthcare-business/2016/09/08/key-fda-decisions-and-trial-results-expected-in-october/,Key FDA Decisions and Trial Results Expected in October
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Reports Interim Analysis of Liver Cancer Trial Data,2016-09-07 22:17:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OAHeBbcZNU0/exelixis-reports-interim-analysis-of-liver-cancer-trial-data-cm675920,Exelixis Inc EXEL announced the outcome from the first planned interim analysis of a randomized phase III trial CELESTIAL on cabozantinib The trial evaluated cabozantinib compared with placebo in patients with advanced hepatocellular carcinoma HCC who have been previously treated
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Reports Interim Analysis of Liver Cancer Trial Data,2016-09-07 19:44:07 +0000,http://finance.yahoo.com/news/exelixis-reports-interim-analysis-liver-194407019.html,Exelixis Reports Interim Analysis of Liver Cancer Trial Data
EXEL,EXEL:UW,BBG000BQ56F4,4 stocks to watch,2016-09-07 16:37:33 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=04435A97-B676-4DF9-9CD9-DC696AEC93B1&siteid=yhoof2,4 stocks to watch
EXEL,EXEL:UW,BBG000BQ56F4,"ETF’s with exposure to Exelixis, Inc. : September 7, 2016",2016-09-07 14:40:03 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-exelixis-inc-september-7-2016/,"ETF’s with exposure to Exelixis, Inc. : September 7, 2016"
EXEL,EXEL:UW,BBG000BQ56F4,"CERC Data Due Dec., SAMURAI Brings Cheer To CLCD, TNXP Slumps As Study Fails",2016-09-07 02:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GVbsP55jeVQ/cerc-data-due-dec-samurai-brings-cheer-to-clcd-tnxp-slumps-as-study-fails-20160907-00032,"CERC Data Due Dec., SAMURAI Brings Cheer To CLCD, TNXP Slumps As Study Fails"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma,2016-09-06 21:29:01 +0000,http://www.publicnow.com/view/711EB229F9846B6ECFB5DBEF6CEAEAEF4FEA581C,"[at noodls] - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 6, 2016-- Exelixis, Inc. (NASDAQ:EXEL) today announced the outcome from the first planned interim analysis of CELESTIAL, a randomized global phase 3 trial ..."
EXEL,EXEL:UW,BBG000BQ56F4,3 Biotech Stocks to Buy in September,2016-09-03 18:50:34 +0000,http://www.fool.com/investing/2016/09/02/3-biotech-stocks-to-buy-in-september.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotech Stocks to Buy in September
EXEL,EXEL:UW,BBG000BQ56F4,3 Biotech Stocks to Buy in September,2016-09-02 20:17:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6XPOFoMIIsc/3-biotech-stocks-to-buy-in-september-cm674298,Image source Getty Images The year 2016 is shaping up to be a rough 160 one for biotech investors The SPDR S amp P Biotech ETF an exchange traded fund that holds a wide variety of biotech stocks is down 160 13 year to date That badly lags the returns of the S amp P
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13,2016-08-31 20:17:00 +0000,http://finance.yahoo.com/news/exelixis-present-morgan-stanley-global-201700982.html,"[Business Wire] - Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will provide an overview of the company at the Morgan Stanley Global Healthcare Conference taking place September 12-14 in New York, NY."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis-discovered Compounds To Be Featured in 15 Presentations at the ESMO 2016 Congress,2016-08-31 12:30:00 +0000,http://finance.yahoo.com/news/exelixis-discovered-compounds-featured-15-123000396.html,"[Business Wire] - Exelixis, Inc. today announced that data from clinical trials of cabozantinib and cobimetinib will be the subject of 15 presentations at the European Society for Medical Oncology 2016 Congress in Copenhagen, October 7 – 11, 2016."
EXEL,EXEL:UW,BBG000BQ56F4,Why Exelixis (EXEL) Could Be Positioned for a Surge,2016-08-26 14:48:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_w_KmIzQ97I/why-exelixis-exel-could-be-positioned-for-a-surge-cm670603,"Exelixis, Inc.EXEL is a Medical Biomedical Genetics company that could be an interesting play for investors. That is because, not only does the stock have decent short term momentum, but it is seeing solid activity on the"
EXEL,EXEL:UW,BBG000BQ56F4,Why Exelixis (EXEL) Could Be Positioned for a Surge,2016-08-26 13:00:01 +0000,http://finance.yahoo.com/news/why-exelixis-exel-could-positioned-130001256.html,Why Exelixis (EXEL) Could Be Positioned for a Surge
EXEL,EXEL:UW,BBG000BQ56F4,4 stocks to watch,2016-08-25 13:38:54 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=1DB6D0F9-69B5-4C57-8217-BCEA9BFC6DBC&siteid=yhoof2,4 stocks to watch
EXEL,EXEL:UW,BBG000BQ56F4,Mobileye And Three More Stocks Breaking Out,2016-08-24 16:39:00 +0000,http://www.forbes.com/sites/greatspeculations/2016/08/24/mobileye-and-three-more-stocks-breaking-out/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,"[at Forbes] - The following stocks have had strong recent breakouts that portend higher prices ahead. Exelixis (EXEL), which has more than tripled since March, recently broke out of a 2-week descending wedge pattern, and has followed through. On Tuesday, it retested the recent highs at $11.66, making a nominal new high by a"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Redemption of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019,2016-08-24 12:48:02 +0000,http://www.publicnow.com/view/2C47785DD0FFCFB6BD960E88056508A8B38D14A4,"[at noodls] - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 24, 2016-- Exelixis, Inc. (NASDAQ:EXEL) today announced that it has called for redemption approximately $48.1 million of its 4.25% Convertible Senior ..."
EXEL,EXEL:UW,BBG000BQ56F4,4 Biotech Stock Charts You Must See,2016-08-23 16:07:00 +0000,https://www.thestreet.com/story/13682913/1/4-biotech-stock-charts-you-must-see.html?puc=yahoo&cm_ven=YAHOO,4 Biotech Stock Charts You Must See
EXEL,EXEL:UW,BBG000BQ56F4,"ETF’s with exposure to Exelixis, Inc. : August 22, 2016",2016-08-22 15:25:00 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-exelixis-inc-august-22-2016/,"ETF’s with exposure to Exelixis, Inc. : August 22, 2016"
EXEL,EXEL:UW,BBG000BQ56F4,"EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement",2016-08-22 12:35:46 +0000,http://biz.yahoo.com/e/160822/exel8-k.html,"EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement"
EXEL,EXEL:UW,BBG000BQ56F4,EXEL Crosses Above Average Analyst Target,2016-08-19 13:39:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MEn36pII5x4/exel-crosses-above-average-analyst-target-cm667543,"In recent trading, shares of Exelixis Inc (Symbol EXEL) have crossed above the average analyst 12 month target price of $10.67, changing hands for $10.97 share. When a stock reaches the target an analyst has set, the analyst logically"
EXEL,EXEL:UW,BBG000BQ56F4,"ETF’s with exposure to Exelixis, Inc. : August 11, 2016",2016-08-11 16:45:33 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-exelixis-inc-august-11-2016/,"ETF’s with exposure to Exelixis, Inc. : August 11, 2016"
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis, Inc. :EXEL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016",2016-08-10 15:19:12 +0000,http://www.capitalcube.com/blog/index.php/exelixis-inc-exel-us-earnings-analysis-q2-2016-by-the-numbers-august-10-2016/,"Exelixis, Inc. :EXEL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016"
EXEL,EXEL:UW,BBG000BQ56F4,This Could Be August's Best Stock,2016-08-09 21:55:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n7jWZfgYtW8/this-could-be-augusts-best-stock-cm662867,"Image source  Getty Images.  Who said anything about selling in May and going away? Since May began, the broad based S&P 500  index has gained nearly 5%, with a post Brexit bounce and"
EXEL,EXEL:UW,BBG000BQ56F4,"EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities",2016-08-09 21:26:38 +0000,http://biz.yahoo.com/e/160809/exel8-k.html,"EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities"
EXEL,EXEL:UW,BBG000BQ56F4,"2 Factors Pushing Exelixis, Inc. Up by 18% in July",2016-08-08 19:16:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eqcSvnVA_I4/2-factors-pushing-exelixis-inc-up-by-18-in-july-cm662032,"Image source  Getty Images.  What  Shares of Exelixis (NASDAQ  EXEL) , a biotechnology company focused on developing drugs to treat cancer, rocketed higher by 18% during July, according to data from"
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis (EXEL) Posts Narrower Loss in Q2, Beats on Revenues",2016-08-04 21:52:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nSEKcLjQvdQ/exelixis-exel-posts-narrower-loss-in-q2-beats-on-revenues-cm660731,"Exelixis, Inc . EXEL posted a second quarter 2016 loss of 16 cents, narrower than both the Zacks Consensus Estimate of a loss of 27 cents and the year ago loss of 22 cents. Net revenue came in at"
EXEL,EXEL:UW,BBG000BQ56F4,"Noteworthy Thursday Option Activity: EXPE, EXEL, JIVE",2016-08-04 20:53:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PFnYoUlwHew/noteworthy-thursday-option-activity-expe-exel-jive-cm660707,"Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Expedia Inc (Symbol EXPE), where a total of 10,486 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts"
EXEL,EXEL:UW,BBG000BQ56F4,"Breaking Down Exelixis, Inc.'s Drug Launch",2016-08-04 19:56:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4fxhnKTkTz4/breaking-down-exelixis-incs-drug-launch-cm660643,Image source  Exelixis.  Exelixis (NASDAQ  EXEL) offered a first look at the launch of the biotech's new kidney cancer drug Cabometyx during its second quarter earnings report. Investors seem to like the
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis (EXEL) Posts Narrower Loss in Q2, Beats on Revenues",2016-08-04 19:52:07 +0000,http://finance.yahoo.com/news/exelixis-exel-posts-narrower-loss-195207237.html,"Exelixis (EXEL) Posts Narrower Loss in Q2, Beats on Revenues"
EXEL,EXEL:UW,BBG000BQ56F4,Why Exelixis (EXEL) Stock Is Soaring Today,2016-08-04 19:46:00 +0000,https://www.thestreet.com/story/13665597/1/why-exelixis-exel-stock-is-soaring-today.html?puc=yahoo&cm_ven=YAHOO,Why Exelixis (EXEL) Stock Is Soaring Today
EXEL,EXEL:UW,BBG000BQ56F4,Correction: Earns-Exelixis story,2016-08-04 15:16:56 +0000,http://sg.finance.yahoo.com/news/exelixis-reports-2q-loss-224737826.html,Correction: Earns-Exelixis story
EXEL,EXEL:UW,BBG000BQ56F4,Don't Roll the Dice on Central Bank News,2016-08-04 14:53:00 +0000,http://realmoney.thestreet.com/articles/08/04/2016/dont-roll-dice-central-bank-news?puc=yahoo&cm_ven=YAHOO,Don't Roll the Dice on Central Bank News
EXEL,EXEL:UW,BBG000BQ56F4,"Earnings Wrap: Transocean (RIG), XPO Logistics (XPO), Exelixis (EXEL), 2 More",2016-08-04 12:00:05 +0000,http://www.insidermonkey.com/blog/earnings-wrap-transocean-rig-xpo-logistics-xpo-exelixis-exel-2-more-467597/,"Earnings Wrap: Transocean (RIG), XPO Logistics (XPO), Exelixis (EXEL), 2 More"
EXEL,EXEL:UW,BBG000BQ56F4,Edited Transcript of EXEL earnings conference call or presentation 3-Aug-16 9:00pm GMT,2016-08-04 01:10:01 +0000,http://finance.yahoo.com/news/edited-transcript-exel-earnings-conference-011001636.html,Edited Transcript of EXEL earnings conference call or presentation 3-Aug-16 9:00pm GMT
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis reports 2Q loss,2016-08-03 22:47:37 +0000,http://finance.yahoo.com/news/exelixis-reports-2q-loss-224737762.html,Exelixis reports 2Q loss
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Inc Earnings Call scheduled for 5:00 pm ET today,2016-08-03 21:00:00 +0000,http://biz.yahoo.com/cc/8/152718.html,Exelixis Inc Earnings Call scheduled for 5:00 pm ET today
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate Update,2016-08-03 20:22:23 +0000,http://www.publicnow.com/view/6119382E3AE5915B5E85741B004C0FA5CCD3DA64,"[at noodls] - www.exelixis.com or follow @ExelixisInc on Twitter. ... This is an abstract of the original noodl. To continue reading this document, click here for the original version."
EXEL,EXEL:UW,BBG000BQ56F4,"EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition",2016-08-03 20:13:49 +0000,http://biz.yahoo.com/e/160803/exel8-k.html,"EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition"
EXEL,EXEL:UW,BBG000BQ56F4,"Earnings Reaction History: Exelixis, Inc., 50.0% Follow-Through Indicator, 4.6% Sensitive",2016-08-03 19:08:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JTSMiIdOHeQ/earnings-reaction-history-exelixis-inc-500-follow-through-indicator-46-sensitive-cm659897,"Expected Earnings Release 08 03 2016, After hours Avg. Extended Hours Dollar Volume $1,259,097 Exelixis, Inc. ( EXEL ) is due to issue its quarterly earnings report in the upcoming extended hours session. Given its history, traders can expect"
EXEL,EXEL:UW,BBG000BQ56F4,Q2 2016 Exelixis Inc Earnings Release - After Market Close,2016-08-03 11:07:02 +0000,http://biz.yahoo.com/research/earncal/20160803.html?t=exel,Q2 2016 Exelixis Inc Earnings Release - After Market Close
EXEL,EXEL:UW,BBG000BQ56F4,Wall Street Locked In Lackluster Phase,2016-08-03 06:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tIfWMugPaz8/wall-street-locked-in-lackluster-phase-20160803-00164,Wall Street Locked In Lackluster Phase
EXEL,EXEL:UW,BBG000BQ56F4,Parker-Hannifin (PH) Q4 Earnings: Disappointment in Store?,2016-08-03 00:55:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HoE0sjFgyhs/parker-hannifin-ph-q4-earnings-disappointment-in-store-cm659285,"Leading manufacturer of motion & control technologies and systems, Parker Hannifin CorporationPH , is slated to report fourth quarter fiscal 2016 results on Aug 4, before the opening bell. Last quarter, the company scored a hat trick of earnings"
EXEL,EXEL:UW,BBG000BQ56F4,"A First Look at Exelixis, Inc.'s Rocket-Ship Drug",2016-08-02 22:59:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AYl2sJVN5QM/a-first-look-at-exelixis-incs-rocket-ship-drug-cm659063,"Image source  Getty Images.  Exelixis (NASDAQ  EXEL) is scheduled to release earnings after the closing bell on Wednesday, when investors will get a first look at how quickly sales of its kidney"
EXEL,EXEL:UW,BBG000BQ56F4,7 Biotech Stocks With Pivotal Catalysts in 2017,2016-08-02 22:56:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-zs3zLoW4Ww/7-biotech-stocks-with-pivotal-catalysts-in-2017-cm659176,"When it comes to biotech stocks, it's no secret that regulatory and clinical catalysts can generate enormous returns    or losses    for investors in the blink of an eye. With this in"
EXEL,EXEL:UW,BBG000BQ56F4,Will Agios (AGIO) Disappoint Estimates in Q2 Earnings?,2016-08-02 17:52:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cBlwTZRDtoM/will-agios-agio-disappoint-estimates-in-q2-earnings-cm659007,"Agios Pharmaceuticals, Inc.AGIO is scheduled to report second quarter 2016 results on Aug 4, before the opening bell. Last quarter, the company had posted a positive surprise of 11.59%. Let's see how things are shaping up for this announcement."
EXEL,EXEL:UW,BBG000BQ56F4,Can GW Pharmaceuticals (GWPH) Surprise in Q3 Earnings?,2016-08-02 17:52:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xwTzSQTmMZQ/can-gw-pharmaceuticals-gwph-surprise-in-q3-earnings-cm659003,"GW Pharmaceuticals plcGWPH is expected to report third quarter fiscal 2016 results on Aug 4. Last quarter, the company had posted a positive surprise of 35.67%. Let's see how things are shaping up for this quarter. Factors to Consider"
EXEL,EXEL:UW,BBG000BQ56F4,Fluor (FLR) Q2 Earnings: Disappointment in the Cards?,2016-08-02 16:59:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cwmDshrG8Uw/fluor-flr-q2-earnings-disappointment-in-the-cards-cm658983,"Fluor CorporationFLR is set to report second quarter 2016 results, after the closing bell on Aug 4. Last quarter, the company disappointed investors by posting a negative earnings surprise of 1.2%. The company has had a disappointing earnings history,"
EXEL,EXEL:UW,BBG000BQ56F4,"Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More",2016-08-02 16:59:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qN_lz_ygz44/drug-stocks-to-watch-for-earnings-on-aug-3-zts-exel-more-cm658976,"In the thick of Q2 earnings season, we see a clear trend of continuing earnings decline for the benchmark S&P 500 index the fifth quarter in a row. As for beat ratios, they aren't all that bad. Of the"
EXEL,EXEL:UW,BBG000BQ56F4,"Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More",2016-08-02 14:30:02 +0000,http://finance.yahoo.com/news/drug-stocks-watch-earnings-aug-143002593.html,"Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More"
EXEL,EXEL:UW,BBG000BQ56F4,What Awaits Aerie Pharmaceuticals (AERI) in Q2 Earnings?,2016-08-02 00:52:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mE9KUKlHsPI/what-awaits-aerie-pharmaceuticals-aeri-in-q2-earnings-cm658490,"Aerie Pharmaceuticals, Inc.AERI is scheduled to report second quarter 2016 results after the market closes on Aug 3. Aerie's performance over the last four quarters has been disappointing. The company reported a wider than expected loss thrice in the"
EXEL,EXEL:UW,BBG000BQ56F4,Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?,2016-08-02 00:52:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jF_XHcmbOiI/merrimack-mack-can-the-stock-surprise-in-q2-earnings-cm658488,"Merrimack Pharmaceuticals, Inc.MACK is scheduled to report second quarter 2016 results on Aug 4. Last quarter, Merrimack delivered an earnings surprise of +15.38%. Let's see how things are shaping up for the company this quarter.Factors Influencing This Quarter Merrimack's"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis (EXEL) Q2 Earnings Preview: Stock Likely to Gain?,2016-08-01 15:55:03 +0000,http://finance.yahoo.com/news/exelixis-exel-q2-earnings-preview-155503011.html,Exelixis (EXEL) Q2 Earnings Preview: Stock Likely to Gain?
EXEL,EXEL:UW,BBG000BQ56F4,"D-Day For TBRA, Nicox Falls As FDA Rejects Vesneo, EXEL Awaits EMA Decision",2016-07-25 01:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DRuFB7GdoP8/dday-for-tbra-nicox-falls-as-fda-rejects-vesneo-exel-awaits-ema-decision-20160725-00013,"D-Day For TBRA, Nicox Falls As FDA Rejects Vesneo, EXEL Awaits EMA Decision"
EXEL,EXEL:UW,BBG000BQ56F4,"Cancer Stocks: 2 to Buy, 1 to Avoid",2016-07-23 19:23:00 +0000,http://www.fool.com/investing/2016/07/23/cancer-stocks-2-to-buy-1-to-avoid.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Cancer Stocks: 2 to Buy, 1 to Avoid"
EXEL,EXEL:UW,BBG000BQ56F4,Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy,2016-07-22 15:18:09 +0000,http://www.publicnow.com/view/958F5B6AD084A3BDE4529A10908B4C36327397D1,[at noodls] - CHMP recommends approval of Cabometyx™ (cabozantinib) for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy based ...
EXEL,EXEL:UW,BBG000BQ56F4,Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx™ (cabozantinib) for the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy,2016-07-22 14:18:12 +0000,http://www.publicnow.com/view/7AAB045AEED578AE3CBF58DA85886B74D957F634,[at noodls] - PR CHMP CABOMETYX PRESS RELEASE CHMP recommends approval of Cabometyx™ (cabozantinib) for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor ...
EXEL,EXEL:UW,BBG000BQ56F4,Exit of Biogen CEO George Scangos could be big for Bay Area biotechs,2016-07-21 18:55:11 +0000,http://www.bizjournals.com/sanfrancisco/blog/biotech/2016/07/biogen-george-scangos-biib-exelixis-exel.html?ana=yahoo,Exit of Biogen CEO George Scangos could be big for Bay Area biotechs
EXEL,EXEL:UW,BBG000BQ56F4,5 Stocks to Buy and Hold for the Next Decade,2016-07-20 12:45:00 +0000,http://www.fool.com/investing/2016/07/20/5-stocks-to-buy-and-hold-for-the-next-decade.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Stocks to Buy and Hold for the Next Decade
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis to Release Second Quarter 2016 Financial Results on Wednesday, August 3, 2016",2016-07-12 20:33:11 +0000,http://www.publicnow.com/view/C96C498E8E45DA56B3210D8AFB5FF96A5369D363,"[at noodls] - - Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m. PDT - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 12, 2016-- Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter ..."
EXEL,EXEL:UW,BBG000BQ56F4,Highlighted Drug Makers From This Year''s Cancer Conference,2016-06-06 12:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-wWQHxfb2iY/highlighted-drug-makers-from-this-years-cancer-conference-20160606-00776,Highlighted Drug Makers From This Year''s Cancer Conference
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX™ (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting,2016-06-06 11:58:11 +0000,http://www.publicnow.com/view/5E2FC8C111F6B113743140B12423812E4A1A0C05,"[at noodls] - - Additional data from pivotal METEOR trial underscore clinically meaningful benefit of CABOMETYX across subgroups of patients - SOUTH SAN FRANCISCO, Calif. & PARIS--(BUSINESS WIRE)--Jun. 6, 2016-- Exelixis, ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CABOMETYX™ (cabozantinib) tablets in advanced renal cell carcinoma at 2016 ASCO annual meeting,2016-06-06 11:48:10 +0000,http://www.publicnow.com/view/25EA024815B1847B4B544E73FF5C43B23C624687,[at noodls] - Microsoft Word - IPSEN FINAL PR Exelixis and Ipsen CABOMETYX METEOR Subgroups.doc PRESS RELEASE Additional data from pivotal METEOR trial underscore clinically meaningful benefit of CABOMETYX™ across subgroups ...
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Renal Cell Carcinoma Presented at ASCO,2016-06-05 12:18:02 +0000,http://www.publicnow.com/view/3387E3EE95928030F9E01BE49ACE49A9FEF37DA1,[at noodls] - - Details of clinically meaningful increase in overall survival from METEOR trial to be presented in an oral abstract session and published simultaneously in The Lancet Oncology- - Overall survival and ...
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting,2016-06-05 11:58:04 +0000,http://www.publicnow.com/view/8AE900AD3AC728BE67297B1659D06C9EC6FDC803,"[at noodls] - - Results are the subject of an oral presentation at ASCO 2016 today- - Phase 3 pivotal trial of combination has been initiated - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 5, 2016-- Exelixis, ..."
EXEL,EXEL:UW,BBG000BQ56F4,"EXEL Rises On Trial Data, XNPT Agrees To Be Acquired, NVO Faces FDA Panel Today",2016-05-24 00:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J-E24y4WrGs/exel-rises-on-trial-data-xnpt-agrees-to-be-acquired-nvo-faces-fda-panel-today-20160524-00007,"EXEL Rises On Trial Data, XNPT Agrees To Be Acquired, NVO Faces FDA Panel Today"
EXEL,EXEL:UW,BBG000BQ56F4,Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma,2016-05-23 17:56:06 +0000,http://www.publicnow.com/view/E76DE12470170DD568E9BC1B7ACA9A8152B988D6,[at noodls] - Microsoft Word - 23 05 2016 PR FINAL FINAL IPSEN CABOSUN Exelixis phase II 1st line RCC.docx PRESS RELEASE Ipsen's partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate ...
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma,2016-05-23 13:26:05 +0000,http://www.publicnow.com/view/3053977A5FEA83A30E6C11E742CF786D480D9FD4,[at noodls] - - Exelixis to consult with regulatory authorities to determine next steps in development and submission strategy for cabozantinib in first-line renal cell carcinoma - SAN FRANCISCO--(BUSINESS WIRE)--May ...
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10,2016-05-05 20:21:13 +0000,http://www.publicnow.com/view/63DC959396EF861CFE31BCCBA2C2E214FB0FD1AF,"[at noodls] - -- Presentation to be webcast on www.exelixis.com -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 5, 2016-- Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis reports 1Q loss,2016-05-04 21:13:29 +0000,http://sg.finance.yahoo.com/news/exelixis-reports-1q-loss-211329450.html,Exelixis reports 1Q loss
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces First Quarter 2016 Financial Results and Provides Corporate Update,2016-05-04 20:31:23 +0000,http://www.publicnow.com/view/A64FA66303987F82C870876754EFF9F2AFF6FD68,"[at noodls] - www.exelixis.com or follow @ExelixisInc on Twitter. ... This is an abstract of the original noodl. To continue reading this document, click here for the original version."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis to Release First Quarter 2016 Financial Results on Wednesday, May 4, 2016",2016-04-26 20:36:31 +0000,http://www.publicnow.com/view/79F1817F1E5DA59D728430564CC81AC8F771E826,"[at noodls] - - Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m. PDT - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 26, 2016-- Exelixis, Inc. (NASDAQ: EXEL) announced today that its first quarter ..."
EXEL,EXEL:UW,BBG000BQ56F4,Ipsen is pleased to announce that its partner Exelixis obtained FDA Approval of CABOMETYX™ (cabozantinib) tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy,2016-04-26 07:41:19 +0000,http://www.publicnow.com/view/174FBDB72D6653613FAEE8A3A32A4CD00321A22A,"[at noodls] - Microsoft Word - 25 04 2016 Cabozantinib approval RCC US.doc PRESS RELEASE CABOMETYX™ (cabozantinib) is the first therapy to demonstrate improved overall survival, progression-free survival and objective ..."
EXEL,EXEL:UW,BBG000BQ56F4,ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX™ (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy,2016-04-25 20:34:06 +0000,http://www.publicnow.com/view/D87C4574AF4326C24DEA2DF46B41D6EF8BF91FE1,"[at noodls] - http://www.businesswire.com/news/home/20160425006329/en/ CABOMETYX™ Tablets 20 mg, 40 mg, 60 mg 'With today's announcement, patients with previously treated advanced kidney cancer now have a new option, ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis Announces FDA Approval of CABOMETYX™ (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy,2016-04-25 18:00:22 +0000,http://www.publicnow.com/view/47F601649388EB9728F2D62CC0BAB19B5D5370B8,"[at noodls] - http://www.businesswire.com/news/home/20160425006329/en/ Renal Cell Carcinoma Fact Sheet 'With today's announcement, patients with previously treated advanced kidney cancer now have a new option, the first ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis-Discovered Compounds to Be Featured in 18 Presentations at 2016 ASCO Annual Meeting,2016-04-20 16:24:37 +0000,http://www.publicnow.com/view/64234E8D3FF6B9B3A965BDBE2C54586EE92FD095,"[at noodls] - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 20, 2016-- Exelixis, Inc. (NASDAQ: EXEL) today announced that new data for cabozantinib, cobimetinib and XL888 will be presented at the upcoming 2016 ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis reports 4Q loss,2016-02-29 21:55:32 +0000,http://sg.finance.yahoo.com/news/exelixis-reports-4q-loss-215532385.html,Exelixis reports 4Q loss
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan",2016-02-29 21:01:00 +0000,http://au.finance.yahoo.com/news/exelixis-ipsen-enter-exclusive-licensing-210100762.html,"[Business Wire] - ADR: IPSEY) today jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib, Exelixis’ lead oncology drug. Under the agreement, Ipsen will have exclusive commercialization rights for current and potential future cabozantinib indications outside of the United States, Canada and Japan. This agreement includes rights to COMETRIQ®, which is currently approved in the European Union (EU) for the treatment of adult patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC)."
EXEL,EXEL:UW,BBG000BQ56F4,"Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma",2016-02-01 13:20:22 +0000,http://www.publicnow.com/view/84156E979E7DE6F44E87881958EE1659D2DDD413,"[at noodls] - - Cabozantinib significantly improved overall survival as compared with everolimus - - First therapy to demonstrate improvement in overall survival, progression-free survival, and objective response rate ..."
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis reports 3Q loss,2015-11-10 21:46:04 +0000,http://sg.finance.yahoo.com/news/exelixis-reports-3q-loss-214604577.html,Exelixis reports 3Q loss
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis reports 2Q loss,2015-08-11 20:43:25 +0000,http://sg.finance.yahoo.com/news/exelixis-reports-2q-loss-204325612.html,Exelixis reports 2Q loss
EXEL,EXEL:UW,BBG000BQ56F4,US stocks flat as Lockheed Martin seals Sikorsky deal,2015-07-20 14:28:33 +0000,http://uk.finance.yahoo.com/news/us-stocks-flat-lockheed-martin-142833666.html,US stocks flat as Lockheed Martin seals Sikorsky deal
EXEL,EXEL:UW,BBG000BQ56F4,Roche open to alliances in hunt for cancer drug combinations,2015-04-01 10:00:00 +0000,http://uk.finance.yahoo.com/news/roche-open-alliances-hunt-cancer-100000652.html,Roche open to alliances in hunt for cancer drug combinations
EXEL,EXEL:UW,BBG000BQ56F4,"BUZZ-U.S. STOCKS ON THE MOVE-Wal-Mart, Priceline, Ocera Therapeutics, Netlist",2015-02-19 14:08:22 +0000,http://uk.finance.yahoo.com/news/buzz-u-stocks-move-wal-140822482.html,"BUZZ-U.S. STOCKS ON THE MOVE-Wal-Mart, Priceline, Ocera Therapeutics, Netlist"
EXEL,EXEL:UW,BBG000BQ56F4,"Ahead of the Bell: Exelixis shares climb, FDA to review drug",2015-02-19 14:03:56 +0000,http://sg.finance.yahoo.com/news/ahead-bell-exelixis-shares-climb-140356615.html,"Ahead of the Bell: Exelixis shares climb, FDA to review drug"
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis tops 3Q profit forecasts,2014-11-05 00:21:50 +0000,http://sg.finance.yahoo.com/news/exelixis-tops-3q-profit-forecasts-002150038--finance.html,Exelixis tops 3Q profit forecasts
EXEL,EXEL:UW,BBG000BQ56F4,Ahead of the Bell: Exelixis shares soar,2014-09-29 13:19:14 +0000,http://sg.finance.yahoo.com/news/ahead-bell-exelixis-shares-soar-131914444--finance.html,Ahead of the Bell: Exelixis shares soar
EXEL,EXEL:UW,BBG000BQ56F4,Ahead of the Bell: Exelixis shares tumble,2014-09-02 13:10:51 +0000,http://sg.finance.yahoo.com/news/ahead-bell-exelixis-shares-tumble-131051717--finance.html,Ahead of the Bell: Exelixis shares tumble
EXEL,EXEL:UW,BBG000BQ56F4,US STOCKS-Wall St set for flat open; manufacturing data on tap,2014-09-02 12:54:03 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-set-125403397.html,US STOCKS-Wall St set for flat open; manufacturing data on tap
EXEL,EXEL:UW,BBG000BQ56F4,US STOCKS-Futures inch higher ahead of manufacturing data,2014-09-02 11:41:40 +0000,http://uk.finance.yahoo.com/news/us-stocks-futures-inch-higher-114140248.html,US STOCKS-Futures inch higher ahead of manufacturing data
EXEL,EXEL:UW,BBG000BQ56F4,Exelixis to cut jobs after prostate cancer drug fails late-stage study,2014-09-01 23:32:13 +0000,http://sg.finance.yahoo.com/news/exelixis-cut-jobs-prostate-cancer-233213184.html,Exelixis to cut jobs after prostate cancer drug fails late-stage study
